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Abstract: ABSTRACT 
Background: The identification of mutated proteins in human cancer cells-
termed proteogenomics requires several technologically independent 
research methodologies including genomics, RNA sequencing, and mass 
spectrometry. Any one of these methodologies are not optimized for 
identifying potential mutated proteins and any one output fails to cover 
completely a specific landscape.  
Methods: An isogenic melanoma cell with a p53-null genotype was created 
by CRISPR/CAS9 system to determine how p53 gene inactivation affects 
mutant proteome expression. A mutant peptide reference database was 
developed by comparing two distinct DNA and RNA variant detection 
platforms using these isogenic cells. Chemically fractionated tryptic 
peptides from lysates were processed using a TripleTOF 5600+ mass 
spectrometer and their spectra were identified against this mutant 
reference database.  
Results: Approximately 190 mutated peptides were enriched in wt-p53 
cells, 187 mutant peptides were enriched in p53-null cells, with an 
overlap of 147 mutated peptides. STRING analysis highlighted that the wt-
p53 cell line was enriched for mutant protein pathways such as CDC5L and 
POLR1B, whilst the p53-null cell line was enriched for mutated proteins 
comprising EGF/YES, Ubiquitination, and RPL26/5 nodes. 
Conclusion: Our study produces a well annotated p53-dependent and p53-
independent mutant proteome of a common melanoma cell line model. Coupled 
to the application of an integrated DNA and RNA variant detection 
platform (CLCbio) and software for identification of proteins 
(ProteinPilot), this pipeline can be used to detect high confident mutant 
proteins in cells. 
General significance: This pipeline forms a blueprint for identifying 
mutated proteins in diseased cell systems. 
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This is an interesting study, which provides a pipeline to study the 
difference in gene expression levels and mutant proteins between p53-
positive and p53-negative melanoma cells. These isogenic cell lines were 
generated using CRISPR/Cas9 genome editing of the parental A375 cells. 
However, it is not clear from the description whether the CRiSPR/Cas9-
introduced mutation in the p53 gene before ARG175 produced clean 
knockout. Depending on the p53 antibody used in the study it may not 
recognize the amino-terminus of p53. Thus, this relevant information 
about p53 antibodies used in the present work should be included in the 
text. 
 
RESPONSE: On the page 26 we added a new figure 7F to show that in both 
HCT116 and A375 p53-null cell lines, there is no p53 protein detected 
using a monoclonal antibody that binds to the N-terminal domain of p53, 
DO–1. As the reviewer correctly suggested, it is possible that the RNA 
edits around codon 175 produced an out of frame stop codon that resulted 
in truncated p53 protein. The use of the monoclonal antibody DO–1 
confirms that the gene edit at codon 175 position does not produce a 
truncated p53 protein and that the A375-p53 edited cell line is a true 
“p53 protein null cell”. We discuss these findings on the page 8. We 
added a section describing how we validated loss of p53 in materials and 
methods (page 11). 
 
Minor comments: 
there are several typos in the text, e.g. how p53 gene deletion effects 
mutant proteome expression (needs to be changed to affect). 
 
RESPONSE: We thoroughly searched entire text for typos and corrected 
them. 
 
BBAGEN-20-251 Revision Cover Letter 
 
July 29, 2020 
 
Lee Graves, Executive Editor 
BBA - General Subjects 
 
Dear Lee, 
we are pleased to submit a revised version of our manuscript entitled “The effects of p53 gene 
inactivation on mutant proteome expression in a human melanoma cell model” (BBAGEN-20-251). 
Thank you for giving us the opportunity to revise and resubmit this manuscript. We are submitting this 
revision upon deadline August 31, 2020. 
 
We thank you and reviewers for careful review and comments that will lead to improvement of the 
original version of the manuscript. We have incorporated the suggested changes into manuscript and 
we respond to all issues raised by reviewers below. We are looking to cooperate with you and reviewers 




This is an interesting study, which provides a pipeline to study the difference in gene expression levels 
and mutant proteins between p53-positive and p53-negative melanoma cells. These isogenic cell lines 
were generated using CRISPR/Cas9 genome editing of the parental A375 cells. However, it is not clear 
from the description whether the CRiSPR/Cas9-introduced mutation in the p53 gene before ARG175 
produced clean knockout. Depending on the p53 antibody used in the study it may not recognize the 
amino-terminus of p53. Thus, this relevant information about p53 antibodies used in the present work 
should be included in the text. 
 
RESPONSE: On the page 26 we added a new figure 7F to show that in both HCT116 and A375 p53-null 
cell lines, there is no p53 protein detected using a monoclonal antibody that binds to the N-terminal 
domain of p53, DO–1. As the reviewer correctly suggested, it is possible that the RNA edits around 
codon 175 produced an out of frame stop codon that resulted in truncated p53 protein. The use of the 
monoclonal antibody DO–1 confirms that the gene edit at codon 175 position does not produce a 
truncated p53 protein and that the A375-p53 edited cell line is a true “p53 protein null cell”. We discuss 
these findings on the page 8. We added a section describing how we validated loss of p53 in materials 
and methods (page 11). 
 
Minor comments: 
there are several typos in the text, e.g. how p53 gene deletion effects mutant proteome expression 
(needs to be changed to affect). 
 




Sincerely, Ted Hupp 
Response to Reviewers
Highlights 
1. The study of mutated proteomes in cancer cells is at its infancy 
 
2. A proteogenomics platform is developed  that exploits DNA and RNA variant 
identification 
 
3. Mass spectrometry was used to identify and validate mutant protein expression 
 
4. P53-dependent mutant proteome networks were identified 
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Background: The identification of mutated proteins in human cancer cells-termed 
proteogenomics, requires several technologically independent research methodologies including 
DNA variant identification, RNA sequencing, and mass spectrometry. Any one of these 
methodologies are not optimized for identifying potential mutated proteins and any one output 
fails to cover completely a specific landscape.  
Methods: An isogenic melanoma cell with a p53-null genotype was created by CRISPR/CAS9 
system to determine how p53 gene inactivation affects mutant proteome expression. A mutant 
peptide reference database was developed by comparing two distinct DNA and RNA variant 
detection platforms using these isogenic cells. Chemically fractionated tryptic peptides from 
lysates were processed using a TripleTOF 5600+ mass spectrometer and their spectra were 
identified against this mutant reference database.  
Results: Approximately 190 mutated peptides were enriched in wt-p53 cells, 187 mutant peptides 
were enriched in p53-null cells, with an overlap of 147 mutated peptides. STRING analysis 
highlighted that the wt-p53 cell line was enriched for mutant protein pathways such as CDC5L and 
POLR1B, whilst the p53-null cell line was enriched for mutated proteins comprising EGF/YES, 
Ubiquitination, and RPL26/5 nodes. 
Conclusion: Our study produces a well annotated p53-dependent and p53-independent mutant 
proteome of a common melanoma cell line model. Coupled to the application of an integrated 
DNA and RNA variant detection platform (CLCbio) and software for identification of proteins 
(ProteinPilot), this pipeline can be used to detect high confident mutant proteins in cells. 







































































Next-generation genome sequencing technologies have revolutionized our understanding of the 
molecular nature of cancer [1] [2]. Parallel innovations in combinatorial chemistry, 
crystallography, high-throughput drug screening, transgenesis, and computational science have 
rapidly generated hundreds of promising targeted drug leads. However, despite this increased 
R&D, the number of effective drugs reaching the clinic is in steady decline [3]. A technical problem 
is the lack of robust age-dependent sporadic immune competent models of human cancer that 
predicts human toxicity and response [4]. Another major hurdle is that sporadic cancers are multi-
gene diseases thus minimizing the likelihood of finding a common (set of) drug(s) to improve 
patient welfare. 
 
Whole genome cancer sequencing has defined the strikingly patient-specific cancer bar code thus 
highlighting the unique genetic signature of any given tumour [5] [6]. However, the vast majority 
of anti-cancer medicines target wild-type proteins, although there are ever emerging successes in 
targeting mutated kinases with effective drug leads [7]. This presents an opportunity to develop 
precision, personalized therapeutics based on expressed, mutant proteins. Such mutant proteins 
could inform target pathway choice for the development of novel Biologics that target the 
mutated cancer landscape in a patient-specific manner [8]. Understanding the expression of 
mutant proteins could also form a platform for the development of mutant neoantigen based anti-
cancer vaccines, that could be based on synthetic proteins [9], dendritic cells primed with 
neoantigens [10], nucleic acids such as RNA [11], or synthetic viral vectors [12]. However, the 
study of mutant proteomes is only in its infancy. The relative difficulty in this task is that building 
mutant proteomes requires integration of robust and user-friendly methods linking the fields of 
informatics, mass spectrometry, and cancer biology. This task is not necessarily trivial. 
 
Computational methodologies as applied to the cancer research field are emerging as approaches 
to define the expressed, mutated genome. There are several challenges with optimizing platforms 
that integrate DNA sequencing, RNA sequencing, and mass spectrometric datasets [13]. One 
overall challenge is integrating these molecular data into one pipeline; and depends on the variant 
detection platform used for DNA sequencing; the algorithms for defining mutations with RNA 
sequencing datasets in exons, non-coding RNAs, and introns [14]. For example, the expression of 
intron encoded mutant peptides is almost completely unexplored at a systems biology level [15], 
as are cancer-specific RNA edits and tumour-specific spliced mRNAs that create cancer-associated 
polypeptide epitopes. In addition, different mass spectrometers, sample preparation and pre-
fractionation methods, coupled to tumor heterogeneity, result in an incomplete understanding in 
the source and extent of expressed mutated proteins using cancer-specific DNA and/or RNA 
sequencing reference databases. 
 
There are several types of platforms recently developed for integrating DNA, RNA and protein data 
integration. ‘Proteoformer’ produces a complete protein synthesis database that can be used to 
identify peptides with mass spectrometry through the use of ribosome profiling [16]. The 
limitation of this approach is that living cells are required to isolate bioactive ribosomes and this 
method might not be conducive to frozen tissues from the clinic. Methods have been established 
for automating spliced variants in cell systems which is especially powerful in cancer genomes 
where there might be DNA fusions, cancer-specific splicing, and trans-splicing [17] [18]. Spliced 
variant detection algorithms are always improving, especially those that capture the pathological, 
heterogeneous splicing specific to cancer cells [19]. Modification of R-packages iterates 
innovations in identifying expressed mutated genes [20]. Translation toolkits have been generated 




































































six-frame genome translation [21]. These examples highlight the types of several bespoke 
algorithms that generate cutting-edge information on the proteogenomic landscape. As the 
diversity in software and computational tools tend not to be benchmarked against each other, 
end-user compatibility, especially crossing different disciplines, can be limited or non-accessible. 
 
In this report, we focus first on benchmarking two distinct DNA and RNA variant calling platforms 
towards identifying the mutant proteome landscape in a biological human cancer cell model. One 
of the variant detection platforms; CLCbio, is an integrated DNA and RNA variant identification 
software platform. This software has been used previously in variant detection using human 
cancer tissue [22] [23] although it was not benchmarked against more classic variant calling 
platforms. The utility of the CLCbio application is that it is a tool not requiring computational 
coding and can therefore open the door for life-scientists to identify tissue or cell-specific genomic 
variants relevant to the biological system of interest. Such an application for life-scientists that 
does not require coding already exists for research in the mass spectrometric field, such as 
Proteome Discoverer [24]. The most common coding-dependent genome analysis toolkits for DNA 
variant detection are platforms such as Varscan and Mutect [25]. In this current study, we not only 
benchmark both the CLCbio software and Varscan2 platforms, we also use these data to create a 
mutant reference dataset to define mutated proteins in a key cancer cell model. We focus our 
biological question on asking an emerging topic in the cancer research field; how does inactivation 
of a major cancer-associated gene impact on the mutant proteome landscape? We answer this 
question by creating an isogenic melanoma cell panel with a p53 gene inactivation to define 




Using CLCbio and Varscan2 DNA variant detection platforms to develop a mutant genomic 
reference database using a human melanoma cancer cell line model. 
The human melanoma A375 cell line has classically been used as a model to study regulation of 
wt-p53 activity in response to DNA damage [26] [27]. Next generation DNA sequencing of the 
A375 wt-p53 containing melanoma genome was performed in order to annotate its genome. This 
also produces a community resource that can be used to develop proteogenomics tools and 
pipelines for use in studying both mutated proteome expression and/or neoantigen production. 
The majority of next-generation data analysis using DNA variant detectors derived from Varscan or 
Mutect requires computational coding skills [25]. By contrast, the CLCbio platform that has been 
developed as an independent variant detection platform for life-scientists with plug-ins that do 
not require computational coding to define variants [22]. In this report, we benchmark both 
CLCbio and Varscan2 as two independent variant detection platforms to define the overlap in their 
mutation detection and define their dual utility in creating a mutant genomic reference database 
for optimizing mutant peptide detection using mass spectrometry (Fig. 1). 
 
Exome Sequencing of DNA derived from A375 cells was performed using Agilent V5+UTR Exome 
Capture Kit and 100 bp paired-end reads were acquired using a coverage of 100x. Paired fastq files 
were imported into the CLC Biomedical Genomics Workbench 3. Adaptor sequences and bases 
with low quality were trimmed, DNA sequencing reads were mapped to the human reference 
genome hg19, and sequences were filtered through dbSNP databases to remove “common” 
germline variants. A total of 120,325 DNA variants were detected at a frequency of 5% or higher at 
the threshold used (Supplementary Table 1A). Filtering this list of tumour specific variants to a 
frequency of 40% or higher in order to capture the most dominant mutant alleles in the cell 





































































When the CLCBio variant calling platform was compared to Varscan2 using the hg19 reference 
database, as well as the more recently updated hg38 reference genome, then 85,793 shared 
variants were detected (Fig. 2A). The CLCbio platform detected more variants than Varscan2 at the 
thresholds used; 36,065 variants were unique to CLCbio using the hg38 reference genome; 17,824 
variants were unique to CLCBio using the hg19 reference genome, and 3,180 variants were unique 
to Varscan2 using the hg38 reference genome (Fig. 2A). Because CLCbio generally identified more 
variants than Varscan2, we focused on using this platform to optimize mutant peptide detection 
by mass spectrometry (Fig. 1).  
 
Using CLCbio RNA variant detection platform to develop a mutant peptide reference database from 
a human melanoma cancer cell line  
Of the filtered CLCbio DNA variants detected (Supplementary Table 1B), 20,419 were synonymous 
mutations within exons, 41,993 variants resided out with exons, and the 1,468 were non-
synonymous mutations. This number of non-synonymous mutations is within the expected range 
of a tumour like melanoma which has a relatively high number of single nucleotide variants 
(Supplementary Table 2). The 1,468 protein-coding variants were derived from 884 genes, 
including single-nucleotide polymorphisms, in frame-insertions, and in-frame deletions. This list is 
very conservative and could be expanded by including DNA sequencing reads below the 40% 
threshold level (Supplementary Table 1B). Representative CLCbio browser views summarizing DNA 
variants are represented in Fig. 2B and 2C. 
 
We next used shotgun RNAseq data derived from A375 cells to identify expressed mutated genes 
under conditions in which more liberal variant calling in the DNA variant files could be tolerated. 
RNAseq from A375 cells was performed using human total RNA, depleted of ribosomal RNA, 
followed by random priming to generate cDNA. From this template paired-end Illumina HiSeq2500 
was used to generate approximately 20 million reads. Paired fastq files (available upon request) 
from RNAseq reads were imported into the CLC Biomedical Genomics Workbench 3. The RNA 
sequencing reads were mapped to the human reference genome hg19, and sequences were 
filtered through the A375 cancer genome sequence where at least 2 mutant DNA reads were 
identified, then dbSNPs were removed, to identify mutated and expressed genes. A total of 18,341 
expressed non-synonymous mRNA variants were identified with a cutoff of 5% of the total RNA 
reads defined as mutated (Supplementary Table 3). 
 
Although DNA variant calling would typically rule out the annotation of 1 mutant DNA sequencing 
read, we also filtered the fastq DNAseq files (Supplementary Table 2) against fastq RNAseq data 
(Supplementary Table 3) with a stringent cutoff requiring at least 40 mutated RNA sequencing 
reads (e.g. relatively highly expressed mutant alleles) and filtered against a more liberal DNA 
variant cutoff of at least 1 mutant genomic DNA sequencing read. This produced 5,980 RNA 
variants including synonymous, non-synonymous, and non-exonic mutations (Supplementary 
Table 4). Upon filtering for non-synonymous variants, a list was generated composed of 1,418 
non-synonymous highly expressed RNA variants encoded by 976 mutant genes (Supplementary 
Table 5). We then determined the overlap of the 1,468 CLCbio derived DNA variants using the 
stringent DNA variant calling (Supplementary Table 2) to the 1,418 expressed mutated RNA 
variants identified using liberal DNA variant calling but requiring high levels of mutated mRNA 
reads; e.g. a highly expressed mutated gene (Supplementary Table 5). 
 
The first thing to note is that the list of highly expressed mutant genes selected based on the 




































































the number of DNA sequencing reads (Fig. 2D). Only 107 variant genes are shared in this subset. 
One example of an overlap between the DNA and RNA variant calling cutoff highlight the 
expressed mutant RNA derived from a mutant gene is the gpatch4 gene (Fig. 2E). This gene is 
homozygous mutant (Supplementary Table 1A and B). A total of 877 out of 985 genes with 
expressed RNA variants are not present in the original DNA variant list (Supplementary Table 6). 
This produces a mutant gene expression rate of 107/774 or 12.1%. The true value will be higher 
than 12.1% since we removed RNA variants that exhibited lower than 40 reads. This mutant gene 
expression frequency is in lower range of ~30% previously published; previous studies have shown 
that 36% of validated somatic SNVs were observed in the transcriptome sequence when RNAseq 
data was compared with the genomes/exomes data in breast cancer [28] and similar proportions 
were also observed in a lymphoma study in which 137 somatic mutations were expressed in 
RNAseq, out of 329 total somatic mutations [29]. 
 
Mutated protein identification using the A375 DNA genomic reference database 
We next aimed to define the extent to which the DNAseq or DNA+RNAseq reference databases 
could be used to identify mutated peptides by mass spectrometry. Proliferating A375 cells were 
lysed and protein was processed using the FASP (Filter-aided sample preparation) method [30]. 
Measured spectra were processed in ProteinPilot 4.5 search engine where a Swiss-prot and 
TrEMBL reference search database (Supplementary Table 7) was used (as described below) [31]. 
This produced a file of 949 wild-type proteins identified at FDR<1%. In order to determine whether 
any of these wild-type identified proteins are mutated, we next filtered the 1,468 non-
synonymous DNA variant set (Supplementary Table 2) with the 949 detectable protein set 
(Supplementary Table 7) to generate a list of 42 potential mutant polypeptide sequences (Table 1). 
Only one high confidence mutated tryptic peptide covering a sequence of mutated protein from 
this group was identified. The peptide was derived from the ribosomal protein rpl14 (Fig. 3A and 
3B). The mutant peptide spectrum and the fragmentation summary were exported from the 
ProteinPilot 4.5 search engine (Fig. 3C and 3F). The wt-rpl14 peptide covering the same position in 
protein sequence was also observed (Fig. 3D and 3E) which is consistent with the heterozygous 
mutation identified by DNA sequencing (Fig. 3A).  
 
Limitations of mass spectrometry to identify mutated protein sequences.  
There could be several reasons why the majority of these mutated proteins might not be 
detectable using mass spectrometry. First, as 18 out of the 42 proteins from this group have a 
homozygous gene mutation (Supplementary Table 1 and Table 1), these 18 expressed proteins 
presumably are mutated. However, there were no mutated tryptic peptides derived from any of 
these 18 proteins. This highlights a general difficulty in relying on mass spectrometry to confirm 
the expression of mutated proteins. The number of identified peptides covering any one protein is 
rarely “100%”. For example, the tryptic coverage of rpl14 highlights just this problem, as only two 
out of over 16 theoretical tryptic peptides (over 8 aminoacids of greater in length) could be 
detected (Fig. 3B). Serendipitously, one of these two peptides covered the mutant region (Fig. 3C 
and 3F). Other reasons for the absence of mutant peptide detection is that the mutant tryptic 
peptide could be relatively small (e.g. less than six amino acids in length) and therefore difficult to 
confidently match to corresponding MS/MS spectrum. For example, the protein LRCC59 has an in-
frame triplet nucleotide insertion resulting in a Q amino acid insertion (Lys137_Pro138insGln) 
resulting in the tryptic penta-peptide QPFPK. It is difficult to identify this mutated peptide, 
unambiguously, as being derived from LRCC59 as there are several proteins in the human 
proteome that could yield this amino acid sequence after trypsinization at the sequence KQPFPK. 
The inability to detect such mutant tryptic peptides from any of the 18 proteins derived from 




































































highlights the need to include different proteases in sample preparation or derive a larger pool of 
tryptic peptides from which to search for mutated peptides. Nevertheless, users of this A375 cell 
model as a resource might want to consider these 18 proteins (with no detectable mutant tryptic 
peptides) expressed from homozygous mutated genes to be bona-fide mutant proteins.  
 
Mutated protein identification using mass spectrometry with the A375 mutant RNA reference 
database 
As mutant peptides were not detectable to a high degree using the DNAseq-only files, we focused 
on using the RNAseq files stratified by 40 or more mutated mRNA reads derived from wt-p53 A375 
cells (Supplementary Table 5) to create a mutant search database. We also next initiated an 
additional pipeline approach that was used to increase number of detectable proteins by pre-
fractionating the peptides using an orthogonal LC method (Fig. 1). The orthogonal approach 
incorporated a reverse phase high pH acetonitrile gradient generating ten fractions that were 
infused for peptide identification using a TripleTOF 5600+ mass spectrometer. Employing peptide 
pre-separation step increased the coverage of total wild-type peptides to over 35,000 (FDR<1%) 
with a coverage of over 4,500 wild-type proteins (FDR<1%) (Supplementary Table 8). 
 
Integrating the RNAseq derived mutant search database (Supplementary table 8) to the 2D LC-
MS/MS data increased the number of identified mutant peptides to 193 (Supplementary Table 9). 
Although the ProteinPilot 4.5 search engine determines the confidence of identified mutated 
peptides, we needed to manually inspect the spectra in each of these 193 proteins to produce a 
list of mutated peptides that were identified based on y and b fragment ions covering the mutated 
amino acid in the mutated peptide sequence. Applying this procedure excludes the possibility that 
we identified wild-type peptides and narrowed the list down to 60 verified mutated proteins (Fig. 
4).  
 
Methodologies for validation of mutated peptides in the wt-p53 A375 cell model. 
Mutated peptide identification in A375 fractions was further examined using targeted mass 
spectrometry in pseudo-selected reaction monitoring mode (pseudo-SRM) on TripleTOF 5600+ 
mass spectrometer. Ten isotope labeled mutant tryptic peptides were acquired (Fig. 5B) to 
validate ten of the 60 mutant tryptic peptides identified in data-dependent mode (Fig. 5A). We 
optimized isotope labelled peptide spike-in into A375 lysates (Fig. 5C and 5D) to yield optimal 
product ion intensity. Comparing the retention times and product ion intensity patterns in product 
ion chromatograms of naturally occurring intrinsic peptide and isotope labelled peptide enabled 
us to determine whether the naturally occurring peptide is present. All ten of the mutant peptides 
were successfully validated by this methodology.  
 
As an example, verification of two mutated peptides is shown in Fig. 6A and 6B. Fragmentation 
evidences described in Fig. 6A and 6B show all possible product ions that represent two selected 
high confidence mutated peptides (peptide confidence > 99%) identified in 2D LC-MS/MS data 
(VSGSPEQAVEENLSSYFLDR and IIPTVLMTEDIK peptides). Only underlined product ion masses 
represent identified product ions that confirm the presence of amino acid mutation in the peptide 
sequence. The fragmentation evidence of the VSGSPEQAVEENLSSYFLDR mutated peptide 
highlights 11 product ions confirming the S to F mutation, whilst the fragmentation evidence of 
the IIPTVLMTEDIK mutated peptide shows only 3 product ions confirming the A to P mutation. The 
fragmentation evidences in Fig. 6A and 6B clearly show that the probability of an amino acid 
mutation is not reflected in the peptide confidence determined in ProteinPilot 4.5 software. 
Therefore, it is important to evaluate the spectra/fragmentation evidence to accurately define 




































































isotope labelled reference peptide and its light naturally occurring variant is shown in Fig. 6C. All 
results from SRM validation of mutant peptides using SRM are summarized in Supplementary 
Table 10 and Fig. 6D. Taken together Fig. 6 summarizes all steps, that were taken to validate any of 
the selected mutated peptides. 
 
Mutated proteomics: Creating a p53-null A375 melanoma cell line as an isogenic model system to 
define p53-dependence in mutated cancer genome protein expression patterns.  
We finally aimed to use this optimized DNA and RNAseq variant detection pipeline (Fig. 1) to ask a 
key biological question; how does inactivation of the tumour suppressor p53 gene impact on the 
mutant proteome landscape? The human melanoma A375 cell line has classically been used as a 
model to study regulation of wt-p53 activity in response to DNA damage [26] [27]. We thus 
focused on using CRISP-R gene editing to develop an A375 cell line with an isogenic p53-null 
status. The guide RNA encoding a targeting sequence near the ARG175 codon in the p53 gene (Fig. 
7A) was transfected into cells, single cells were isolated following cell sorting, and individual clones 
were selected based on absence of p53 induction after X-irradiation (data not shown). Nine 
independent p53-edited clones were obtained (data not shown). One A375 p53-null cell clone was 
taken forward with the edits as indicated in Fig. 7B and 7D. The sequences across the breakpoint 
in edited p53 alleles (Fig. 7) results in a stop codon (Fig. 7C and 7E). Immunoblotting of lysates 
using the N-terminal epitope antibody DO-1 confirmed that the A375 p53-null cells do not express 
p53 protein, nor do the HCT116 p53-null cells (Fig 7F). In addition, MHC Class I protein (HLA-B 
allele) was also determined to be elevated in the p53-null cells (Fig 7G). We also observed 
elevated HLA-A and HLA-C alleles in p53-null cells (data not shown), further highlighting the utility 
of this p53 –null cell as a tool to study in the future how p53 status impacts upon mutated protein 
expression as well as mutant peptide presentation by the MHC Class I system. 
 
SWATH (Sequential Windowed Acquisition of all Theoretical Mass Spectra) was used as a 
complementary methodology to further determine the presence of target mutated peptides and 
to evaluate an effect of p53 inactivation on mutated protein levels. We first set-up large scale 
SWATH quantitation on TripleTOF 5600+ mass spectrometer and focused towards two mutated 
proteins that were previously verified and validated in wt-p53 A375 cells; PYGB and PLEC (Fig. 8). 
We extracted product ion chromatograms corresponding to these mutated peptides using a 
product ions m/z’s included in a spectral library derived from data-dependent measurement of 
same sample. We found high correlation between product ion intensity pattern in extracted 
product ion chromatograms and the product ion intensities in spectral library for both peptides 
(Fig. 8A, 8B, 8D, 8E). Following quantification of the PYGB mutant peptide using three technical 
replicates obtained from A375 p53-null cells and A375 p53 wild-type cells shows an up-regulation 
of the PYGB (LIINLVTSIGDVVNHDPVVGDR) mutated tryptic peptide in A375 null cells. However, the 
quantification we observed based on the set of automatically intensity based selected product 
ions does not specifically represent the mutated peptide, and as such we cannot rule out the 
possibility that the quantitative data are derived from wild-type tryptic peptide. Therefore, as a 
robust SWATH pipeline we would again recommend to carefully select product ions referring 
uniquely to the mutation in a peptide sequence. In case of PYGB mutated peptide 
(LIINLVTSIGDVVNHDPVVGDR) it would be ions encompassing b4 – b21 and y19 – y21. The set of 
automatically selected product ions from spectral library contains y6, y16, y17, y9 (Fig. 8A). 
Therefore, SWATH quantitation of peptide LIINLVTSIGDVVNHDPVVGDR does not uniquely refer to 
the mutated peptide form and could be biased by changes in wild-type form. 
 
We next extracted quantitative SWATH data for mutated peptide from PLEC (SIITYVSSLYDTMPR) 




































































quantitative data referring to product ions that uniquely involve mutated amino acid in the 
product ion sequence. The mutated peptide SIITYVSSLYDTMPR must be quantitated by any 
product ions encompassing b12 – b15 and y4 – y15. The set of automatically selected product ions 
from spectral library for quantitation of SIITYVSSLYDTMPR 3+ contains y4, y5, y6, y7 (Fig. 8D). 
Therefore, quantitation of the mutated peptide refers uniquely to mutated peptide form. The 
corresponding spectral library evidence and product ion intensity rank in product ion 
chromatogram are highlighted (Fig. 8D and 8E) along with the quantitation of mutated peptides in 
three technical replicates of A375 p53-null cells and A375 p53 wild-type cells (Fig. 8F). As a control, 
SWATH quantitation of a control peptide VAPEEHPVLLTEAPLNPK (ACTB) was used to evaluate 
quantitative differences as a consequence of deleting the p53 gene in A375 cell line, differences in 
sample loading, and the possible effects of sample preparation on MS analysis (Fig. 8G). 
 
Differences in mutant protein expression in wt-p53 and p53-null cells. 
We finally determined the major differences in mutant peptides enriched between wt-p53 and 
p53-null cells using CLCBio and Varscan variant detection platforms. Parameters were set requiring 
at least 10 mutant mRNA variants and 1 mutant DNA variant. Using CLCbio, there were 190 
mutant peptides detected enriched in wt-p53 cells, with 187 mutated peptides enriched in the 
p53-null cells (Fig. 9A). The largest number of mutant peptides were detected using CLCbio when 
compared to Varscan (Fig. 9B and 9C). Using STRING protein annotation, we evaluated the 
dominating mutant protein networks defined (Fig. 10 and 11). 
 
In cells containing wt-p53 there were dominating peptides that could be used to highlight mutated 
protein networks centered on CDC5L (Fig. 11, center). The CDC5L network in turn is linked to a 
mutant protein splicing network composed of SRSF7, SF35B, SLU7, CSTF3, and YBX1. In turn these 
networks also connect to mutant proteins in DNA repair pathways including POLR1b, ERCC2, 
FANCD2, XRCC6, and others (Fig. 10). By comparison, the STRING analysis in p53-null cells 
highlighted a different dominating mutant proteome. This consisted of a ribosomal mutant protein 
network including RPL5 and RPL26L (Fig. 11). This node was in turn connected to a mutant 
ubiquitin protein node including USP7, UBE2V2, USP9X, and MRE11. An independent node 
composed of mutant proteins was present in kinase signalling including EGF, YES1, PPP2CB, CSK, 
and PPP2R5C (Fig. 11). Together, these data highlight that inactivation of the p53 gene can switch 
the expression of distinct mutant protein signalling nodes encoded by a cancer genome. This in 
part, can shed light on how tumour cells adapt to gene mutation by changing the expression of 





The identification of mutated proteins in human cancer cells can assist in defining expressed, 
mutated oncogenic signalling landscapes as well as facilitating the identification of potential 
neoantigen vaccine ligands. Most often, proteomics studies using cancer cell lines uses a normal 
reference proteome and under-estimates mutated protein signalling functions. We report on an 
optimized pipeline for identifying tumour variants in A375 cells using; (i) the CLCBio integrated 
DNA and RNA variant calling platform; (ii) the incorporation of RNAseq to stratify highly expressed 
variants; (iii) the use of 2D LC-MS/MS to identify potentially mutated peptide sequences in a 
tumor cell line; and (iv) the use of manual spectral annotation and SRM to estimate a false 
discovery rate of mutant peptides using LC-MS/MS. Our pipeline has identified high confidence list 
of protein mutations in the A375 cell line and its p53-null derivative (Supplementary Tables 13 and 




































































shotgun mass spectrometry to identify mutated peptides. This underestimates the extent of 
mutant protein expression in the A375 cell because of; (i) incomplete tryptic coverage of any one 
given protein; (ii) we only included very abundant mutant mRNA species (with relatively high 
numbers of reads; i.e. >40) to create a reference database of relatively highly expressed mutant 
genes; and (iii) stringent manual annotation of mutated peptides identified in the mass spectra 
eliminates some likely mutant peptides from the dataset.  
 
We focused this study on using a human melanoma has emerged as a cancer type with one of the 
highest rates of single-nucleotide variation in a cancer genome and this tumour type is expected 
to form important models to define mutated protein expression networks [32]. As a result, 
melanoma patients can benefit from cancer-specific immuno therapeutics that exploit this high 
rate of mutated protein production [33]. Understanding how cancer associated genes impact on 
steady-state mutant protein expression levels and ultimately neoantigen assembly into the MHC 
Class I pathway has thus recently gained more relevance. Thus, it is important to begin to develop 
isogenic cancer cell models with specific cancer gene mutations to accelerate our understanding 
of how mutant protein production and re-wired mutated signalling proteins are enhanced in 
cancer cells. This could facilitate developing new therapeutics that exploit mutant protein or 
mutated pathway expression. We focused here on applying these methods to the question of how 
p53 gene inactivation can impact on mutant protein expression in an isogenic melanoma cell 
model. 
 
P53 protein has been termed the guardian of the genome [34]. The p53 gene is one of the most 
frequently mutated in the vast majority of cancers [35] leading to loss of wt-function and 
enhanced genome instability [36]. It is therefore interesting that the majority of human 
melanomas retain wt-p53 alleles [32], possibly because the selections pressures driving the 
survival of cells with a mutant p53 gene is reduced due to frequent inactivation of the p53 
regulatory cdkn2a locus in melanoma. Oesophageal adenocarcinoma also has very high rate of 
single nucleotide variation [37] but also a high rate of both p53 gene mutation and cdkn2a 
mutation [38]. These data might suggest there could be two distinct pathways that drive a high 
rate of single nucleotide variation in a cancer genome via attenuation of wt-p53 function (as in 
melanoma) or mutation in the p53 gene (as in oesophageal adenocarcinoma). We focus in this 
report on generating an isogenic wt and p53-null cell panel using CRISP-R/CAS9 gene editing 
methodology to define how loss of p53 can impact on a mutant proteomic landscape. Integrating 
genomics, RNA expression, and mass spectrometric data produces a baseline mutant protein 
library in melanoma that can be used as a community resource to facilitate interrogation of signal 
transduction pathways in this model. A similar cancer cell model has been developed in 
oesophageal adenocarcinoma that has the features of high rate of single nucleotide variation, but 
which has mutations in the p53 tumour suppressor gene [39]. Using our optimized pipelines, we 
define specific sets of mutant proteins that are differentially expressed as a result of p53 gene 
status. These data indicate that loss of a tumour suppressor gene such a p53 can begin to switch 
expression of the mutated protein landscape in a tumour cell (Fig. 10 and 11).  
 
One impact of this pipeline will be in the future identification of tumour-specific mutated proteins 
that can be processed by the MHC Class I pathway; neoantigens. Within this list of mutant 
proteins detected in the A375 cell line, we were also able to identify some trimmed peptides that 
have a predicted high affinity for MHC class I peptides as defined using netMHC 4.0 [40], based on 
our isotyping that A375 cells have the MHC Class I alleles, HLA-A*-3:01 and HLA-B*07:02. One of 




































































10mer LPNIQAVLL for HLA-B*07:02 is 518.5 nM and the predicted affinity of the mutant-10mer 
LPNIQAVVL for HLA-B*07:02 is 87.8 nM. Additionally, SRP14, with a P124A mutation resulted in a 
mutant 10mer APAAAATAA peptide with a predicted affinity of 17.9 nM for HLA-A*03:01 whilst 
the wt-peptide APAAAATAP peptide with a predicted affinity of 641.5 nM for HLA-A*03:01. Such 
datasets will provide neoantigen models to study MHC Class I peptide flux in this A375 cell line. 
 
A second impact of this pipeline will be on mutant proteomics studies. We have used a gene 
editing tool (CRISP-R) to begin to ask a biological question on how loss of p53 can impact on the 
mutant protein landscape. Pathway annotation using STRING provides evidence for mutated 
protein expression in pathways including adhesion, ubiquitination, metabolism, and DNA repair. 
Mutant protein expression in a cancer cell line provides another way of thinking about 
‘proteomics’ compared to its usual application which is examining protein expression in a cancer 
cell line using a ‘normal’ reference protein database. When screening the mass spectral data from 
A375 cells and the p53-null A375 cells against the mutant genomic reference databases, we 
identified a relatively high overlap in the proteins identified between the two cell lines (Fig. 9A). 
This might not be unexpected since p53 is stress activated. On the other hand, the difference in 
the proteome between the two cell lines (Fig. 9A) also highlights the fact that inactivation of the 
p53 gene did give rise to spontaneous changes in some mutated proteins without further selection 
pressures. Future studies could examine how loss of p53 in this isogenic model impacts on 
radiation or GAS/STING-dependent mutant protein signalling. Together, our study produces a well 
annotated mutant proteome of this A375 cell line model, coupled to the application of an 
integrated variant detection platform (CLCbio), that can be used to detect high confident mutant 
proteins cells. This can facilitate the use of this isogenic model as a resource to identify the p53-
dependence on the mutant proteome and normal proteome landscape. 
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Materials and Methods 
P53 knockout using the CRISPR/CAS9 system. 
The p53-specific gRNA sequence was 5’-CTGAGCAGCGCTCATGGTGGNGG-3’, which was designed 
by Applied StemCell, Inc. The gRNA was cloned into pBT-U6-CAS9-2A-GFP expression vector from 
Applied StemCell, Inc. The P53 knockout in A375 cell line was performed as described before with 
minor alterations [41]. Briefly, 3x105/well A375 cells [27] were seeded in 6-wells plates. 24 hours 
later, cells were transfected with pBT-U6-CAS9-2A-GFP expression vector using Attractene 
Transfection Reagent (QIAGEN, UK). 48 hours later, mutations were tested using a Surveyor 
Mutation Detection Kit (Integrated DNA Technologies, USA) and GFP positive cells were sorted and 
collected by BD FACSCanto II (BD Bioscience, USA). GFP positive cells were seeded in 96 wells 
plates 1 cell/well for colony formation. After 2 weeks, all colonies were collected and tested by 
western blot using the in-house developed DO-1 monoclonal antibody to demonstrate loss of p53 
protein (Fig 7F) and sequencing to validate p53 gene editing in the A375 cell lines. The HLA-B 
antibody was from Thermofisher (PA5-35345). The loading control for immunoblotting (Fig 7F) 




































































mouse monoclonal anti-β-actin (Sigma). The HCT116 wt and p53-null  cells were a gift of Dr. B 
Vogelstein (Johns Hopkins University, USA). 
 
CLCbio variant calling. 
Next generation DNA sequencing of the A375 wt-p53 containing melanoma cell line was 
performed in order to annotate its genome. Exome Sequencing was performed using Agilent 
V5+UTR Exome Capture Kit (75Mb) and 100 bp paired-end reads were acquired using a coverage 
of 100x. Paired fastq files from the A375 cell line (available upon request) from DNA-exome 
libraries were imported into the CLC Biomedical Genomics Workbench 3. Adaptor sequences and 
bases with low quality were trimmed, DNA sequencing reads were mapped to the human 
reference genome hg19, and sequences were filtered through dbSNP databases to remove 
“common” germline variants. A total of 120,325 tumour specific variants were detected at a 
frequency of 5% or higher when the threshold was set at calling variants detected in at least two 
variant DNA sequencing reads in the exome data from A375 cells (Supplementary Table 1A). 
RNAseq from A375 cells was performed using human total RNA, depleted of ribosomal RNA, 
followed by random priming to generate cDNA. From this template paired-end Illumina HiSeq2500 
was used to generate approximately 20 million reads. Paired fastq files (available upon request) 
from RNAseq reads were imported into the CLC Biomedical Genomics Workbench 3. The RNA 
sequencing reads were mapped to the human reference genome hg19, and sequences were 
filtered through the A375 cancer genome sequence where at least 2 mutant DNA reads were 
identified, then dbSNPs were removed, to identify mutated and expressed genes. A total of 18,341 
expressed non-synonymous mRNA variants were identified with a cutoff of 5% of the total RNA 
reads defined as mutated (Supplementary Table 3). 
 
Varscan2 variant calling. 
The same paired fastq files from the A375 cell line (as used for CLCbio analysis, above) from DNA-
exome libraries were used for following analysis pipeline. Variant calling was performed using 
Varscan, adaptor sequences and bases with low quality (QualityScore < 30) were trimmed by 
FASTX-Toolkit version 0.0.14 (Retrieved from http://hannonlab.cshl.edu /fastx_toolkit), DNA 
sequencing reads were mapped to the human reference genome hg19 and hg38 (by TopHat2 [42]) 
(See Fig. 1), and results were imported into VarScan2 [43]. Sequences were filtered through dbSNP 
databases to remove “common” germline variants. A total of 101,072 tumor specific variants 
(coverage 1 DNA mutation) and 10,545 non-synonymous mutations were detected using hg38 
(coverage 1 DNA mutation; See Supplementary Table 11). A total of 17,822 tumor specific variants 
were obtained from RNA seq (using a minimal cutoff of 10 mutated RNA reads) and 2,662 were 
classified as a non-synonymous RNA mutation (using a minimal cutoff of 10 mutated RNA reads). A 
total of 5,590 tumor specific variants were obtained from RNA seq (using a minimal cutoff of 40 
mutated RNA reads, data not shown) and 1,007 were classified as non-synonymous RNA 
mutations (using a minimal cutoff of 40 mutated RNA reads). The number of 2,461 tumor specific 
variants from the wt-p53 A375 cell line (1 DNA mutation and at least 10 mutant RNA reads) and 
945 tumor specific variants from the p53-null cell line (1 DNA mutation and at least 10 mutant 
RNA reads), were used as the input file for reference database to identify mutant peptides using 
mass spectrometry Supplementary Table 12. A comparison of the DNA mutations detected using 
Varscan and CLCbio are summarized in Fig. 2 and the number of mutated peptides detected, using 
either Varscan or CLCbio driven analysis are summarized in Fig. 9. 
 
Peptide sample preparation for MS. 
Cells were plated and grown on five 10 cm Petri dishes to 80% confluence. Cells were harvested 




































































facilitated using needle sonication in three 4 second cycles and protein concentration was 
determined using RC-DC assay (Bio-Rad, USA). An aliquot corresponding to 200 µg of protein was 
digested to peptides using Filter-aided sample preparation (FASP) [30]. Briefly, cell lysate was 
mixed with 200 µl of urea buffer and added to centrifugation filter unit Vivacon 500 with 10 kDa 
cut-off (Sartorius Stedim Biotech, Germany) followed by centrifugation (15000 g/ 20 min/ RT). 16.7 
mM TCEP in urea buffer was added to filter unit to reduce disulphide bridges in protein. Reduction 
was done on thermomixer (600 rpm/ 30 min/ 37˚C) followed by centrifugation (15000 g/ 20 min/ 
RT). Sample alkylation was performed in the darkness for 20 min at RT with 300 mM 
Iodoacetamide in urea buffer followed by centrifugation (15000 g/ 20 min/ RT). Buffer was 
exchanged to 100 mM NH4HCO3 using 3 washes to enable efficient trypsin digestion of samples. 
Proteins were digested in 100 µl of 50 mM NH4HCO3 buffer where 1 µg of trypsin was added per 
each 33 µg of protein to be digested. The samples were mixed with digestion buffer at 600 rpm on 
thermomixer for 1 min before incubation for 18 h in a wet chamber, 37˚C. Peptides were eluted 
from the filter by centrifugation (15000 g/ 20 min/ RT). To increase peptide recovery 0.5 M NaCl 
was added followed by centrifugation (15000 g/ 20 min/ RT). Peptide samples for direct MS 
analysis were desalted on Micro SpinColumns C18 (Harvard Apparatus, USA). First, C18 columns 
were conditioned twice with 100% acetonitrile (AcN)/ 0.1% formic acid (FA), centrifuged at (120 g/ 
2 min/ RT), and washed with 0.1% FA followed by centrifugation (200 g/ 2 min/ RT). The columns 
were hydrated for 15 min in 0.1% FA, centrifuged (200 g/ 2 min/ RT). Samples were loaded to 
columns and centrifuged (550 g/ 2 min/ RT). Next, the columns were washed thrice with 0.1% FA. 
Peptide elution was done using 50% AcN/ 0.1% FA in water, 80% AcN/ 0.1% FA in water and 100% 
AcN/ 0.1% FA. The peptide eluates were evaporated using a SpeedVac and dissolved in 5% AcN/ 
0.05% trifluoroacetic acid (TFA) in water. Concentration of peptides was determined in each 
sample on NanoDrop 2000 (Thermo Scientific, USA) at 220 nm and 280 nm prior MS analysis. 
 
RP-basic fractionation using spin columns. 
FASP digested peptide samples for RP-basic fractionation were separated in basic pH (pH 10) on 
Macro SpinColumns C18 (Harvard Apparatus, USA) packed with C18 sorbent. First, mobile phase A 
composed from 10 mM ammonium formate (AF) in water pH 10 and mobile phase B composed 
from 10 mM AF in 90% AcN pH 10 were prepared [44]. C18 columns were conditioned twice with 
mobile phase A followed by centrifugation at (200 g/ 2 min/ RT). Columns were then washed with 
mobile phase B followed by centrifugation (300 g/ 2 min/ RT). Columns were hydrated for 15 min 
using mobile phase A, centrifuged (300 g/ 2 min/ RT). Peptide samples were added to hydrated 
columns and centrifuged (650 g/ 2 min/ RT). Next, the columns were washed thrice with mobile 
phase A. Peptide separation into 11 fractions was done using a step gradient composed from 
5% B + 95% A, 9% B + 91% A, 13% B + 87% A, 17% B + 83% A, 21% B + 79% A, 25% B + 75% A, 
35% B + 65% A, 50% B + 50% A, 80% B + 20% A and 100% B. Ten fractions were evaporated using a 
SpeedVac concentrator. Each fraction was dissolved in 100 µl of 50% methanol and then 
evaporated in SpeedVac concentrator. This step was repeated three times to get rid of volatile 
salts. Dried samples were dissolved in 20 µl of 5% AcN / 0.05% TFA. Concentration of peptides was 
determined in each sample on NanoDrop 2000 (Thermo Scientific, USA) at 220 nm and 280 nm 
prior MS analysis. 
 
Spiking sample with reference heavy peptides. 
JPT synthetic heavy reference peptides (JPT, Germany) derived from 10 mutant peptide 
candidates were ordered with isotopically labelled amino acids. A content of the vial containing 
heavy reference peptide was dissolved in 5% AcN + 0.05% TFA in water to prepare 1.43 nmol/µl 
stock solution. Next, LOD of each peptide was determined (data not shown). A pool representing 




































































concentration and injection volume was set based on crude Nanodrop measurement A220 and 
A280) in order to load onto the column an identical amount of reference peptide corresponding to 
at least 10 times LOD. Three µl of this mixture were injected onto nano-LC-MS/MS to perform 
pseudo-SRM analyses in analytical triplicates. 
 
LC setup for analysis of fractions. 
Eksigent Ekspert nanoLC 400 system (AB-SCIEX, USA) nano-LC system was used for peptide 
concentration and separation. Peptides were concentrated and desalted on a cartridge trap 
column (300 μm i.d. × 5 mm) packed with C18 PepMap100 sorbent with 5 μm particle size 
(Thermo Fisher Scientific, MA, USA). Peptides were 10 min washed using 0.05% TFA in 5% AcN in 
water. Separation was performed on a 25 cm fused-silica emitter column with 75 μm inner 
diameter (New Objective, USA), packed in-house with ProntoSIL C18 AQ 3 μm beads (Bischoff 
Analysentechnik GmbH, Germany). LC solvents were composed from 0.1% FA in water (solvent A) 
and 0.1% FA in AcN (solvent B). Sample was eluted in a 120 min gradient starting at 5% B up to 
40% B with a flow rate 300 nL/min in DDA and SWATH experiments while 61 min gradient starting 
at 5% B up to 40% B with a flow rate 300 nL/min was used in pseudo-SRM experiments. Peptides 
eluting from column were ionized in nano-electrospray and entered mass spectrometer. 
 
Shotgun MS/MS (DDA). 
Mass spectrometer TripleTOF 5600+ (AB-SCIEX, Toronto, Canada) operated in data dependent 
mode. Each cycle was accompanied with fragmentation of top 20 most intense precursor ions. 
Exclusion time was set to 12 seconds. Minimum precursor ion intensity was set to 50 cps and 100 
milliseconds accumulation time per precursor. Shotgun were searched using ProteinPilot 4.5 (AB-
SCIEX, Canada) against custom built human mutant proteome reference database derived from 
human reference database (Uniprot+Swissprot 2016_2) and against wild-type human reference 
proteome database (Uniprot+Swissprot 2016_2). Search parameters were set as follows: trypsin 
protease, carbamidomethyl (C) (fixed). Protein FDR was determined by searching MS/MS data 
against decoy databases. 
 
Building-up custom search library with mutant protein sequences. 
MS/MS data from fractions were inspected for presence of MS/MS spectra corresponding to 
genes identified as high confidence RNA and DNA variant hits. Amino acid sequences 
corresponding to these genes were listed in a mutant search database where a mutant position in 
a protein was inserted based on genomic data. Mutant search database was assembled in FASTA 
format. Corresponding wild-type FASTA sequences of protein forms were downloaded from the 
human (2016_2) reference database. A custom mutant FASTA file containing mutant and WT 
forms of proteins was created in a text editor and subsequently imported into ProteinPilot 4.5. 
Quality of mutant IDs was inspected in ProteinPilot 4.5. (AB-SCIEX, USA), focusing mainly to a 
peptide covering mutation position in a sequence. Spectral evidence of high and mid confidence 
mutant peptides (peptide confidence > 95% and between > 50% and < 95%) was manually 
inspected. In mutant peptides we focused to corresponding product ions directly proving a shift in 
mass as a consequence of mutation. A protein referred as “mutant” had covered potential 
mutation position by high or mid confidence peptides bearing substitution, insertion, deletion of 
amino acid in its sequences. On the other hand, a protein referred as “wild-type” has a place of 
potential mutation covered by wild-type sequence of a high or mid confidence peptide. 
Identification of mutant or wild-type form was accomplished by Uniprot BLAST of peptide 






































































SWATH method for label free quantification was developed according to previously published 
methods [45] [46] [47]. TripleTOF 5600+ (AB-SCIEX, Canada) operated in high sensitivity positive 
polarity SWATH mode. Effective precursor range was selected from 400 amu up to 1200 amu and 
the cycle time was set to 3.5 seconds. An optimal SWATH width was 13 Da including 1 Da overlap 
resulting in a method with 67 SWATH windows. Accumulation time per SWATH was 50 
milliseconds. Product ion range was scanned from 360 amu up to 1360 amu and rolling collision 
energy was used with collision energy spread (CES) of 15 mV.  
 
Building-up wild-type spectral library and SWATH quantification of wild-type proteins. 
PeakView software 1.2.0.3 (AB-SCIEX, Canada) was used to index 1045 proteins FDR 1% in a 
spectral library. Retention time window was set to 2.5 min to the left and 2.5 min from expected 
retention time. Protein quantitation was based on extracting peak areas for four peptides per 
protein and 6 product ions per each peptide. Extracted quantitative data from three technical 
replicates were statistically evaluated in MarkerView 1.2.1.1 (AB-SCIEX, Canada). Pairwise T-test 
was performed to determine protein fold changes and P values of fold change for all proteins 
listed in spectral library. 
 
Building up a mutant spectral library and SWATH quantification of mutant proteins. 
Results from mutant database MS/MS search were imported into Skyline-daily (64-bit) software 
version 2.6.1.6899 (MacCoss Lab, WA, USA) where the mutant spectral library was generated. 
FASTA sequences of 10 candidate mutant proteins listed in Supplementary Table 10 were 
imported into Skyline software. Results from mutant peptides are shown in Supplementary Table 
10. An example of mutant peptides from RPL14 and PLEC is shown in Fig. 8. Peptide settings were 
as follows: digestion – trypsin, 1 missed cleavage was permitted, length of peptide was in range 
from 7 – 25 amino acids, 25 amino acids from N-terminus were excluded, carbamidomethyl was 
set as structural (fixed) modification. Transition settings were as follows: precursor charge was 2+, 
3+ or 4+, fragment charge 1+, fragment series y or b, product ions, fragment ions from 3 up to last, 
including the N-terminal fragment to proline. After data extraction, start and end points of each 
peak in extracted product ion chromatogram were inspected manually. We checked co-elution of 
selected product ions, product ion ranks according to the spectral library, retention times across 
replicates, and data acquisition modes to confirm peak identity. Peak areas corresponding to 
mutant peptides were evaluated and visualized in Skyline software. 
 
Pseudo-SRM analysis. 
The TripleTOF 5600+ (AB-SCIEX, Canada) was operated in high sensitivity positive mode. Each cycle 
involved one TOF-MS scan with 250 ms accumulation time and 38 product ion scans of 70 
milliseconds accumulation time per precursor. Total cycle time was 3.0 seconds. Product ions were 
scanned in a range from 100 to 1800 amu. Pseudo-SRM data were analysed in Skyline. Sequences 
of ten mutated peptide candidates were imported into the Skyline version 2.6.1.6899 (MacCoss 
Lab, WA, USA) with the following settings: Peptide settings were as follows: digestion – trypsin, 1 
missed cleavages were permitted, length of peptide was in range from 7 – 25 amino acids, 0 amino 
acids from N-terminus were excluded, carbamidomethyl was set as structural (fixed) modification, 
heavy isotope peptide labeling 13C 15N on lysine, arginine and leucine was permitted. Transition 
settings were as follows: precursor charge was 2+, 3+, fragment charge 1+, fragment series y or b, 
product ions, fragment ions from 3 up to last, including the N-terminal fragment to proline. After 
data extraction, start and end points of each peak in extracted product ion chromatogram were 
inspected manually. We checked co-elution of selected product ions, product ion-rank according 
to the spectral library, retention times across replicates, and data acquisition modes to confirm 




































































Skyline software. dot-product (dotp) correlation for the ratio of the observed SRM peak intensities 
of a peptide in a specific biological matrix as correlation of observed SRM peak intensities of a 
peptide in a specific biological matrix versus the reference isotope labelled peptide were 
calculated. Peptides considered as high-quality validated hits showed good signal and dotp>0.9 






































































Figure 1. Experimental plan for optimizing mutant protein detection in cell models. Two different 
variant calling platforms, CLCBio and Varscan, were used to identify DNA variants from the A375 
cell line. Shotgun RNA seq was then performed on both parental and p53-null A375 cell lines to 
create a mutant expressed reference database for both cell lines. This mutant RNA database forms 
the reference from which mutant proteins will be identified using fractionation of the mutant 





Figure 2. Representative variant calls from mutated genes. (A). Summary of the number of DNA 
mutations detected using the CLCBio and Varscan variant calling platforms. (B and C). Example 
CLCbio browser highlights mutated genes including a single nucleotide variant (MEIS1, chr2, 
66691338) and an and in-frame insertion (SYNGR1, chr22, 39777822). The data are plotted by (i) 
chromosome position including hg19 reference genome (top, numbering); (ii) intron-exon 
boundaries. The thick line and thin line represent the exon and intron, respectively. Reference sets 
include: the blue line, that highlights ensemble v74 gene locus; the green line that represents 
ensemble v74 mRNA; and the yellow line that represents ensemble v74, CDS; (iii) highlights some 
of the DNA sequencing reads in blue aligned to hg19 with the DNA mutation variant (in A and B) 
highlighted by a color change and arrow. (D). An analysis of shared DNA v RNA mutations in A375 
cells. A comparison of the overlap of variants detected in RNAseq and DNAseq filtered through 
distinct processes. The variants identified by DNAseq were filtered based on the presence of at 
least 4 mutant sequencing reads and at least a 50% frequency. A total of 1,468 variants were 




































































40 mutant RNA sequencing reads and at least 1 mutation in the DNAseq. This generated a 
different list of 1,418 mutated genes with highly expressed mutated RNA. Fusing the datasets 
produces a relatively small overlap of 107 common variants. The data suggest that the majority of 
mutated genes with a high confidence variant calling (774/887) are not highly expressed. E. An 
example of one of the 107 shared mutated RNA and DNA CLCbio defined variants from the data 
filtered in Fig. 2D. GPATCH4 RNAseq reads are highlighted as an example containing a frame-shift 











































































Figure 3. Identification of mutated rpl14 protein in A375 cells. The reference mutated DNA 
database was used to screen peptide spectra for evidence of mutant tryptic peptides. One mutant 
protein was detected by this method; rpl14. (A). The rpl14 mutation is generated by an in-frame 
insertion of 6 bases encoding an AlaAla. The mutation is heterozygous as defined by the presence 
of 12 mutant reads and 11 wild-type reads (from Supplementary Table 1 and highlighted in the 
browser view by gaps in the sequence that matches the hg19 reference). The data are plotted by 
(i) chromosome position including hg19 reference genome (top, numbering); (ii) intron-exon 
boundaries. The thick line and thin line represent the exon and intron, respectively. Reference sets 
include: the blue line, that highlights ensemble v74 gene locus; the green line that represents 
ensemble v74 mRNA; and the yellow line that represents ensemble v74, CDS; (iii) highlights some 
of the DNA sequencing reads in blue aligned to hg19 with the DNA mutation variant highlighted by 
a color change and arrow. (B). The mutant protein tryptic coverage of rpl14 protein with the green 
highlighting high confident detection of two tryptic peptide sequences in (in green). (C and F). The 
mutant tryptic sequence containing 12 strings of alanine GTAAAAAAAAAAAAK (mass 1156.60) has 
a 99% confidence of identification after fragmentation using ProteinPilot and there is no other 
such peptide in the human database. (D and E). The wild-type sequence containing 10 strings of 
alanine GTAAAAAAAAAAAAK (mass 957.5117) was also detected and has a 90% confidence of 
identification using ProteinPilot and there is no other such peptide in the human database. The 






































































































































































Figure 4. Optimization of mutant peptide identification using combined RNAseq and 2D LC-
MS/MS datasets. A mutated reference search database file was based on RNAseq expression data 
(Supplementary Table 5) and then used to search 2D LC-MS/MS data leading to an increase in the 
number of peptides derived from potentially mutant proteins to 193 (Supplementary Table 9). The 
spectra in each of these were manually evaluated for the presence of y and b fragment 
ions that cover mutated amino acids characteristic by a m/z shift relative to product ions derived 
from the wild-type peptide. The data highlight successfully inspected mutated peptide candidates 
with an evidence of mutation in their peptide sequence. Tabulated are; Uniprot 
accession; mutation; mutated peptide sequence; peptide confidence; peptide charge state; 
peptide modifications and miscleavages; and product ions providing evidence of mutation 
(product ions that covered the mutant position in a peptide). The underlined peptides in the 















































































































































Figure 5. SRM validation of mutant peptide levels. (A). A List of identified mutated proteins and 
(B). corresponding peptides selected for validation using pseudo-selected reaction monitoring 
(pseudo-SRM). (B).highlights peptide sequences with green letters representing amino acids that 
are isotope labelled in the reference peptides. Red letters represent positions in peptide 
sequences that are mutated. (C). and (D). represent optimization of isotope labelled reference 
peptide QRVDEFEAL spiked-in into the A375 lysate. Extracted product ion chromatogram (C). 
shows intensity of SRM transitions from QRVDEFEAL mutated reference isotope labelled peptide 
at various concentrations, while D shows peak areas of corresponding product ions (y3 - y8). From 
(C). and (D). we determined that optimal spike in of QRVDEFEAL reference peptide is 
approximately 14.3 fmol which corresponds to a 10,000x dilution of stock reference peptide 











































































Figure 6. Extracted product ion chromatograms for SRM validated mutated peptides. (A). and 
(B). a list of product ions representing two selected high confidence mutated peptides (peptide 
confidence > 99%) identified using the 2D LC-MS/MS data. Product ions labelled with brown color 
were identified in the LC-MS/MS spectra of VSGSPEQAVEENLSSYFLDR and IIPTVLMTEDIK peptides 
(A. and B., respectively). Underlined product ion masses represent identified product ions that 
confirm presence of the amino acid mutation in the peptide sequence. (A). Fragmentation 
evidence of the VSGSPEQAVEENLSSYFLDR mutated peptide highlights 11 product ions confirming 
the S to F mutation. (B). Fragmentation evidence of the IIPTVLMTEDIK mutated peptide identifies 
only 3 product ions confirming the A to P mutation. The fragmentation evidences clearly highlight 
that the probability of amino acid mutation is not reflected in peptide confidence; therefore, these 
two peptides are shown as an example that it is important to evaluate the spectra/fragmentation 
evidence to determine mutant sequence status. (C). and (D). example of pseudo-SRM quantitation 
of the SIITYVSSLYDTMPR peptide referencing the heavy and light peptide titrations and defining 
key features required for high confidence validation (1-5) and other peak features (1-3). Left 
section of (C). highlighted in red shows product ions representing light and heavy form of peptide. 
While product ion chromatograms show MS/MS signal of these product ions across the LC run. 
(D). Tabulated results from a pseudo-SRM validation of selected mutated peptides using isotope 
labelled reference peptides. The table highlights sequences and charge states of the mutated 
peptides (the first and the second columns) followed by columns with key characteristics of the 
product ions representing intrinsic or reference mutated peptides in a sample. The third column 
defines the consistency of retention times among the reference and intrinsically mutated 
peptides. The intrinsic peptide must have an identical retention time to the reference peptide as 
its chromatographic characteristics remain unchanged by isotope labelling. The fourth column 
defines the intensity of the intrinsic and the reference mutated peptide. Both peptides must have 
a sufficient intensity (peak height) to be considered as detected. A peptide is defined as detected 
when its intensity is at least 3 times the background noise of the method (noise of pseudo-SRM 
was approximately 100 counts per second) according to FDA directions. The fifth column filters 
out wild-type peptides; the spectra of which could overlay with the spectra of the mutated 
peptides. We list detected product ions as having the characteristic mass shift of a mutated amino 
acid; this further validates the existence of a mutated peptide. The higher the number of product 
ions with the characteristic mass shift of mutated amino acid, the higher the confidence of a 
mutated peptide. The sixth column describes the similarity of an intensity pattern between the 
intrinsic and the mutated peptide. The ionization efficiency of both peptides must be the same, 
therefore we expect the same intensity rank of product ions in both peptides. We inspected 
corresponding product ion chromatograms and we selected only product ions that show similar 
patterns in terms of the intensity. The higher the number of product ions the higher the similarity 
between the intrinsic and the reference mutated peptide. The seventh column shows dotP value. 
This value reflects and summarizes the similarity between the intrinsic and the reference mutated 
peptide. It ranges in between 0 to 1 and the higher the value is, the higher the similarity of both 
peptides. Usually, pseudo-SRM validated peptides have high dotP values. The last column 
summarizes values determined from the pseudo-SRM assay. Peptides with an excellent pseudo-
SRM evidence could be considered as certainly validated. Abbreviations: L = (light) naturally 
occurring intrinsic form of mutated peptide, H = (heavy) reference isotope labelled peptide, WT = 











































































































































Figure 7. Generating a melanoma cell line with a p53-null status using CRISP-R mediated gene 
editing. (A). Position of guide RNA-binding motif. Guide RNAs targeting exon 5 of the p53 gene 
were cloned into pBT-U6-CAS9-2A-GFP. The intron-exon-intron sequence of the p53 gene is 
highlighted along with the position and orientation of the guide RNA (reverse arrow; in blue with 
the PAM sequence in red). A375 melanoma cells were transfected with the guide RNA and clones 
were selected using GFP selection by FACS followed by plating for single cells. Individual cells were 
grown and screened for evidence of gene editing and p53 activation status. (B and D). DNA 
sequencing. Sequence of the chromosomal DNA derived from the p53 knock-out cells by 
amplification of the chromosomal region using PCR primers flanking the guide RNA target motif. (C 
and E). Translation of the gene edits produces theoretical stop codons. (F and G). Immunoblotting 
to define the p53 and HLA expression status. (F). Lysates from A375 (wt and p53-null) and HCT116 
cells (wt and p53-null) were immunoblotted with the p53 antibody DO-1. This antibody binds to 
the N-terminal domain of p53. A loading control was detecting PCNA using the PC10 antibody. (G). 
Cell lysates from the indicated A375 variants (wt and -/-), as SiHa cells (as a control, C) were 







































































Figure 8. SWATH quantitation pipeline of mutated peptides in isogenic p53 wt and null cell 
panels. (A). An example of extracted product ion chromatogram corresponding to a mutated 
peptide from Glycogen phosphorylase, brain form (PYGB) detected using SWATH acquisition in 
A375 cell lysate. A legend in the right shows rank of the most intensive product ions from mutated 
peptide. (B). A spectral library MS/MS spectrum corresponding to peptide 
LIINLVTSIGDVVNHDPVVGDR. An intensity-based product ion rank in spectral library should be 
identical to product ion rank in product ion chromatogram to consider peptide hit as valid. (C). 
Quantification using three technical replicates between A375 p53-null cells and A375 p53 wild-
type cells shows an up-regulation of mutated peptide in A375 null cells. Here, as problematic we 
see a quantification on a set of product ions which might refer also to wild-type peptide form. 
Therefore, we recommend inspecting a set of selected product ions for quantitation and filter out 
only product ions uniquely covering the mutant position in a peptide sequence. In case of PYGB 
LIINLVTSIGDVVNHDPVVGDR mutated peptide it is b4 – b21 and y19 – y21 and in case of PLEC 
mutated peptide SIITYVSSLYDTMPR it is b12 – b15 and y4 – y15. (D). Extraction of product ion 
chromatogram for SIITYVSSLYDTMPR mutated peptide (PLEC). SIITYVSSLYDTMPR quantitation 
refers more uniquely to the mutated peptide form compared to quantitation of  
LIINLVTSIGDVVNHDPVVGDR peptide. It relies on product ions that are characteristic exclusively for 
mutant peptide form (y4, y5, y6, y7). (E). Shows corresponding spectral library for 
SIITYVSSLYDTMPR mutated peptide and intensity rank of product ions. (F). Shows quantitation of 
SIITYVSSLYDTMPR mutated peptide in three technical replicates of A375 p53-null cells and A375 
p53 wild-type cells. Relative quantitation of both mutated peptides in A375 p53- and A375 WT cell 
line (C). and (F). was determined from a sum of 4 product ion peak areas by integration of AUC. 
Bar graph (C and F). represents peak areas corresponding to these 4 product ions. Overall peptide 
quantity in each replicate is represented by an entire bar. (G). SWATH quantitation of a control 































































































































































Figure 9. Summary of mutated peptides detected using the optimized platforms. Using both 
CLCbio (CLC) and Varscan (VS), variants were detected requiring at least 10 RNA mutant reads and 
1 DNA mutant read. A. A comparison of the enriched mutant peptides detected in wt-p53 vs p53-
null cells using mass spectral data summarized in Supplementary Tables 13 and 14. B and C. 
Summarizes the mutant tryptic peptides detected in wt-p53 or p53-null cells, using CLCbio and 
Varscan platforms. The reference database generated from the DNA and RNAseq was converted 
to protein amino acid sequences by TransPEM [47] and subsequently this reference database was 







































































Figure 10. STRING analysis of mutant protein networks in wt-p53 cells. STRING (https://string-
db.org) is a database of protein-protein interactions including direct experimental data, indirect 
functional associations, from computational prediction, from knowledge transfer between 
organisms, and from interactions aggregated from additional primary databases [48]. The known 
interactions are defined as: curated databases (_____), and experimentally determined (_____). The 
predicted interactions are defined as: gene neighborhoods (_____), gene fusions (_____), gene co-
occurrence (_____), textmining (_____), co-expression (_____), and protein homology (_____). The 
minimum required interaction score was defined as high confidence (0.7). STRING was used to 
define interaction networks composed of mutant proteins in the wt-p53 cell tryptic peptide 
dataset that differ from p53-null cells. The mutant peptides from wt-p53 cells are summarized in 









































































Figure 11. STRING analysis of mutant protein networks in p53-null cells. STRING was used as in 
Fig. 10 to define interaction networks composed of mutant proteins in the p53-null cell tryptic 
peptide dataset that differs from wt-p53 cells. The known interactions are defined as: curated 
databases (_____), and experimentally determined (_____). The predicted interactions are defined as: 
gene neighborhoods (_____), gene fusions (_____), gene co-occurance (_____), textmining (_____), co-
expression (_____), and protein homology (_____). The minimum required interaction score was 
defined as high confidence (0.7). The mutant peptides from p53-null cells are summarized in 












































































TABLE 1. SWATH-MS analysis of proteins whose genes are mutated using wt-p53 and p53-null 
A375 cells. The table highlights gene name, amino acid substitution, and fold change in the 
expression of wt vs p53-null cells. Only one protein on this list has a mutated peptide detected 
using mass spectrometry (rpl14, Fig. 3). The other 18 proteins with homozygous mutations do not 





























































































Supplementary Table 1A. Excel file showing a list of mutated genes with mutations detected at a 
5% frequency or higher in DNA from A375 cells using the CLCbio variant platform detector. The 
analysis identified 120,325 genes. Represented are data including chromosome number and 
position, reference allele and mutation type, zygosity, Count (mutation number) and coverage 
(total sequencing reads), frequency of mutation, gene cards name, ensemble qualifiers, amino 
acid change, coding region change (Syn or non-syn), and dbSNP identifiers. Supplementary Table 
1B. Excel file showing a list of mutated genes detected at a 40% frequency or higher in DNA from 
A375 cells (from Supplementary Table 1A) using the CLCbio variant detector. This analysis 
generated 63,880 variants with mutations. The data are plotted as a function of; chromosome; 
region; type of mutation; reference base; allele base; reference allele; zygosity; count; coverage; 
frequency of mutation; gene card name; ensemble name; gene name; gene biotype; transcript 
name; coding region change; amino acid change; amino acid change in longest transcript; other 
variants in codon; whether the mutation is non-synonymous, synonymous, or out with exons; and 
dbsnp reference. 
 
Supplementary Table 2. Excel file showing a list of mutated genes with non-synonymous 
mutations detected at a 40% frequency or higher in A375 cells (from Supplementary Table 1B) 
using the CLCbio variant detector. This analysis generated 1,468 genes with non-synonymous 
mutations. The data are plotted as a function of; chromosome; region; type of mutation; 
reference base; allele base; reference allele; length of change; zygosity; count; coverage; 
frequency of mutation; probability; forward read count; reverse read count; ratio; average quality; 
exact match to dbsnp; gene card name; ensembl name; gene name; gene biotype; transcript 
name; coding region change; amino acid change; amino acid change in longest transcript; other 
variants in codon; whether the mutation is non-synonymous, synonymous, or out with exons; and 
dbsnp reference. 
 
Supplementary Table 3. Excel file showing RNA sequencing reads mapped to the human reference 
genome hg19, with dbSNPs removed, to identify mutated and expressed genes. A total of 18,341 
expressed non-synonymous mRNA variants were identified with a cutoff of 5% of the total RNA 
reads defined as mutated. The data are plotted as a function of; chromosome; position; type of 
mutation; reference; allele; reference allele; length of change; zygosity; RNA count; RNA coverage; 
RNA frequency; RNA forward reads; RNA reverse reads; DNA read count; DNA read coverage; gene 
card name; ensemble name; gene name; transcript ID; coding region change; amino acid change; 
and whether the mutation is non-synonymous, synonymous, or out with exons. 
 
Supplementary Table 4. Excel file showing RNAseq data with a stringent cutoff requiring at least 
40 mutated RNA sequencing reads and filtered against genomic DNA cutoff of at least 1 mutant 
genomic DNA sequencing read.  This produced 5,980 RNA variants including synonymous, non-
synonymous, and non-exonic mutations. The data are plotted as a function of; chromosome 
number; type of mutation; zygosity; gene card name; ensemble name; gene name; amino acid 
change; and whether the mutation is non-synonymous, synonymous, or out with exons.  
 
Supplementary Table 5. Excel file showing RNAseq data with a stringent cutoff requiring at least 
40 mutated RNA sequencing reads and filtered against genomic DNA cutoff of at least 1 mutant 
genomic DNA sequencing read (from Supplementary Table 4). Upon filtering for non-synonymous 
variants, a list was generated composed of 1,418 non-synonymous highly expressed RNA variants. 




































































line, as there are many mutated mRNAs quantified at reads from 39 and lower. However, we focus 
on those mutant mRNA species which are abundant, perhaps not degraded by NMD or perhaps 
not resulting from expression of minor subclones in the A375 cell population. 
 
Supplementary Table 6. Excel file showing a subset of genes acquired after the list composed of 
1,418 non-synonymous highly expressed RNA variants (Supplementary Table 5) with the 1,468 CLC 
genomic DNA variants using the stringent DNA variant calling (Supplementary Table 2). The excel 
file highlights a total of 877 out of 985 genes with expressed mRNA variants are not present in the 
original DNA variant list. 
 
Supplementary Table 7. Excel file showing the tryptic peptides processed using SWATH mass 
spectrometry to identify proteins differentially expressed in the wt and p53-null cells using the 
normal reference proteome Swiss-prot and TrEMBL (potential mutant proteins from this are listed 
in Table 1). 
 
Supplementary Table 8. Excel file showing tryptic peptides identified from shotgun mass 
spectrometry including a pre-fractionation step to increase the coverage of total peptides to over 
35,000 with a coverage of over 4,500 proteins. (A). represents data from wt-A375 cells and (B). 
represents data from p53-null A375 cells.  
 
Supplementary Table 9. Excel file showing a subset of proteins listed by selecting proteins from 
the expressed (mRNA) and mutated genes detectable in the shotgun 2D LC-MS/MS experiment 
(Supplementary Table 8A and 8B) using the RNA variant file (Supplementary Table 5). Applying 
RNAseq derived mutant search database to search the 2D LC-MS/MS data, this increased the 
number of detectable mutant peptides to 193. Of this selection, we manually validated all spectra 
from the 193 peptides and we produced data (Fig. 4) of 60 mutated proteins of relatively high 
confidence. Of these 60 mutant proteins, 10 were validated by SRM (Fig. 5; Supplementary Table 
10) to produce a conservative FDR of 20%. Thus, 4 out of 5 of the manually validated, high 
confidence mutated peptides are likely to be mutated. 
 
Supplementary Table 10. Excel file showing results summary of SRM mass spectrometry 
analysis in a subset of 10 mutated proteins. Evaluating similarity of product ion peakgroups 
referring to neopeptides is summarised by dotp value ranging from 0 to 1. Neopeptides with dotp 
above 0.9 and with more than 2 product ions above LOD (three times noise) are considered as 
successfully validated. Abbreviation H refers to spiked-in "heavy" isotope labelled neopeptide and 
L refers to endogenous "Light" form of neopeptide. 
 
Supplementary Table 11. A list of DNA variants detected using VarScan2 using a minimal 
coverage of 1 and hg38.  
Supplementary Table 12. A list of RNA variants detected using VarScan2 using a minimal 
coverage of 10 and hg38.  
Supplementary Table 13. Mutant tryptic peptide lists derived from lysates from wt-p53 cells 
using CLCbio software. 
Supplementary Table 14. Mutant tryptic peptide lists derived from lysates from p53-null cells 
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Background: The identification of mutated proteins in human cancer cells-termed 
proteogenomics, requires several technologically independent research methodologies including 
DNA variant identification, RNA sequencing, and mass spectrometry. Any one of these 
methodologies are not optimized for identifying potential mutated proteins and any one output 
fails to cover completely a specific landscape.  
Methods: An isogenic melanoma cell with a p53-null genotype was created by CRISPR/CAS9 
system to determine how p53 gene inactivation affects mutant proteome expression. A mutant 
peptide reference database was developed by comparing two distinct DNA and RNA variant 
detection platforms using these isogenic cells. Chemically fractionated tryptic peptides from 
lysates were processed using a TripleTOF 5600+ mass spectrometer and their spectra were 
identified against this mutant reference database.  
Results: Approximately 190 mutated peptides were enriched in wt-p53 cells, 187 mutant peptides 
were enriched in p53-null cells, with an overlap of 147 mutated peptides. STRING analysis 
highlighted that the wt-p53 cell line was enriched for mutant protein pathways such as CDC5L and 
POLR1B, whilst the p53-null cell line was enriched for mutated proteins comprising EGF/YES, 
Ubiquitination, and RPL26/5 nodes. 
Conclusion: Our study produces a well annotated p53-dependent and p53-independent mutant 
proteome of a common melanoma cell line model. Coupled to the application of an integrated 
DNA and RNA variant detection platform (CLCbio) and software for identification of proteins 
(ProteinPilot), this pipeline can be used to detect high confident mutant proteins in cells. 







































































Next-generation genome sequencing technologies have revolutionized our understanding of the 
molecular nature of cancer [1] [2]. Parallel innovations in combinatorial chemistry, 
crystallography, high-throughput drug screening, transgenesis, and computational science have 
rapidly generated hundreds of promising targeted drug leads. However, despite this increased 
R&D, the number of effective drugs reaching the clinic is in steady decline [3]. A technical problem 
is the lack of robust age-dependent sporadic immune competent models of human cancer that 
predicts human toxicity and response [4]. Another major hurdle is that sporadic cancers are multi-
gene diseases thus minimizing the likelihood of finding a common (set of) drug(s) to improve 
patient welfare. 
 
Whole genome cancer sequencing has defined the strikingly patient-specific cancer bar code thus 
highlighting the unique genetic signature of any given tumour [5] [6]. However, the vast majority 
of anti-cancer medicines target wild-type proteins, although there are ever emerging successes in 
targeting mutated kinases with effective drug leads [7]. This presents an opportunity to develop 
precision, personalized therapeutics based on expressed, mutant proteins. Such mutant proteins 
could inform target pathway choice for the development of novel Biologics that target the 
mutated cancer landscape in a patient-specific manner [8]. Understanding the expression of 
mutant proteins could also form a platform for the development of mutant neoantigen based anti-
cancer vaccines, that could be based on synthetic proteins [9], dendritic cells primed with 
neoantigens [10], nucleic acids such as RNA [11], or synthetic viral vectors [12]. However, the 
study of mutant proteomes is only in its infancy. The relative difficulty in this task is that building 
mutant proteomes requires integration of robust and user-friendly methods linking the fields of 
informatics, mass spectrometry, and cancer biology. This task is not necessarily trivial. 
 
Computational methodologies as applied to the cancer research field are emerging as approaches 
to define the expressed, mutated genome. There are several challenges with optimizing platforms 
that integrate DNA sequencing, RNA sequencing, and mass spectrometric datasets [13]. One 
overall challenge is integrating these molecular data into one pipeline; and depends on the variant 
detection platform used for DNA sequencing; the algorithms for defining mutations with RNA 
sequencing datasets in exons, non-coding RNAs, and introns [14]. For example, the expression of 
intron encoded mutant peptides is almost completely unexplored at a systems biology level [15], 
as are cancer-specific RNA edits and tumour-specific spliced mRNAs that create cancer-associated 
polypeptide epitopes. In addition, different mass spectrometers, sample preparation and pre-
fractionation methods, coupled to tumor heterogeneity, result in an incomplete understanding in 
the source and extent of expressed mutated proteins using cancer-specific DNA and/or RNA 
sequencing reference databases. 
 
There are several types of platforms recently developed for integrating DNA, RNA and protein data 
integration. ‘Proteoformer’ produces a complete protein synthesis database that can be used to 
identify peptides with mass spectrometry through the use of ribosome profiling [16]. The 
limitation of this approach is that living cells are required to isolate bioactive ribosomes and this 
method might not be conducive to frozen tissues from the clinic. Methods have been established 
for automating spliced variants in cell systems which is especially powerful in cancer genomes 
where there might be DNA fusions, cancer-specific splicing, and trans-splicing [17] [18]. Spliced 
variant detection algorithms are always improving, especially those that capture the pathological, 
heterogeneous splicing specific to cancer cells [19]. Modification of R-packages iterates 
innovations in identifying expressed mutated genes [20]. Translation toolkits have been generated 




































































six-frame genome translation [21]. These examples highlight the types of several bespoke 
algorithms that generate cutting-edge information on the proteogenomic landscape. As the 
diversity in software and computational tools tend not to be benchmarked against each other, 
end-user compatibility, especially crossing different disciplines, can be limited or non-accessible. 
 
In this report, we focus first on benchmarking two distinct DNA and RNA variant calling platforms 
towards identifying the mutant proteome landscape in a biological human cancer cell model. One 
of the variant detection platforms; CLCbio, is an integrated DNA and RNA variant identification 
software platform. This software has been used previously in variant detection using human 
cancer tissue [22] [23] although it was not benchmarked against more classic variant calling 
platforms. The utility of the CLCbio application is that it is a tool not requiring computational 
coding and can therefore open the door for life-scientists to identify tissue or cell-specific genomic 
variants relevant to the biological system of interest. Such an application for life-scientists that 
does not require coding already exists for research in the mass spectrometric field, such as 
Proteome Discoverer [24]. The most common coding-dependent genome analysis toolkits for DNA 
variant detection are platforms such as Varscan and Mutect [25]. In this current study, we not only 
benchmark both the CLCbio software and Varscan2 platforms, we also use these data to create a 
mutant reference dataset to define mutated proteins in a key cancer cell model. We focus our 
biological question on asking an emerging topic in the cancer research field; how does inactivation 
of a major cancer-associated gene impact on the mutant proteome landscape? We answer this 
question by creating an isogenic melanoma cell panel with a p53 gene inactivation to define 




Using CLCbio and Varscan2 DNA variant detection platforms to develop a mutant genomic 
reference database using a human melanoma cancer cell line model. 
The human melanoma A375 cell line has classically been used as a model to study regulation of 
wt-p53 activity in response to DNA damage [26] [27]. Next generation DNA sequencing of the 
A375 wt-p53 containing melanoma genome was performed in order to annotate its genome. This 
also produces a community resource that can be used to develop proteogenomics tools and 
pipelines for use in studying both mutated proteome expression and/or neoantigen production. 
The majority of next-generation data analysis using DNA variant detectors derived from Varscan or 
Mutect requires computational coding skills [25]. By contrast, the CLCbio platform that has been 
developed as an independent variant detection platform for life-scientists with plug-ins that do 
not require computational coding to define variants [22]. In this report, we benchmark both 
CLCbio and Varscan2 as two independent variant detection platforms to define the overlap in their 
mutation detection and define their dual utility in creating a mutant genomic reference database 
for optimizing mutant peptide detection using mass spectrometry (Fig. 1). 
 
Exome Sequencing of DNA derived from A375 cells was performed using Agilent V5+UTR Exome 
Capture Kit and 100 bp paired-end reads were acquired using a coverage of 100x. Paired fastq files 
were imported into the CLC Biomedical Genomics Workbench 3. Adaptor sequences and bases 
with low quality were trimmed, DNA sequencing reads were mapped to the human reference 
genome hg19, and sequences were filtered through dbSNP databases to remove “common” 
germline variants. A total of 120,325 DNA variants were detected at a frequency of 5% or higher at 
the threshold used (Supplementary Table 1A). Filtering this list of tumour specific variants to a 
frequency of 40% or higher in order to capture the most dominant mutant alleles in the cell 





































































When the CLCBio variant calling platform was compared to Varscan2 using the hg19 reference 
database, as well as the more recently updated hg38 reference genome, then 85,793 shared 
variants were detected (Fig. 2A). The CLCbio platform detected more variants than Varscan2 at the 
thresholds used; 36,065 variants were unique to CLCbio using the hg38 reference genome; 17,824 
variants were unique to CLCBio using the hg19 reference genome, and 3,180 variants were unique 
to Varscan2 using the hg38 reference genome (Fig. 2A). Because CLCbio generally identified more 
variants than Varscan2, we focused on using this platform to optimize mutant peptide detection 
by mass spectrometry (Fig. 1).  
 
Using CLCbio RNA variant detection platform to develop a mutant peptide reference database from 
a human melanoma cancer cell line  
Of the filtered CLCbio DNA variants detected (Supplementary Table 1B), 20,419 were synonymous 
mutations within exons, 41,993 variants resided out with exons, and the 1,468 were non-
synonymous mutations. This number of non-synonymous mutations is within the expected range 
of a tumour like melanoma which has a relatively high number of single nucleotide variants 
(Supplementary Table 2). The 1,468 protein-coding variants were derived from 884 genes, 
including single-nucleotide polymorphisms, in frame-insertions, and in-frame deletions. This list is 
very conservative and could be expanded by including DNA sequencing reads below the 40% 
threshold level (Supplementary Table 1B). Representative CLCbio browser views summarizing DNA 
variants are represented in Fig. 2B and 2C. 
 
We next used shotgun RNAseq data derived from A375 cells to identify expressed mutated genes 
under conditions in which more liberal variant calling in the DNA variant files could be tolerated. 
RNAseq from A375 cells was performed using human total RNA, depleted of ribosomal RNA, 
followed by random priming to generate cDNA. From this template paired-end Illumina HiSeq2500 
was used to generate approximately 20 million reads. Paired fastq files (available upon request) 
from RNAseq reads were imported into the CLC Biomedical Genomics Workbench 3. The RNA 
sequencing reads were mapped to the human reference genome hg19, and sequences were 
filtered through the A375 cancer genome sequence where at least 2 mutant DNA reads were 
identified, then dbSNPs were removed, to identify mutated and expressed genes. A total of 18,341 
expressed non-synonymous mRNA variants were identified with a cutoff of 5% of the total RNA 
reads defined as mutated (Supplementary Table 3). 
 
Although DNA variant calling would typically rule out the annotation of 1 mutant DNA sequencing 
read, we also filtered the fastq DNAseq files (Supplementary Table 2) against fastq RNAseq data 
(Supplementary Table 3) with a stringent cutoff requiring at least 40 mutated RNA sequencing 
reads (e.g. relatively highly expressed mutant alleles) and filtered against a more liberal DNA 
variant cutoff of at least 1 mutant genomic DNA sequencing read. This produced 5,980 RNA 
variants including synonymous, non-synonymous, and non-exonic mutations (Supplementary 
Table 4). Upon filtering for non-synonymous variants, a list was generated composed of 1,418 
non-synonymous highly expressed RNA variants encoded by 976 mutant genes (Supplementary 
Table 5). We then determined the overlap of the 1,468 CLCbio derived DNA variants using the 
stringent DNA variant calling (Supplementary Table 2) to the 1,418 expressed mutated RNA 
variants identified using liberal DNA variant calling but requiring high levels of mutated mRNA 
reads; e.g. a highly expressed mutated gene (Supplementary Table 5). 
 
The first thing to note is that the list of highly expressed mutant genes selected based on the 




































































the number of DNA sequencing reads (Fig. 2D). Only 107 variant genes are shared in this subset. 
One example of an overlap between the DNA and RNA variant calling cutoff highlight the 
expressed mutant RNA derived from a mutant gene is the gpatch4 gene (Fig. 2E). This gene is 
homozygous mutant (Supplementary Table 1A and B). A total of 877 out of 985 genes with 
expressed RNA variants are not present in the original DNA variant list (Supplementary Table 6). 
This produces a mutant gene expression rate of 107/774 or 12.1%. The true value will be higher 
than 12.1% since we removed RNA variants that exhibited lower than 40 reads. This mutant gene 
expression frequency is in lower range of ~30% previously published; previous studies have shown 
that 36% of validated somatic SNVs were observed in the transcriptome sequence when RNAseq 
data was compared with the genomes/exomes data in breast cancer [28] and similar proportions 
were also observed in a lymphoma study in which 137 somatic mutations were expressed in 
RNAseq, out of 329 total somatic mutations [29]. 
 
Mutated protein identification using the A375 DNA genomic reference database 
We next aimed to define the extent to which the DNAseq or DNA+RNAseq reference databases 
could be used to identify mutated peptides by mass spectrometry. Proliferating A375 cells were 
lysed and protein was processed using the FASP (Filter-aided sample preparation) method [30]. 
Measured spectra were processed in ProteinPilot 4.5 search engine where a Swiss-prot and 
TrEMBL reference search database (Supplementary Table 7) was used (as described below) [31]. 
This produced a file of 949 wild-type proteins identified at FDR<1%. In order to determine whether 
any of these wild-type identified proteins are mutated, we next filtered the 1,468 non-
synonymous DNA variant set (Supplementary Table 2) with the 949 detectable protein set 
(Supplementary Table 7) to generate a list of 42 potential mutant polypeptide sequences (Table 1). 
Only one high confidence mutated tryptic peptide covering a sequence of mutated protein from 
this group was identified. The peptide was derived from the ribosomal protein rpl14 (Fig. 3A and 
3B). The mutant peptide spectrum and the fragmentation summary were exported from the 
ProteinPilot 4.5 search engine (Fig. 3C and 3F). The wt-rpl14 peptide covering the same position in 
protein sequence was also observed (Fig. 3D and 3E) which is consistent with the heterozygous 
mutation identified by DNA sequencing (Fig. 3A).  
 
Limitations of mass spectrometry to identify mutated protein sequences.  
There could be several reasons why the majority of these mutated proteins might not be 
detectable using mass spectrometry. First, as 18 out of the 42 proteins from this group have a 
homozygous gene mutation (Supplementary Table 1 and Table 1), these 18 expressed proteins 
presumably are mutated. However, there were no mutated tryptic peptides derived from any of 
these 18 proteins. This highlights a general difficulty in relying on mass spectrometry to confirm 
the expression of mutated proteins. The number of identified peptides covering any one protein is 
rarely “100%”. For example, the tryptic coverage of rpl14 highlights just this problem, as only two 
out of over 16 theoretical tryptic peptides (over 8 aminoacids of greater in length) could be 
detected (Fig. 3B). Serendipitously, one of these two peptides covered the mutant region (Fig. 3C 
and 3F). Other reasons for the absence of mutant peptide detection is that the mutant tryptic 
peptide could be relatively small (e.g. less than six amino acids in length) and therefore difficult to 
confidently match to corresponding MS/MS spectrum. For example, the protein LRCC59 has an in-
frame triplet nucleotide insertion resulting in a Q amino acid insertion (Lys137_Pro138insGln) 
resulting in the tryptic penta-peptide QPFPK. It is difficult to identify this mutated peptide, 
unambiguously, as being derived from LRCC59 as there are several proteins in the human 
proteome that could yield this amino acid sequence after trypsinization at the sequence KQPFPK. 
The inability to detect such mutant tryptic peptides from any of the 18 proteins derived from 




































































highlights the need to include different proteases in sample preparation or derive a larger pool of 
tryptic peptides from which to search for mutated peptides. Nevertheless, users of this A375 cell 
model as a resource might want to consider these 18 proteins (with no detectable mutant tryptic 
peptides) expressed from homozygous mutated genes to be bona-fide mutant proteins.  
 
Mutated protein identification using mass spectrometry with the A375 mutant RNA reference 
database 
As mutant peptides were not detectable to a high degree using the DNAseq-only files, we focused 
on using the RNAseq files stratified by 40 or more mutated mRNA reads derived from wt-p53 A375 
cells (Supplementary Table 5) to create a mutant search database. We also next initiated an 
additional pipeline approach that was used to increase number of detectable proteins by pre-
fractionating the peptides using an orthogonal LC method (Fig. 1). The orthogonal approach 
incorporated a reverse phase high pH acetonitrile gradient generating ten fractions that were 
infused for peptide identification using a TripleTOF 5600+ mass spectrometer. Employing peptide 
pre-separation step increased the coverage of total wild-type peptides to over 35,000 (FDR<1%) 
with a coverage of over 4,500 wild-type proteins (FDR<1%) (Supplementary Table 8). 
 
Integrating the RNAseq derived mutant search database (Supplementary table 8) to the 2D LC-
MS/MS data increased the number of identified mutant peptides to 193 (Supplementary Table 9). 
Although the ProteinPilot 4.5 search engine determines the confidence of identified mutated 
peptides, we needed to manually inspect the spectra in each of these 193 proteins to produce a 
list of mutated peptides that were identified based on y and b fragment ions covering the mutated 
amino acid in the mutated peptide sequence. Applying this procedure excludes the possibility that 
we identified wild-type peptides and narrowed the list down to 60 verified mutated proteins (Fig. 
4).  
 
Methodologies for validation of mutated peptides in the wt-p53 A375 cell model. 
Mutated peptide identification in A375 fractions was further examined using targeted mass 
spectrometry in pseudo-selected reaction monitoring mode (pseudo-SRM) on TripleTOF 5600+ 
mass spectrometer. Ten isotope labeled mutant tryptic peptides were acquired (Fig. 5B) to 
validate ten of the 60 mutant tryptic peptides identified in data-dependent mode (Fig. 5A). We 
optimized isotope labelled peptide spike-in into A375 lysates (Fig. 5C and 5D) to yield optimal 
product ion intensity. Comparing the retention times and product ion intensity patterns in product 
ion chromatograms of naturally occurring intrinsic peptide and isotope labelled peptide enabled 
us to determine whether the naturally occurring peptide is present. All ten of the mutant peptides 
were successfully validated by this methodology.  
 
As an example, verification of two mutated peptides is shown in Fig. 6A and 6B. Fragmentation 
evidences described in Fig. 6A and 6B show all possible product ions that represent two selected 
high confidence mutated peptides (peptide confidence > 99%) identified in 2D LC-MS/MS data 
(VSGSPEQAVEENLSSYFLDR and IIPTVLMTEDIK peptides). Only underlined product ion masses 
represent identified product ions that confirm the presence of amino acid mutation in the peptide 
sequence. The fragmentation evidence of the VSGSPEQAVEENLSSYFLDR mutated peptide 
highlights 11 product ions confirming the S to F mutation, whilst the fragmentation evidence of 
the IIPTVLMTEDIK mutated peptide shows only 3 product ions confirming the A to P mutation. The 
fragmentation evidences in Fig. 6A and 6B clearly show that the probability of an amino acid 
mutation is not reflected in the peptide confidence determined in ProteinPilot 4.5 software. 
Therefore, it is important to evaluate the spectra/fragmentation evidence to accurately define 




































































isotope labelled reference peptide and its light naturally occurring variant is shown in Fig. 6C. All 
results from SRM validation of mutant peptides using SRM are summarized in Supplementary 
Table 10 and Fig. 6D. Taken together Fig. 6 summarizes all steps, that were taken to validate any of 
the selected mutated peptides. 
 
Mutated proteomics: Creating a p53-null A375 melanoma cell line as an isogenic model system to 
define p53-dependence in mutated cancer genome protein expression patterns.  
We finally aimed to use this optimized DNA and RNAseq variant detection pipeline (Fig. 1) to ask a 
key biological question; how does inactivation of the tumour suppressor p53 gene impact on the 
mutant proteome landscape? The human melanoma A375 cell line has classically been used as a 
model to study regulation of wt-p53 activity in response to DNA damage [26] [27]. We thus 
focused on using CRISP-R gene editing to develop an A375 cell line with an isogenic p53-null 
status. The guide RNA encoding a targeting sequence near the ARG175 codon in the p53 gene (Fig. 
7A) was transfected into cells, single cells were isolated following cell sorting, and individual clones 
were selected based on absence of p53 induction after X-irradiation (data not shown). Nine 
independent p53-edited clones were obtained (data not shown). One A375 p53-null cell clone was 
taken forward with the edits as indicated in Fig. 7B and 7D. The sequences across the breakpoint 
in edited p53 alleles (Fig. 7) results in a stop codon (Fig. 7C and 7E). Immunoblotting of lysates 
using the N-terminal epitope antibody DO-1 confirmed that the A375 p53-null cells do not express 
p53 protein, nor do the HCT116 p53-null cells (Fig 7F). In addition, MHC Class I protein (HLA-B 
allele) was also determined to be elevated in the p53-null cells (Fig 7G). We also observed 
elevated HLA-A and HLA-C alleles in p53-null cells (data not shown), further highlighting the utility 
of this p53 –null cell as a tool to study in the future how p53 status impacts upon mutated protein 
expression as well as mutant peptide presentation by the MHC Class I system.  
 
SWATH (Sequential Windowed Acquisition of all Theoretical Mass Spectra) was used as a 
complementary methodology to further determine the presence of target mutated peptides and 
to evaluate an effect of p53 inactivation on mutated protein levels. We first set-up large scale 
SWATH quantitation on TripleTOF 5600+ mass spectrometer and focused towards two mutated 
proteins that were previously verified and validated in wt-p53 A375 cells; PYGB and PLEC (Fig. 8). 
We extracted product ion chromatograms corresponding to these mutated peptides using a 
product ions m/z’s included in a spectral library derived from data-dependent measurement of 
same sample. We found high correlation between product ion intensity pattern in extracted 
product ion chromatograms and the product ion intensities in spectral library for both peptides 
(Fig. 8A, 8B, 8D, 8E). Following quantification of the PYGB mutant peptide using three technical 
replicates obtained from A375 p53-null cells and A375 p53 wild-type cells shows an up-regulation 
of the PYGB (LIINLVTSIGDVVNHDPVVGDR) mutated tryptic peptide in A375 null cells. However, the 
quantification we observed based on the set of automatically intensity based selected product 
ions does not specifically represent the mutated peptide, and as such we cannot rule out the 
possibility that the quantitative data are derived from wild-type tryptic peptide. Therefore, as a 
robust SWATH pipeline we would again recommend to carefully select product ions referring 
uniquely to the mutation in a peptide sequence. In case of PYGB mutated peptide 
(LIINLVTSIGDVVNHDPVVGDR) it would be ions encompassing b4 – b21 and y19 – y21. The set of 
automatically selected product ions from spectral library contains y6, y16, y17, y9 (Fig. 8A). 
Therefore, SWATH quantitation of peptide LIINLVTSIGDVVNHDPVVGDR does not uniquely refer to 
the mutated peptide form and could be biased by changes in wild-type form. 
 
We next extracted quantitative SWATH data for mutated peptide from PLEC (SIITYVSSLYDTMPR) 




































































quantitative data referring to product ions that uniquely involve mutated amino acid in the 
product ion sequence. The mutated peptide SIITYVSSLYDTMPR must be quantitated by any 
product ions encompassing b12 – b15 and y4 – y15. The set of automatically selected product ions 
from spectral library for quantitation of SIITYVSSLYDTMPR 3+ contains y4, y5, y6, y7 (Fig. 8D). 
Therefore, quantitation of the mutated peptide refers uniquely to mutated peptide form. The 
corresponding spectral library evidence and product ion intensity rank in product ion 
chromatogram are highlighted (Fig. 8D and 8E) along with the quantitation of mutated peptides in 
three technical replicates of A375 p53-null cells and A375 p53 wild-type cells (Fig. 8F). As a control, 
SWATH quantitation of a control peptide VAPEEHPVLLTEAPLNPK (ACTB) was used to evaluate 
quantitative differences as a consequence of deleting the p53 gene in A375 cell line, differences in 
sample loading, and the possible effects of sample preparation on MS analysis (Fig. 8G). 
 
Differences in mutant protein expression in wt-p53 and p53-null cells. 
We finally determined the major differences in mutant peptides enriched between wt-p53 and 
p53-null cells using CLCBio and Varscan variant detection platforms. Parameters were set requiring 
at least 10 mutant mRNA variants and 1 mutant DNA variant. Using CLCbio, there were 190 
mutant peptides detected enriched in wt-p53 cells, with 187 mutated peptides enriched in the 
p53-null cells (Fig. 9A). The largest number of mutant peptides were detected using CLCbio when 
compared to Varscan (Fig. 9B and 9C). Using STRING protein annotation, we evaluated the 
dominating mutant protein networks defined (Fig. 10 and 11). 
 
In cells containing wt-p53 there were dominating peptides that could be used to highlight mutated 
protein networks centered on CDC5L (Fig. 11, center). The CDC5L network in turn is linked to a 
mutant protein splicing network composed of SRSF7, SF35B, SLU7, CSTF3, and YBX1. In turn these 
networks also connect to mutant proteins in DNA repair pathways including POLR1b, ERCC2, 
FANCD2, XRCC6, and others (Fig. 10). By comparison, the STRING analysis in p53-null cells 
highlighted a different dominating mutant proteome. This consisted of a ribosomal mutant protein 
network including RPL5 and RPL26L (Fig. 11). This node was in turn connected to a mutant 
ubiquitin protein node including USP7, UBE2V2, USP9X, and MRE11. An independent node 
composed of mutant proteins was present in kinase signalling including EGF, YES1, PPP2CB, CSK, 
and PPP2R5C (Fig. 11). Together, these data highlight that inactivation of the p53 gene can switch 
the expression of distinct mutant protein signalling nodes encoded by a cancer genome. This in 
part, can shed light on how tumour cells adapt to gene mutation by changing the expression of 





The identification of mutated proteins in human cancer cells can assist in defining expressed, 
mutated oncogenic signalling landscapes as well as facilitating the identification of potential 
neoantigen vaccine ligands. Most often, proteomics studies using cancer cell lines uses a normal 
reference proteome and under-estimates mutated protein signalling functions. We report on an 
optimized pipeline for identifying tumour variants in A375 cells using; (i) the CLCBio integrated 
DNA and RNA variant calling platform; (ii) the incorporation of RNAseq to stratify highly expressed 
variants; (iii) the use of 2D LC-MS/MS to identify potentially mutated peptide sequences in a 
tumor cell line; and (iv) the use of manual spectral annotation and SRM to estimate a false 
discovery rate of mutant peptides using LC-MS/MS. Our pipeline has identified high confidence list 
of protein mutations in the A375 cell line and its p53-null derivative (Supplementary Tables 13 and 




































































shotgun mass spectrometry to identify mutated peptides. This underestimates the extent of 
mutant protein expression in the A375 cell because of; (i) incomplete tryptic coverage of any one 
given protein; (ii) we only included very abundant mutant mRNA species (with relatively high 
numbers of reads; i.e. >40) to create a reference database of relatively highly expressed mutant 
genes; and (iii) stringent manual annotation of mutated peptides identified in the mass spectra 
eliminates some likely mutant peptides from the dataset.  
 
We focused this study on using a human melanoma has emerged as a cancer type with one of the 
highest rates of single-nucleotide variation in a cancer genome and this tumour type is expected 
to form important models to define mutated protein expression networks [32]. As a result, 
melanoma patients can benefit from cancer-specific immuno therapeutics that exploit this high 
rate of mutated protein production [33]. Understanding how cancer associated genes impact on 
steady-state mutant protein expression levels and ultimately neoantigen assembly into the MHC 
Class I pathway has thus recently gained more relevance. Thus, it is important to begin to develop 
isogenic cancer cell models with specific cancer gene mutations to accelerate our understanding 
of how mutant protein production and re-wired mutated signalling proteins are enhanced in 
cancer cells. This could facilitate developing new therapeutics that exploit mutant protein or 
mutated pathway expression. We focused here on applying these methods to the question of how 
p53 gene inactivation can impact on mutant protein expression in an isogenic melanoma cell 
model. 
 
P53 protein has been termed the guardian of the genome [34]. The p53 gene is one of the most 
frequently mutated in the vast majority of cancers [35] leading to loss of wt-function and 
enhanced genome instability [36]. It is therefore interesting that the majority of human 
melanomas retain wt-p53 alleles [32], possibly because the selections pressures driving the 
survival of cells with a mutant p53 gene is reduced due to frequent inactivation of the p53 
regulatory cdkn2a locus in melanoma. Oesophageal adenocarcinoma also has very high rate of 
single nucleotide variation [37] but also a high rate of both p53 gene mutation and cdkn2a 
mutation [38]. These data might suggest there could be two distinct pathways that drive a high 
rate of single nucleotide variation in a cancer genome via attenuation of wt-p53 function (as in 
melanoma) or mutation in the p53 gene (as in oesophageal adenocarcinoma). We focus in this 
report on generating an isogenic wt and p53-null cell panel using CRISP-R/CAS9 gene editing 
methodology to define how loss of p53 can impact on a mutant proteomic landscape. Integrating 
genomics, RNA expression, and mass spectrometric data produces a baseline mutant protein 
library in melanoma that can be used as a community resource to facilitate interrogation of signal 
transduction pathways in this model. A similar cancer cell model has been developed in 
oesophageal adenocarcinoma that has the features of high rate of single nucleotide variation, but 
which has mutations in the p53 tumour suppressor gene [39]. Using our optimized pipelines, we 
define specific sets of mutant proteins that are differentially expressed as a result of p53 gene 
status. These data indicate that loss of a tumour suppressor gene such a p53 can begin to switch 
expression of the mutated protein landscape in a tumour cell (Fig. 10 and 11).  
 
One impact of this pipeline will be in the future identification of tumour-specific mutated proteins 
that can be processed by the MHC Class I pathway; neoantigens. Within this list of mutant 
proteins detected in the A375 cell line, we were also able to identify some trimmed peptides that 
have a predicted high affinity for MHC class I peptides as defined using netMHC 4.0 [40], based on 
our isotyping that A375 cells have the MHC Class I alleles, HLA-A*-3:01 and HLA-B*07:02. One of 




































































10mer LPNIQAVLL for HLA-B*07:02 is 518.5 nM and the predicted affinity of the mutant-10mer 
LPNIQAVVL for HLA-B*07:02 is 87.8 nM. Additionally, SRP14, with a P124A mutation resulted in a 
mutant 10mer APAAAATAA peptide with a predicted affinity of 17.9 nM for HLA-A*03:01 whilst 
the wt-peptide APAAAATAP peptide with a predicted affinity of 641.5 nM for HLA-A*03:01. Such 
datasets will provide neoantigen models to study MHC Class I peptide flux in this A375 cell line. 
 
A second impact of this pipeline will be on mutant proteomics studies. We have used a gene 
editing tool (CRISP-R) to begin to ask a biological question on how loss of p53 can impact on the 
mutant protein landscape. Pathway annotation using STRING provides evidence for mutated 
protein expression in pathways including adhesion, ubiquitination, metabolism, and DNA repair. 
Mutant protein expression in a cancer cell line provides another way of thinking about 
‘proteomics’ compared to its usual application which is examining protein expression in a cancer 
cell line using a ‘normal’ reference protein database. When screening the mass spectral data from 
A375 cells and the p53-null A375 cells against the mutant genomic reference databases, we 
identified a relatively high overlap in the proteins identified between the two cell lines (Fig. 9A). 
This might not be unexpected since p53 is stress activated. On the other hand, the difference in 
the proteome between the two cell lines (Fig. 9A) also highlights the fact that inactivation of the 
p53 gene did give rise to spontaneous changes in some mutated proteins without further selection 
pressures. Future studies could examine how loss of p53 in this isogenic model impacts on 
radiation or GAS/STING-dependent mutant protein signalling. Together, our study produces a well 
annotated mutant proteome of this A375 cell line model, coupled to the application of an 
integrated variant detection platform (CLCbio), that can be used to detect high confident mutant 
proteins cells. This can facilitate the use of this isogenic model as a resource to identify the p53-
dependence on the mutant proteome and normal proteome landscape. 
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Materials and Methods 
P53 knockout using the CRISPR/CAS9 system. 
The p53-specific gRNA sequence was 5’-CTGAGCAGCGCTCATGGTGGNGG-3’, which was designed 
by Applied StemCell, Inc. The gRNA was cloned into pBT-U6-CAS9-2A-GFP expression vector from 
Applied StemCell, Inc. The P53 knockout in A375 cell line was performed as described before with 
minor alterations [41]. Briefly, 3x105/well A375 cells [27] were seeded in 6-wells plates. 24 hours 
later, cells were transfected with pBT-U6-CAS9-2A-GFP expression vector using Attractene 
Transfection Reagent (QIAGEN, UK). 48 hours later, mutations were tested using a Surveyor 
Mutation Detection Kit (Integrated DNA Technologies, USA) and GFP positive cells were sorted and 
collected by BD FACSCanto II (BD Bioscience, USA). GFP positive cells were seeded in 96 wells 
plates 1 cell/well for colony formation. After 2 weeks, all colonies were collected and tested by 
western blot using the in-house developed DO-1 monoclonal antibody to demonstrate loss of p53 
protein (Fig 7F) and sequencing to validate p53 gene editing in the A375 cell lines. The HLA-B 
antibody was from Thermofisher (PA5-35345). The loading control for immunoblotting (Fig 7F) 




































































mouse monoclonal anti-β-actin (Sigma). The HCT116 wt and p53-null  cells were a gift of Dr. B 
Vogelstein (Johns Hopkins University, USA). 
 
CLCbio variant calling. 
Next generation DNA sequencing of the A375 wt-p53 containing melanoma cell line was 
performed in order to annotate its genome. Exome Sequencing was performed using Agilent 
V5+UTR Exome Capture Kit (75Mb) and 100 bp paired-end reads were acquired using a coverage 
of 100x. Paired fastq files from the A375 cell line (available upon request) from DNA-exome 
libraries were imported into the CLC Biomedical Genomics Workbench 3. Adaptor sequences and 
bases with low quality were trimmed, DNA sequencing reads were mapped to the human 
reference genome hg19, and sequences were filtered through dbSNP databases to remove 
“common” germline variants. A total of 120,325 tumour specific variants were detected at a 
frequency of 5% or higher when the threshold was set at calling variants detected in at least two 
variant DNA sequencing reads in the exome data from A375 cells (Supplementary Table 1A). 
RNAseq from A375 cells was performed using human total RNA, depleted of ribosomal RNA, 
followed by random priming to generate cDNA. From this template paired-end Illumina HiSeq2500 
was used to generate approximately 20 million reads. Paired fastq files (available upon request) 
from RNAseq reads were imported into the CLC Biomedical Genomics Workbench 3. The RNA 
sequencing reads were mapped to the human reference genome hg19, and sequences were 
filtered through the A375 cancer genome sequence where at least 2 mutant DNA reads were 
identified, then dbSNPs were removed, to identify mutated and expressed genes. A total of 18,341 
expressed non-synonymous mRNA variants were identified with a cutoff of 5% of the total RNA 
reads defined as mutated (Supplementary Table 3). 
 
Varscan2 variant calling. 
The same paired fastq files from the A375 cell line (as used for CLCbio analysis, above) from DNA-
exome libraries were used for following analysis pipeline. Variant calling was performed using 
Varscan, adaptor sequences and bases with low quality (QualityScore < 30) were trimmed by 
FASTX-Toolkit version 0.0.14 (Retrieved from http://hannonlab.cshl.edu /fastx_toolkit), DNA 
sequencing reads were mapped to the human reference genome hg19 and hg38 (by TopHat2 [42]) 
(See Fig. 1), and results were imported into VarScan2 [43]. Sequences were filtered through dbSNP 
databases to remove “common” germline variants. A total of 101,072 tumor specific variants 
(coverage 1 DNA mutation) and 10,545 non-synonymous mutations were detected using hg38 
(coverage 1 DNA mutation; See Supplementary Table 11). A total of 17,822 tumor specific variants 
were obtained from RNA seq (using a minimal cutoff of 10 mutated RNA reads) and 2,662 were 
classified as a non-synonymous RNA mutation (using a minimal cutoff of 10 mutated RNA reads). A 
total of 5,590 tumor specific variants were obtained from RNA seq (using a minimal cutoff of 40 
mutated RNA reads, data not shown) and 1,007 were classified as non-synonymous RNA 
mutations (using a minimal cutoff of 40 mutated RNA reads). The number of 2,461 tumor specific 
variants from the wt-p53 A375 cell line (1 DNA mutation and at least 10 mutant RNA reads) and 
945 tumor specific variants from the p53-null cell line (1 DNA mutation and at least 10 mutant 
RNA reads), were used as the input file for reference database to identify mutant peptides using 
mass spectrometry Supplementary Table 12. A comparison of the DNA mutations detected using 
Varscan and CLCbio are summarized in Fig. 2 and the number of mutated peptides detected, using 
either Varscan or CLCbio driven analysis are summarized in Fig. 9. 
 
Peptide sample preparation for MS. 
Cells were plated and grown on five 10 cm Petri dishes to 80% confluence. Cells were harvested 




































































facilitated using needle sonication in three 4 second cycles and protein concentration was 
determined using RC-DC assay (Bio-Rad, USA). An aliquot corresponding to 200 µg of protein was 
digested to peptides using Filter-aided sample preparation (FASP) [30]. Briefly, cell lysate was 
mixed with 200 µl of urea buffer and added to centrifugation filter unit Vivacon 500 with 10 kDa 
cut-off (Sartorius Stedim Biotech, Germany) followed by centrifugation (15000 g/ 20 min/ RT). 16.7 
mM TCEP in urea buffer was added to filter unit to reduce disulphide bridges in protein. Reduction 
was done on thermomixer (600 rpm/ 30 min/ 37˚C) followed by centrifugation (15000 g/ 20 min/ 
RT). Sample alkylation was performed in the darkness for 20 min at RT with 300 mM 
Iodoacetamide in urea buffer followed by centrifugation (15000 g/ 20 min/ RT). Buffer was 
exchanged to 100 mM NH4HCO3 using 3 washes to enable efficient trypsin digestion of samples. 
Proteins were digested in 100 µl of 50 mM NH4HCO3 buffer where 1 µg of trypsin was added per 
each 33 µg of protein to be digested. The samples were mixed with digestion buffer at 600 rpm on 
thermomixer for 1 min before incubation for 18 h in a wet chamber, 37˚C. Peptides were eluted 
from the filter by centrifugation (15000 g/ 20 min/ RT). To increase peptide recovery 0.5 M NaCl 
was added followed by centrifugation (15000 g/ 20 min/ RT). Peptide samples for direct MS 
analysis were desalted on Micro SpinColumns C18 (Harvard Apparatus, USA). First, C18 columns 
were conditioned twice with 100% acetonitrile (AcN)/ 0.1% formic acid (FA), centrifuged at (120 g/ 
2 min/ RT), and washed with 0.1% FA followed by centrifugation (200 g/ 2 min/ RT). The columns 
were hydrated for 15 min in 0.1% FA, centrifuged (200 g/ 2 min/ RT). Samples were loaded to 
columns and centrifuged (550 g/ 2 min/ RT). Next, the columns were washed thrice with 0.1% FA. 
Peptide elution was done using 50% AcN/ 0.1% FA in water, 80% AcN/ 0.1% FA in water and 100% 
AcN/ 0.1% FA. The peptide eluates were evaporated using a SpeedVac and dissolved in 5% AcN/ 
0.05% trifluoroacetic acid (TFA) in water. Concentration of peptides was determined in each 
sample on NanoDrop 2000 (Thermo Scientific, USA) at 220 nm and 280 nm prior MS analysis. 
 
RP-basic fractionation using spin columns. 
FASP digested peptide samples for RP-basic fractionation were separated in basic pH (pH 10) on 
Macro SpinColumns C18 (Harvard Apparatus, USA) packed with C18 sorbent. First, mobile phase A 
composed from 10 mM ammonium formate (AF) in water pH 10 and mobile phase B composed 
from 10 mM AF in 90% AcN pH 10 were prepared [44]. C18 columns were conditioned twice with 
mobile phase A followed by centrifugation at (200 g/ 2 min/ RT). Columns were then washed with 
mobile phase B followed by centrifugation (300 g/ 2 min/ RT). Columns were hydrated for 15 min 
using mobile phase A, centrifuged (300 g/ 2 min/ RT). Peptide samples were added to hydrated 
columns and centrifuged (650 g/ 2 min/ RT). Next, the columns were washed thrice with mobile 
phase A. Peptide separation into 11 fractions was done using a step gradient composed from 
5% B + 95% A, 9% B + 91% A, 13% B + 87% A, 17% B + 83% A, 21% B + 79% A, 25% B + 75% A, 
35% B + 65% A, 50% B + 50% A, 80% B + 20% A and 100% B. Ten fractions were evaporated using a 
SpeedVac concentrator. Each fraction was dissolved in 100 µl of 50% methanol and then 
evaporated in SpeedVac concentrator. This step was repeated three times to get rid of volatile 
salts. Dried samples were dissolved in 20 µl of 5% AcN / 0.05% TFA. Concentration of peptides was 
determined in each sample on NanoDrop 2000 (Thermo Scientific, USA) at 220 nm and 280 nm 
prior MS analysis. 
 
Spiking sample with reference heavy peptides. 
JPT synthetic heavy reference peptides (JPT, Germany) derived from 10 mutant peptide 
candidates were ordered with isotopically labelled amino acids. A content of the vial containing 
heavy reference peptide was dissolved in 5% AcN + 0.05% TFA in water to prepare 1.43 nmol/µl 
stock solution. Next, LOD of each peptide was determined (data not shown). A pool representing 




































































concentration and injection volume was set based on crude Nanodrop measurement A220 and 
A280) in order to load onto the column an identical amount of reference peptide corresponding to 
at least 10 times LOD. Three µl of this mixture were injected onto nano-LC-MS/MS to perform 
pseudo-SRM analyses in analytical triplicates. 
 
LC setup for analysis of fractions. 
Eksigent Ekspert nanoLC 400 system (AB-SCIEX, USA) nano-LC system was used for peptide 
concentration and separation. Peptides were concentrated and desalted on a cartridge trap 
column (300 μm i.d. × 5 mm) packed with C18 PepMap100 sorbent with 5 μm particle size 
(Thermo Fisher Scientific, MA, USA). Peptides were 10 min washed using 0.05% TFA in 5% AcN in 
water. Separation was performed on a 25 cm fused-silica emitter column with 75 μm inner 
diameter (New Objective, USA), packed in-house with ProntoSIL C18 AQ 3 μm beads (Bischoff 
Analysentechnik GmbH, Germany). LC solvents were composed from 0.1% FA in water (solvent A) 
and 0.1% FA in AcN (solvent B). Sample was eluted in a 120 min gradient starting at 5% B up to 
40% B with a flow rate 300 nL/min in DDA and SWATH experiments while 61 min gradient starting 
at 5% B up to 40% B with a flow rate 300 nL/min was used in pseudo-SRM experiments. Peptides 
eluting from column were ionized in nano-electrospray and entered mass spectrometer. 
 
Shotgun MS/MS (DDA). 
Mass spectrometer TripleTOF 5600+ (AB-SCIEX, Toronto, Canada) operated in data dependent 
mode. Each cycle was accompanied with fragmentation of top 20 most intense precursor ions. 
Exclusion time was set to 12 seconds. Minimum precursor ion intensity was set to 50 cps and 100 
milliseconds accumulation time per precursor. Shotgun were searched using ProteinPilot 4.5 (AB-
SCIEX, Canada) against custom built human mutant proteome reference database derived from 
human reference database (Uniprot+Swissprot 2016_2) and against wild-type human reference 
proteome database (Uniprot+Swissprot 2016_2). Search parameters were set as follows: trypsin 
protease, carbamidomethyl (C) (fixed). Protein FDR was determined by searching MS/MS data 
against decoy databases. 
 
Building-up custom search library with mutant protein sequences. 
MS/MS data from fractions were inspected for presence of MS/MS spectra corresponding to 
genes identified as high confidence RNA and DNA variant hits. Amino acid sequences 
corresponding to these genes were listed in a mutant search database where a mutant position in 
a protein was inserted based on genomic data. Mutant search database was assembled in FASTA 
format. Corresponding wild-type FASTA sequences of protein forms were downloaded from the 
human (2016_2) reference database. A custom mutant FASTA file containing mutant and WT 
forms of proteins was created in a text editor and subsequently imported into ProteinPilot 4.5. 
Quality of mutant IDs was inspected in ProteinPilot 4.5. (AB-SCIEX, USA), focusing mainly to a 
peptide covering mutation position in a sequence. Spectral evidence of high and mid confidence 
mutant peptides (peptide confidence > 95% and between > 50% and < 95%) was manually 
inspected. In mutant peptides we focused to corresponding product ions directly proving a shift in 
mass as a consequence of mutation. A protein referred as “mutant” had covered potential 
mutation position by high or mid confidence peptides bearing substitution, insertion, deletion of 
amino acid in its sequences. On the other hand, a protein referred as “wild-type” has a place of 
potential mutation covered by wild-type sequence of a high or mid confidence peptide. 
Identification of mutant or wild-type form was accomplished by Uniprot BLAST of peptide 






































































SWATH method for label free quantification was developed according to previously published 
methods [45] [46] [47]. TripleTOF 5600+ (AB-SCIEX, Canada) operated in high sensitivity positive 
polarity SWATH mode. Effective precursor range was selected from 400 amu up to 1200 amu and 
the cycle time was set to 3.5 seconds. An optimal SWATH width was 13 Da including 1 Da overlap 
resulting in a method with 67 SWATH windows. Accumulation time per SWATH was 50 
milliseconds. Product ion range was scanned from 360 amu up to 1360 amu and rolling collision 
energy was used with collision energy spread (CES) of 15 mV.  
 
Building-up wild-type spectral library and SWATH quantification of wild-type proteins. 
PeakView software 1.2.0.3 (AB-SCIEX, Canada) was used to index 1045 proteins FDR 1% in a 
spectral library. Retention time window was set to 2.5 min to the left and 2.5 min from expected 
retention time. Protein quantitation was based on extracting peak areas for four peptides per 
protein and 6 product ions per each peptide. Extracted quantitative data from three technical 
replicates were statistically evaluated in MarkerView 1.2.1.1 (AB-SCIEX, Canada). Pairwise T-test 
was performed to determine protein fold changes and P values of fold change for all proteins 
listed in spectral library. 
 
Building up a mutant spectral library and SWATH quantification of mutant proteins. 
Results from mutant database MS/MS search were imported into Skyline-daily (64-bit) software 
version 2.6.1.6899 (MacCoss Lab, WA, USA) where the mutant spectral library was generated. 
FASTA sequences of 10 candidate mutant proteins listed in Supplementary Table 10 were 
imported into Skyline software. Results from mutant peptides are shown in Supplementary Table 
10. An example of mutant peptides from RPL14 and PLEC is shown in Fig. 8. Peptide settings were 
as follows: digestion – trypsin, 1 missed cleavage was permitted, length of peptide was in range 
from 7 – 25 amino acids, 25 amino acids from N-terminus were excluded, carbamidomethyl was 
set as structural (fixed) modification. Transition settings were as follows: precursor charge was 2+, 
3+ or 4+, fragment charge 1+, fragment series y or b, product ions, fragment ions from 3 up to last, 
including the N-terminal fragment to proline. After data extraction, start and end points of each 
peak in extracted product ion chromatogram were inspected manually. We checked co-elution of 
selected product ions, product ion ranks according to the spectral library, retention times across 
replicates, and data acquisition modes to confirm peak identity. Peak areas corresponding to 
mutant peptides were evaluated and visualized in Skyline software. 
 
Pseudo-SRM analysis. 
The TripleTOF 5600+ (AB-SCIEX, Canada) was operated in high sensitivity positive mode. Each cycle 
involved one TOF-MS scan with 250 ms accumulation time and 38 product ion scans of 70 
milliseconds accumulation time per precursor. Total cycle time was 3.0 seconds. Product ions were 
scanned in a range from 100 to 1800 amu. Pseudo-SRM data were analysed in Skyline. Sequences 
of ten mutated peptide candidates were imported into the Skyline version 2.6.1.6899 (MacCoss 
Lab, WA, USA) with the following settings: Peptide settings were as follows: digestion – trypsin, 1 
missed cleavages were permitted, length of peptide was in range from 7 – 25 amino acids, 0 amino 
acids from N-terminus were excluded, carbamidomethyl was set as structural (fixed) modification, 
heavy isotope peptide labeling 13C 15N on lysine, arginine and leucine was permitted. Transition 
settings were as follows: precursor charge was 2+, 3+, fragment charge 1+, fragment series y or b, 
product ions, fragment ions from 3 up to last, including the N-terminal fragment to proline. After 
data extraction, start and end points of each peak in extracted product ion chromatogram were 
inspected manually. We checked co-elution of selected product ions, product ion-rank according 
to the spectral library, retention times across replicates, and data acquisition modes to confirm 




































































Skyline software. dot-product (dotp) correlation for the ratio of the observed SRM peak intensities 
of a peptide in a specific biological matrix as correlation of observed SRM peak intensities of a 
peptide in a specific biological matrix versus the reference isotope labelled peptide were 
calculated. Peptides considered as high-quality validated hits showed good signal and dotp>0.9 






































































Figure 1. Experimental plan for optimizing mutant protein detection in cell models. Two different 
variant calling platforms, CLCBio and Varscan, were used to identify DNA variants from the A375 
cell line. Shotgun RNA seq was then performed on both parental and p53-null A375 cell lines to 
create a mutant expressed reference database for both cell lines. This mutant RNA database forms 
the reference from which mutant proteins will be identified using fractionation of the mutant 





Figure 2. Representative variant calls from mutated genes. (A). Summary of the number of DNA 
mutations detected using the CLCBio and Varscan variant calling platforms. (B and C). Example 
CLCbio browser highlights mutated genes including a single nucleotide variant (MEIS1, chr2, 
66691338) and an and in-frame insertion (SYNGR1, chr22, 39777822). The data are plotted by (i) 
chromosome position including hg19 reference genome (top, numbering); (ii) intron-exon 
boundaries. The thick line and thin line represent the exon and intron, respectively. Reference sets 
include: the blue line, that highlights ensemble v74 gene locus; the green line that represents 
ensemble v74 mRNA; and the yellow line that represents ensemble v74, CDS; (iii) highlights some 
of the DNA sequencing reads in blue aligned to hg19 with the DNA mutation variant (in A and B) 
highlighted by a color change and arrow. (D). An analysis of shared DNA v RNA mutations in A375 
cells. A comparison of the overlap of variants detected in RNAseq and DNAseq filtered through 
distinct processes. The variants identified by DNAseq were filtered based on the presence of at 
least 4 mutant sequencing reads and at least a 50% frequency. A total of 1,468 variants were 




































































40 mutant RNA sequencing reads and at least 1 mutation in the DNAseq. This generated a 
different list of 1,418 mutated genes with highly expressed mutated RNA. Fusing the datasets 
produces a relatively small overlap of 107 common variants. The data suggest that the majority of 
mutated genes with a high confidence variant calling (774/887) are not highly expressed. E. An 
example of one of the 107 shared mutated RNA and DNA CLCbio defined variants from the data 
filtered in Fig. 2D. GPATCH4 RNAseq reads are highlighted as an example containing a frame-shift 











































































Figure 3. Identification of mutated rpl14 protein in A375 cells. The reference mutated DNA 
database was used to screen peptide spectra for evidence of mutant tryptic peptides. One mutant 
protein was detected by this method; rpl14. (A). The rpl14 mutation is generated by an in-frame 
insertion of 6 bases encoding an AlaAla. The mutation is heterozygous as defined by the presence 
of 12 mutant reads and 11 wild-type reads (from Supplementary Table 1 and highlighted in the 
browser view by gaps in the sequence that matches the hg19 reference). The data are plotted by 
(i) chromosome position including hg19 reference genome (top, numbering); (ii) intron-exon 
boundaries. The thick line and thin line represent the exon and intron, respectively. Reference sets 
include: the blue line, that highlights ensemble v74 gene locus; the green line that represents 
ensemble v74 mRNA; and the yellow line that represents ensemble v74, CDS; (iii) highlights some 
of the DNA sequencing reads in blue aligned to hg19 with the DNA mutation variant highlighted by 
a color change and arrow. (B). The mutant protein tryptic coverage of rpl14 protein with the green 
highlighting high confident detection of two tryptic peptide sequences in (in green). (C and F). The 
mutant tryptic sequence containing 12 strings of alanine GTAAAAAAAAAAAAK (mass 1156.60) has 
a 99% confidence of identification after fragmentation using ProteinPilot and there is no other 
such peptide in the human database. (D and E). The wild-type sequence containing 10 strings of 
alanine GTAAAAAAAAAAAAK (mass 957.5117) was also detected and has a 90% confidence of 
identification using ProteinPilot and there is no other such peptide in the human database. The 






































































































































































Figure 4. Optimization of mutant peptide identification using combined RNAseq and 2D LC-
MS/MS datasets. A mutated reference search database file was based on RNAseq expression data 
(Supplementary Table 5) and then used to search 2D LC-MS/MS data leading to an increase in the 
number of peptides derived from potentially mutant proteins to 193 (Supplementary Table 9). The 
spectra in each of these were manually evaluated for the presence of y and b fragment 
ions that cover mutated amino acids characteristic by a m/z shift relative to product ions derived 
from the wild-type peptide. The data highlight successfully inspected mutated peptide candidates 
with an evidence of mutation in their peptide sequence. Tabulated are; Uniprot 
accession; mutation; mutated peptide sequence; peptide confidence; peptide charge state; 
peptide modifications and miscleavages; and product ions providing evidence of mutation 
(product ions that covered the mutant position in a peptide). The underlined peptides in the 















































































































































Figure 5. SRM validation of mutant peptide levels. (A). A List of identified mutated proteins and 
(B). corresponding peptides selected for validation using pseudo-selected reaction monitoring 
(pseudo-SRM). (B).highlights peptide sequences with green letters representing amino acids that 
are isotope labelled in the reference peptides. Red letters represent positions in peptide 
sequences that are mutated. (C). and (D). represent optimization of isotope labelled reference 
peptide QRVDEFEAL spiked-in into the A375 lysate. Extracted product ion chromatogram (C). 
shows intensity of SRM transitions from QRVDEFEAL mutated reference isotope labelled peptide 
at various concentrations, while D shows peak areas of corresponding product ions (y3 - y8). From 
(C). and (D). we determined that optimal spike in of QRVDEFEAL reference peptide is 
approximately 14.3 fmol which corresponds to a 10,000x dilution of stock reference peptide 











































































Figure 6. Extracted product ion chromatograms for SRM validated mutated peptides. (A). and 
(B). a list of product ions representing two selected high confidence mutated peptides (peptide 
confidence > 99%) identified using the 2D LC-MS/MS data. Product ions labelled with brown color 
were identified in the LC-MS/MS spectra of VSGSPEQAVEENLSSYFLDR and IIPTVLMTEDIK peptides 
(A. and B., respectively). Underlined product ion masses represent identified product ions that 
confirm presence of the amino acid mutation in the peptide sequence. (A). Fragmentation 
evidence of the VSGSPEQAVEENLSSYFLDR mutated peptide highlights 11 product ions confirming 
the S to F mutation. (B). Fragmentation evidence of the IIPTVLMTEDIK mutated peptide identifies 
only 3 product ions confirming the A to P mutation. The fragmentation evidences clearly highlight 
that the probability of amino acid mutation is not reflected in peptide confidence; therefore, these 
two peptides are shown as an example that it is important to evaluate the spectra/fragmentation 
evidence to determine mutant sequence status. (C). and (D). example of pseudo-SRM quantitation 
of the SIITYVSSLYDTMPR peptide referencing the heavy and light peptide titrations and defining 
key features required for high confidence validation (1-5) and other peak features (1-3). Left 
section of (C). highlighted in red shows product ions representing light and heavy form of peptide. 
While product ion chromatograms show MS/MS signal of these product ions across the LC run. 
(D). Tabulated results from a pseudo-SRM validation of selected mutated peptides using isotope 
labelled reference peptides. The table highlights sequences and charge states of the mutated 
peptides (the first and the second columns) followed by columns with key characteristics of the 
product ions representing intrinsic or reference mutated peptides in a sample. The third column 
defines the consistency of retention times among the reference and intrinsically mutated 
peptides. The intrinsic peptide must have an identical retention time to the reference peptide as 
its chromatographic characteristics remain unchanged by isotope labelling. The fourth column 
defines the intensity of the intrinsic and the reference mutated peptide. Both peptides must have 
a sufficient intensity (peak height) to be considered as detected. A peptide is defined as detected 
when its intensity is at least 3 times the background noise of the method (noise of pseudo-SRM 
was approximately 100 counts per second) according to FDA directions. The fifth column filters 
out wild-type peptides; the spectra of which could overlay with the spectra of the mutated 
peptides. We list detected product ions as having the characteristic mass shift of a mutated amino 
acid; this further validates the existence of a mutated peptide. The higher the number of product 
ions with the characteristic mass shift of mutated amino acid, the higher the confidence of a 
mutated peptide. The sixth column describes the similarity of an intensity pattern between the 
intrinsic and the mutated peptide. The ionization efficiency of both peptides must be the same, 
therefore we expect the same intensity rank of product ions in both peptides. We inspected 
corresponding product ion chromatograms and we selected only product ions that show similar 
patterns in terms of the intensity. The higher the number of product ions the higher the similarity 
between the intrinsic and the reference mutated peptide. The seventh column shows dotP value. 
This value reflects and summarizes the similarity between the intrinsic and the reference mutated 
peptide. It ranges in between 0 to 1 and the higher the value is, the higher the similarity of both 
peptides. Usually, pseudo-SRM validated peptides have high dotP values. The last column 
summarizes values determined from the pseudo-SRM assay. Peptides with an excellent pseudo-
SRM evidence could be considered as certainly validated. Abbreviations: L = (light) naturally 
occurring intrinsic form of mutated peptide, H = (heavy) reference isotope labelled peptide, WT = 












































































































































Figure 7. Generating a melanoma cell line with a p53-null status using CRISP-R mediated gene 
editing. (A). Position of guide RNA-binding motif. Guide RNAs targeting exon 5 of the p53 gene 
were cloned into pBT-U6-CAS9-2A-GFP. The intron-exon-intron sequence of the p53 gene is 
highlighted along with the position and orientation of the guide RNA (reverse arrow; in blue with 
the PAM sequence in red). A375 melanoma cells were transfected with the guide RNA and clones 
were selected using GFP selection by FACS followed by plating for single cells. Individual cells were 
grown and screened for evidence of gene editing and p53 activation status. (B and D). DNA 
sequencing. Sequence of the chromosomal DNA derived from the p53 knock-out cells by 
amplification of the chromosomal region using PCR primers flanking the guide RNA target motif. (C 
and E). Translation of the gene edits produces theoretical stop codons. (F and G). Immunoblotting 
to define the p53 and HLA expression status. (F). Lysates from A375 (wt and p53-null) and HCT116 
cells (wt and p53-null) were immunoblotted with the p53 antibody DO-1. This antibody binds to 
the N-terminal domain of p53. A loading control was detecting PCNA using the PC10 antibody.  
(G). Cell lysates from the indicated A375 variants (wt and -/-), as SiHa cells (as a control, C) were 







































































Figure 8. SWATH quantitation pipeline of mutated peptides in isogenic p53 wt and null cell 
panels. (A). An example of extracted product ion chromatogram corresponding to a mutated 
peptide from Glycogen phosphorylase, brain form (PYGB) detected using SWATH acquisition in 
A375 cell lysate. A legend in the right shows rank of the most intensive product ions from mutated 
peptide. (B). A spectral library MS/MS spectrum corresponding to peptide 
LIINLVTSIGDVVNHDPVVGDR. An intensity-based product ion rank in spectral library should be 
identical to product ion rank in product ion chromatogram to consider peptide hit as valid. (C). 
Quantification using three technical replicates between A375 p53-null cells and A375 p53 wild-
type cells shows an up-regulation of mutated peptide in A375 null cells. Here, as problematic we 
see a quantification on a set of product ions which might refer also to wild-type peptide form. 
Therefore, we recommend inspecting a set of selected product ions for quantitation and filter out 
only product ions uniquely covering the mutant position in a peptide sequence. In case of PYGB 
LIINLVTSIGDVVNHDPVVGDR mutated peptide it is b4 – b21 and y19 – y21 and in case of PLEC 
mutated peptide SIITYVSSLYDTMPR it is b12 – b15 and y4 – y15. (D). Extraction of product ion 
chromatogram for SIITYVSSLYDTMPR mutated peptide (PLEC). SIITYVSSLYDTMPR quantitation 
refers more uniquely to the mutated peptide form compared to quantitation of  
LIINLVTSIGDVVNHDPVVGDR peptide. It relies on product ions that are characteristic exclusively for 
mutant peptide form (y4, y5, y6, y7). (E). Shows corresponding spectral library for 
SIITYVSSLYDTMPR mutated peptide and intensity rank of product ions. (F). Shows quantitation of 
SIITYVSSLYDTMPR mutated peptide in three technical replicates of A375 p53-null cells and A375 
p53 wild-type cells. Relative quantitation of both mutated peptides in A375 p53- and A375 WT cell 
line (C). and (F). was determined from a sum of 4 product ion peak areas by integration of AUC. 
Bar graph (C and F). represents peak areas corresponding to these 4 product ions. Overall peptide 
quantity in each replicate is represented by an entire bar. (G). SWATH quantitation of a control 































































































































































Figure 9. Summary of mutated peptides detected using the optimized platforms. Using both 
CLCbio (CLC) and Varscan (VS), variants were detected requiring at least 10 RNA mutant reads and 
1 DNA mutant read. A. A comparison of the enriched mutant peptides detected in wt-p53 vs p53-
null cells using mass spectral data summarized in Supplementary Tables 13 and 14. B and C. 
Summarizes the mutant tryptic peptides detected in wt-p53 or p53-null cells, using CLCbio and 
Varscan platforms. The reference database generated from the DNA and RNAseq was converted 
to protein amino acid sequences by TransPEM [47] and subsequently this reference database was 











































































Figure 10. STRING analysis of mutant protein networks in wt-p53 cells. STRING (https://string-
db.org) is a database of protein-protein interactions including direct experimental data, indirect 
functional associations, from computational prediction, from knowledge transfer between 
organisms, and from interactions aggregated from additional primary databases [48]. The known 
interactions are defined as: curated databases (_____), and experimentally determined (_____). The 
predicted interactions are defined as: gene neighborhoods (_____), gene fusions (_____), gene co-
occurance (_____), textmining (_____), co-expression (_____), and protein homology (_____). The 
minimum required interaction score was defined as high confidence (0.7). STRING was used to 
define interaction networks composed of mutant proteins in the wt-p53 cell tryptic peptide 
dataset that differ from p53-null cells. The mutant peptides from wt-p53 cells are summarized in 









































































Figure 11. STRING analysis of mutant protein networks in p53-null cells. STRING was used as in 
Fig. 10 to define interaction networks composed of mutant proteins in the p53-null cell tryptic 
peptide dataset that differs from wt-p53 cells. The known interactions are defined as: curated 
databases (_____), and experimentally determined (_____). The predicted interactions are defined as: 
gene neighborhoods (_____), gene fusions (_____), gene co-occurance (_____), textmining (_____), co-
expression (_____), and protein homology (_____). The minimum required interaction score was 
defined as high confidence (0.7). The mutant peptides from p53-null cells are summarized in 












































































TABLE 1. SWATH-MS analysis of proteins whose genes are mutated using wt-p53 and p53-null 
A375 cells. The table highlights gene name, amino acid substitution, and fold change in the 
expression of wt vs p53-null cells. Only one protein on this list has a mutated peptide detected 
using mass spectrometry (rpl14, Fig. 3). The other 18 proteins with homozygous mutations do not 





























































































Supplementary Table 1A. Excel file showing a list of mutated genes with mutations detected at a 
5% frequency or higher in DNA from A375 cells using the CLCbio variant platform detector. The 
analysis identified 120,325 genes. Represented are data including chromosome number and 
position, reference allele and mutation type, zygosity, Count (mutation number) and coverage 
(total sequencing reads), frequency of mutation, gene cards name, ensemble qualifiers, amino 
acid change, coding region change (Syn or non-syn), and dbSNP identifiers. Supplementary Table 
1B. Excel file showing a list of mutated genes detected at a 40% frequency or higher in DNA from 
A375 cells (from Supplementary Table 1A) using the CLCbio variant detector. This analysis 
generated 63,880 variants with mutations. The data are plotted as a function of; chromosome; 
region; type of mutation; reference base; allele base; reference allele; zygosity; count; coverage; 
frequency of mutation; gene card name; ensemble name; gene name; gene biotype; transcript 
name; coding region change; amino acid change; amino acid change in longest transcript; other 
variants in codon; whether the mutation is non-synonymous, synonymous, or out with exons; and 
dbsnp reference. 
 
Supplementary Table 2. Excel file showing a list of mutated genes with non-synonymous 
mutations detected at a 40% frequency or higher in A375 cells (from Supplementary Table 1B) 
using the CLCbio variant detector. This analysis generated 1,468 genes with non-synonymous 
mutations. The data are plotted as a function of; chromosome; region; type of mutation; 
reference base; allele base; reference allele; length of change; zygosity; count; coverage; 
frequency of mutation; probability; forward read count; reverse read count; ratio; average quality; 
exact match to dbsnp; gene card name; ensembl name; gene name; gene biotype; transcript 
name; coding region change; amino acid change; amino acid change in longest transcript; other 
variants in codon; whether the mutation is non-synonymous, synonymous, or out with exons; and 
dbsnp reference. 
 
Supplementary Table 3. Excel file showing RNA sequencing reads mapped to the human reference 
genome hg19, with dbSNPs removed, to identify mutated and expressed genes. A total of 18,341 
expressed non-synonymous mRNA variants were identified with a cutoff of 5% of the total RNA 
reads defined as mutated. The data are plotted as a function of; chromosome; position; type of 
mutation; reference; allele; reference allele; length of change; zygosity; RNA count; RNA coverage; 
RNA frequency; RNA forward reads; RNA reverse reads; DNA read count; DNA read coverage; gene 
card name; ensemble name; gene name; transcript ID; coding region change; amino acid change; 
and whether the mutation is non-synonymous, synonymous, or out with exons. 
 
Supplementary Table 4. Excel file showing RNAseq data with a stringent cutoff requiring at least 
40 mutated RNA sequencing reads and filtered against genomic DNA cutoff of at least 1 mutant 
genomic DNA sequencing read.  This produced 5,980 RNA variants including synonymous, non-
synonymous, and non-exonic mutations. The data are plotted as a function of; chromosome 
number; type of mutation; zygosity; gene card name; ensemble name; gene name; amino acid 
change; and whether the mutation is non-synonymous, synonymous, or out with exons.  
 
Supplementary Table 5. Excel file showing RNAseq data with a stringent cutoff requiring at least 
40 mutated RNA sequencing reads and filtered against genomic DNA cutoff of at least 1 mutant 
genomic DNA sequencing read (from Supplementary Table 4). Upon filtering for non-synonymous 
variants, a list was generated composed of 1,418 non-synonymous highly expressed RNA variants. 




































































line, as there are many mutated mRNAs quantified at reads from 39 and lower. However, we focus 
on those mutant mRNA species which are abundant, perhaps not degraded by NMD or perhaps 
not resulting from expression of minor subclones in the A375 cell population. 
 
Supplementary Table 6. Excel file showing a subset of genes acquired after the list composed of 
1,418 non-synonymous highly expressed RNA variants (Supplementary Table 5) with the 1,468 CLC 
genomic DNA variants using the stringent DNA variant calling (Supplementary Table 2). The excel 
file highlights a total of 877 out of 985 genes with expressed mRNA variants are not present in the 
original DNA variant list. 
 
Supplementary Table 7. Excel file showing the tryptic peptides processed using SWATH mass 
spectrometry to identify proteins differentially expressed in the wt and p53-null cells using the 
normal reference proteome Swiss-prot and TrEMBL (potential mutant proteins from this are listed 
in Table 1). 
 
Supplementary Table 8. Excel file showing tryptic peptides identified from shotgun mass 
spectrometry including a pre-fractionation step to increase the coverage of total peptides to over 
35,000 with a coverage of over 4,500 proteins. (A). represents data from wt-A375 cells and (B). 
represents data from p53-null A375 cells.  
 
Supplementary Table 9. Excel file showing a subset of proteins listed by selecting proteins from 
the expressed (mRNA) and mutated genes detectable in the shotgun 2D LC-MS/MS experiment 
(Supplementary Table 8A and 8B) using the RNA variant file (Supplementary Table 5). Applying 
RNAseq derived mutant search database to search the 2D LC-MS/MS data, this increased the 
number of detectable mutant peptides to 193. Of this selection, we manually validated all spectra 
from the 193 peptides and we produced data (Fig. 4) of 60 mutated proteins of relatively high 
confidence. Of these 60 mutant proteins, 10 were validated by SRM (Fig. 5; Supplementary Table 
10) to produce a conservative FDR of 20%. Thus, 4 out of 5 of the manually validated, high 
confidence mutated peptides are likely to be mutated. 
 
Supplementary Table 10. Excel file showing results summary of SRM mass spectrometry 
analysis in a subset of 10 mutated proteins. Evaluating similarity of product ion peakgroups 
referring to neopeptides is summarised by dotp value ranging from 0 to 1. Neopeptides with dotp 
above 0.9 and with more than 2 product ions above LOD (three times noise) are considered as 
successfully validated. Abbreviation H refers to spiked-in "heavy" isotope labelled neopeptide and 
L refers to endogenous "Light" form of neopeptide. 
 
Supplementary Table 11. A list of DNA variants detected using VarScan2 using a minimal 
coverage of 1 and hg38.  
Supplementary Table 12. A list of RNA variants detected using VarScan2 using a minimal 
coverage of 10 and hg38.  
Supplementary Table 13. Mutant tryptic peptide lists derived from lysates from wt-p53 cells 
using CLCbio software. 
Supplementary Table 14. Mutant tryptic peptide lists derived from lysates from p53-null cells 
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Chromoso
me Region Type Reference Allele
Reference 
allele Length Zygosity Count Coverage
1 783029 SNV C A No 1 Heterozygous 2 22
1 783029 SNV C C Yes 1 Heterozygous 20 22
1 824115 SNV A C No 1 Heterozygous 7 10
1 824142 SNV C T No 1 Heterozygous 8 11
1 824145..824146MNV CT TG No 2 Heterozygous 8 11
1 877992 SNV C A No 1 Heterozygous 2 12
1 877992 SNV C C Yes 1 Heterozygous 10 12
1 880101 SNV C A No 1 Heterozygous 2 12
1 880101 SNV C C Yes 1 Heterozygous 10 12
1 881679 SNV G T No 1 Heterozygous 4 46
1 881679 SNV G G Yes 1 Heterozygous 42 46
1 884091 SNV C G No 1 Heterozygous 23 63
1 884091 SNV C C Yes 1 Heterozygous 39 63
1 884101 SNV A C No 1 Heterozygous 30 56
1 884101 SNV A A Yes 1 Heterozygous 26 56
1 894642 Deletion C - No 1 Heterozygous 2 29
1 898085 SNV T C No 1 Heterozygous 2 40
1 898085 SNV T T Yes 1 Heterozygous 38 40
1 906643 SNV G A No 1 Heterozygous 2 37
1 906643 SNV G G Yes 1 Heterozygous 34 37
1 908654 SNV C A No 1 Heterozygous 3 51
1 908654 SNV C C Yes 1 Heterozygous 48 51
1 915885 SNV G A No 1 Heterozygous 58 84
1 915885 SNV G G Yes 1 Heterozygous 26 84
1 977191..977193MNV CGG TCT No 3 Heterozygous 3 13
1 977191..977193MNV CGG CGG Yes 3 Heterozygous 10 13
1 977202 SNV T C No 1 Heterozygous 2 13
1 977202 SNV T T Yes 1 Heterozygous 11 13
1 978581 SNV G C No 1 Heterozygous 2 40
1 978581 SNV G G Yes 1 Heterozygous 38 40
1 983673 SNV C A No 1 Heterozygous 4 65
1 983673 SNV C C Yes 1 Heterozygous 61 65
1 984267 SNV G A No 1 Heterozygous 2 13
1 984267 SNV G G Yes 1 Heterozygous 11 13
1 990380 SNV C T No 1 Heterozygous 16 24
1 990380 SNV C C Yes 1 Heterozygous 8 24
1 1133117 SNV C A No 1 Heterozygous 2 14
1 1133117 SNV C C Yes 1 Heterozygous 12 14
1 1133120 SNV G T No 1 Heterozygous 2 14
1 1133120 SNV G G Yes 1 Heterozygous 12 14
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Chromosome Region Type Reference Allele
Reference 
allele Length
1 12887549 SNV T C No 1
1 13036587 SNV C T No 1
1 16383742 SNV C G No 1
1 28268833^28268834Insertion - G No 1
1 79128570^79128571Insertion - T No 1
1 152187562 SNV A C No 1
1 161514542 SNV A C No 1
1 248458717 SNV C G No 1
1 248651927 SNV A G No 1
1 248722722 SNV T C No 1
1 248801610..248801611MNV GC AT No 2
2 24402127^24402128Insertion - AA No 2
2 73675227^73675228Insertion - CTC No 3
2 95847041..95847043Deletion GCG - No 3
2 120194651^120194652Insertion - GTGTGC No 6
2 120704166 SNV G T No 1
2 130738163 SNV G A No 1
2 169830328 SNV A G No 1
2 172182386 SNV C G No 1
2 178494173^178494174Insertion - GGA No 3
3 33879770 SNV G A No 1
3 64619524 SNV G A No 1
3 96336047 SNV G A No 1
3 96336057 SNV T G No 1
3 96336077 SNV C T No 1
3 96336080 SNV G A No 1
3 96336084..96336085MNV AA GG No 2
3 96336087 Deletion G - No 1
3 96336090^96336091Insertion - G No 1
3 96336098 SNV C T No 1
3 96336100..96336102MNV GAA ATG No 3
3 96336111 SNV G T No 1
3 96336113 SNV G A No 1
3 96336116 SNV A T No 1
3 97983391 SNV C T No 1
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Chromosome Region Type Reference Allele
Reference 
allele Length
1 12887549 SNV T C No 1
1 13036587 SNV C T No 1
1 16383742 SNV C G No 1
1 28268833^28268834Insertion - G No 1
1 79128570^79128571Insertion - T No 1
1 152187562 SNV A C No 1
1 161514542 SNV A C No 1
1 248458717 SNV C G No 1
1 248651927 SNV A G No 1
1 248722722 SNV T C No 1
1 248801610..248801611MNV GC AT No 2
2 24402127^24402128Insertion - AA No 2
2 73675227^73675228Insertion - CTC No 3
2 95847041..95847043Deletion GCG - No 3
2 120194651^120194652Insertion - GTGTGC No 6
2 120704166 SNV G T No 1
2 130738163 SNV G A No 1
2 169830328 SNV A G No 1
2 172182386 SNV C G No 1
2 178494173^178494174Insertion - GGA No 3
3 33879770 SNV G A No 1
3 64619524 SNV G A No 1
3 96336047 SNV G A No 1
3 96336057 SNV T G No 1
3 96336077 SNV C T No 1
3 96336080 SNV G A No 1
3 96336084..96336085MNV AA GG No 2
3 96336087 Deletion G - No 1
3 96336090^96336091Insertion - G No 1
3 96336098 SNV C T No 1
3 96336100..96336102MNV GAA ATG No 3
3 96336111 SNV G T No 1
3 96336113 SNV G A No 1
3 96336116 SNV A T No 1
3 97983391 SNV C T No 1
3 123457893 SNV G A No 1
3 184429133^184429134Insertion - TCC No 3
3 195512107 SNV T A No 1
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ChromosomeR gion Type Reference Allele Reference alleleLength Zygosity Count
3 52027853^52027854Insertion - CCTTGG No 6 Homozygous 4247
3 40503520^40503521Insertion - CTGCTG No 6 Heterozygous 667
6 1.6E+08 SNV T C No 1 Heterozygous 591
12 7080212 SNV T C No 1 Homozygous 559
X 1.36E+08 SNV G T No 1 Heterozygous 535
2 232325415..232325417Deletion TCA - No 3 Heterozygous 475
1 6257784^6257785Insertion - T No 1 Heterozygous 442
8 86126827^86126828Insertion - AACATT No 6 Homozygous 424
8 1.45E+08 SNV C T No 1 Heterozygous 407
6 26157119^26157120Insertion - A No 1 Heterozygous 372
11 86519181 SNV G T No 1 Heterozygous 368
12 53690045 SNV C T No 1 Heterozygous 344
19 51850290 SNV G A No 1 Homozygous 334
20 21314624 SNV A G No 1 Heterozygous 321
20 25271155 SNV G C No 1 Heterozygous 310
12 7077684 SNV G A No 1 Heterozygous 305
8 125528031..125528128Deletion TTTAAAAAGATAAAGAAGAATAATTACTCCTAACTTATACAGAACAAATTACTTATTTTCAAACAATGTCACTCTAAGAGGCGAGGCTGGCACTCACC- No 98 Heterozygous 277
1 156565049^156565050Insertion - AC No 2 Homozygous 275
X 12994411 SNV G A No 1 Heterozygous 270
6 29912856 SNV A T No 1 Heterozygous 266
6 29911092 SNV G T No 1 Heterozygous 258
7 80433462 SNV C T No 1 Homozygous 255
6 29911114..29911115MNV GG AC No 2 Heterozygous 246
6 29911119 SNV G T No 1 Heterozygous 243
2 26477125^26477126Insertion - ACT No 3 Homozygous 237
6 29911154 SNV C A No 1 Heterozygous 236
6 29911207 SNV G A No 1 Heterozygous 233
6 29911901 SNV C G No 1 Heterozygous 232
6 29911056 SNV A G No 1 Heterozygous 230
6 29911228 SNV A T No 1 Heterozygous 225
14 21679995^21679996Insertion - T No 1 Heterozygous 223
9 1.31E+08 SNV G A No 1 Heterozygous 222
1 2.37E+08 SNV A G No 1 Heterozygous 219
8 56982391..56982392ReplacementAA T No 2 Homozygous 213
6 29911198 SNV T C No 1 Heterozygous 213
14 102549379^102549380Insertion - T No 1 Heterozygous 210
4 1.91E+08 Deletion T - No 1 Heterozygous 209
17 17039562..17039564Deletion CAG - No 3 Homozygous 206
6 29911928 SNV C G No 1 Heterozygous 201
6 29911930..29911931MNV CA TG No 2 Heterozygous 201
1 2.29E+08 SNV C G No 1 Heterozygous 201
1 21091915 SNV C T No 1 Heterozygous 195
2 55898372..55898457Deletion AATCCCAAGAAGCAAGAGTCAGGCCATGCCTTATTAAAGCTGCCCTCAGCAAAAAAATAAAATAAAATAAAATAAAATTTACCTTT- No 86 Homozygous 185
4 1.09E+08 SNV G A No 1 Homozygous 180
5 1.38E+08 SNV T G No 1 Heterozygous 178
13 31037379^31037380Insertion - T No 1 Heterozygous 176
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ChromosomeRegion Type Zygosity Gene Cards ENSEMBL gene_name (Homo_sapiens_ensembl_v74_mRNA)
1 888659 SNV Homozygous NOC2L ENSG00000188976 , ENST00000327044 , ENSE00003486680 , ENSE00001375393 , ENSE00003682181 , ENSE00003603800 , ENSE00003554589 , ENSE00003657824 , ENSE00003500440 , ENSE00003521833 , ENSE00003527689 , ENSE00003638394 , ENSE00003560627 , ENSE00003602238 , ENSE00001380352 , ENSE00003687250 , ENSE00003589494 , ENSE00003567731 , ENSE00003620005 , ENSE00003591928 , ENSE00001926296 , ENST00000477976 , ENSE00001954015 , ENSE00001826211 , ENSE00003481297 , ENSE00003681316 , ENSE00003688779 , ENSE00003630998 , ENSE00003524730 , ENSE00003679235 , ENSE00003485617 , ENSE00003543641 , ENSE00003483523 , ENSE00003642636 , ENSE00001918683 , ENSE00003472906 , ENSE00003497251 , ENSE00003546702 , ENSE00001944259NOC2L
1 979748 SNV Heterozygous AGRN ENSG00000188157 , ENST00000379370 , ENSE00002277560 , ENSE00001673004 , ENSE00003635914 , ENSE00003677060 , ENSE00003472518 , ENSE00001627476 , ENSE00001700910 , ENSE00001605257 , ENSE00001701194 , ENSE00001762402 , ENSE00001653556 , ENSE00001773423 , ENSE00001688790 , ENSE00001737074 , ENSE00003686258 , ENSE00003684009 , ENSE00001652878 , ENSE00001750513 , ENSE00001787340 , ENSE00001622111 , ENSE00003529542 , ENSE00001667688 , ENSE00001650172 , ENSE00001641464 , ENSE00001706121 , ENSE00001622861 , ENSE00001756488 , ENSE00001657020 , ENSE00001693596 , ENSE00001367302 , ENSE00001385905 , ENSE00001374645 , ENSE00001381606 , ENSE00002692404 , ENSE00003619422 , ENSE00001883271AGRN
1 1E+06 SNV Homozygous CPSF3L ENSG00000127054 , ENST00000470030 , ENSE00001225702 , ENSE00003667474 , ENSE00003564118 , ENSE00003588285 , ENSE00003579189 , ENSE00003654424 , ENSE00001885934 , ENSE00003604060 , ENSE00003464675 , ENSE00002157633 , ENST00000435064 , ENSE00001606556 , ENSE00003580641 , ENSE00003524405 , ENSE00003642378 , ENSE00003493216 , ENSE00003480282 , ENSE00003521162 , ENSE00003692932 , ENSE00003568595 , ENSE00003481468 , ENSE00003604585 , ENSE00003562382 , ENSE00003625354 , ENSE00003522925 , ENSE00003666435 , ENSE00003594178 , ENSE00001730173 , ENST00000323275 , ENSE00001873980 , ENSE00003616764 , ENSE00003594177 , ENSE00003620245 , ENSE00003493634 , ENSE00003488128 , ENSE00003607355 , ENSE00001824639 , ENSE00001955950 , ENST00000411962 , ENSE00001684027 , ENSE00003473777 , ENSE00001664761 , ENST00000462432 , ENSE00001661816 , ENSE00001945772 , ENST00000478641 , ENSE00003529299 , ENSE00001816794 , ENSE00001868536 , ENSE00001905465 , ENST00000540437 , ENSE00003465286 , ENSE00003482551 , ENSE00003591275 , ENSE00002257542 CPSF3L
1 1E+06 SNV Heterozygous ATAD3B ENSG00000160072 , ENST00000308647 , ENSE00001833190 , ENSE00003467707 , ENSE00003569130 , ENSE00003608502 , ENSE00003474888 , ENSE00003654064 , ENSE00003510521 , ENSE00003459370 , ENSE00003655926 , ENSE00003594545 , ENSE00003662125 , ENSE00003689846 , ENSE00003670332 , ENSE00003505365 , ENSE00003497242 , ENSE00003481470 , ENST00000472194 , ENSE00001943609 , ENSE00003589422 , ENSE00003672769 , ENSE00003661157 , ENSE00003517812 , ENSE00003542737 , ENSE00003479480 , ENSE00003503434 , ENSE00003513162 , ENSE00003528975 , ENSE00003611023 , ENSE00003653402 , ENSE00003486643 , ENSE00001863816 , ENST00000485748 , ENSE00001893282 , ENSE00001885858 , ENSE00003689276 , ENST00000474481 , ENSE00001844843 , ENSE00001818637 , ENSE00001832340 , ENSE00001844973ATAD3B
1 1E+06 SNV Heterozygous ATAD3A ENSG00000197785 , ENST00000378756 , ENSE00001948795 , ENSE00003592232 , ENSE00001769953 , ENSE00003689904 , ENSE00003620804 , ENSE00003607995 , ENSE00003505667 , ENSE00001615816 , ENSE00001745869 , ENSE00001784657 , ENSE00001792016 , ENSE00000875540 , ENSE00001664426 , ENSE00001304286 , ENSE00003686145 , ENSE00001386419 , ENST00000378755 , ENSE00002685283 , ENSE00001624063 , ENST00000339113 , ENSE00003520187 , ENST00000536055 , ENSE00003549567 , ENSE00003601804 , ENSE00002313718ATAD3A
1 1647893^1647894Insertion Unknown CDK11A , RP1-283E3.8ENSG00000008128 , ENSG00000268575 , ENST00000356200 , ENSE00001425777 , ENSE00003646560 , ENSE00003652156 , ENSE00003507378 , ENSE00003476013 , ENSE00003538477 , ENSE00003629837 , ENSE00003673770 , ENSE00003484918 , ENSE00003573320 , ENSE00003490604 , ENSE00003540484 , ENSE00003493098 , ENSE00003532668 , ENSE00003466910 , ENSE00003647264 , ENSE00001714517 , ENSE00003525046 , ENSE00003500548 , ENST00000598846 , ENSE00003169804 , ENSE00003525671 , ENSE00003579997 , ENSE00003467598 , ENSE00003549784 , ENSE00003604931 , ENSE00003496413 , ENSE00003582288 , ENSE00003663196 , ENSE00003558967 , ENSE00003590009 , ENSE00003636205 , ENSE00003461022 , ENSE00003468921 , ENSE00003672483 , ENSE00003637566 , ENSE00003634757 , ENSE00003575907 , ENSE00003556340 , ENSE00003226367 , ENST00000356937 , ENSE00003646300 , ENSE00003535326 , ENSE00003477001 , ENSE00003468898 , ENSE00001876481 , ENSE00003645656 , ENSE00003594351 , ENSE00003591780 , ENSE00003621129 , ENSE00003502274 , ENSE00003459912 , ENSE00003568909 , ENSE00003592140 CDK11A, RP1-283E3.
1 2E+06 SNV Unknown CDK11A , RP1-283E3.8ENSG00000008128 , ENSG00000268575 , ENST00000356200 , ENSE00001425777 , ENSE00003646560 , ENSE00003652156 , ENSE00003507378 , ENSE00003476013 , ENSE00003538477 , ENSE00003629837 , ENSE00003673770 , ENSE00003484918 , ENSE00003573320 , ENSE00003490604 , ENSE00003540484 , ENSE00003493098 , ENSE00003532668 , ENSE00003466910 , ENSE00003647264 , ENSE00001714517 , ENSE00003525046 , ENSE00003500548 , ENST00000378638 , ENSE00003675617 , ENSE00001478182 , ENSE00003490829 , ENST00000509982 , ENSE00003646300 , ENSE00003535326 , ENSE00003477001 , ENSE00003468898 , ENSE00003555976 , ENSE00003612771 , ENSE00003645656 , ENSE00003649099 , ENSE00003648668 , ENSE00003557609 , ENSE00001643586 , ENSE00002060556 , ENST00000404249 , ENSE00003563203 , ENSE00001357141 , ENST00000460465 , ENST00000498810 , ENSE00001832645 , ENSE00001912903CDK11A
1 2E+06 SNV Unknown CDK11A , RP1-283E3.8ENSG00000008128 , ENSG00000268575 , ENST00000356200 , ENSE00001425777 , ENSE00003646560 , ENSE00003652156 , ENSE00003507378 , ENSE00003476013 , ENSE00003538477 , ENSE00003629837 , ENSE00003673770 , ENSE00003484918 , ENSE00003573320 , ENSE00003490604 , ENSE00003540484 , ENSE00003493098 , ENSE00003532668 , ENSE00003466910 , ENSE00003647264 , ENSE00001714517 , ENSE00003525046 , ENSE00003500548 , ENST00000598846 , ENSE00003169804 , ENSE00003525671 , ENSE00003579997 , ENSE00003467598 , ENSE00003549784 , ENSE00003604931 , ENSE00003496413 , ENSE00003582288 , ENSE00003663196 , ENSE00003558967 , ENSE00003590009 , ENSE00003636205 , ENSE00003461022 , ENSE00003468921 , ENSE00003672483 , ENSE00003637566 , ENSE00003634757 , ENSE00003575907 , ENSE00003556340 , ENSE00003226367 , ENST00000356937 , ENSE00003646300 , ENSE00003535326 , ENSE00003477001 , ENSE00003468898 , ENSE00001876481 , ENSE00003645656 , ENSE00003594351 , ENSE00003591780 , ENSE00003621129 , ENSE00003502274 , ENSE00003459912 , ENSE00003568909 , ENSE00003592140 CDK11A, RP1-283E3.
1 2E+06 SNV Unknown CDK11A , RP1-283E3.8ENSG00000008128 , ENSG00000268575 , ENST00000356200 , ENSE00001425777 , ENSE00003646560 , ENSE00003652156 , ENSE00003507378 , ENSE00003476013 , ENSE00003538477 , ENSE00003629837 , ENSE00003673770 , ENSE00003484918 , ENSE00003573320 , ENSE00003490604 , ENSE00003540484 , ENSE00003493098 , ENSE00003532668 , ENSE00003466910 , ENSE00003647264 , ENSE00001714517 , ENSE00003525046 , ENSE00003500548 , ENST00000598846 , ENSE00003169804 , ENSE00003525671 , ENSE00003579997 , ENSE00003467598 , ENSE00003549784 , ENSE00003604931 , ENSE00003496413 , ENSE00003582288 , ENSE00003663196 , ENSE00003558967 , ENSE00003590009 , ENSE00003636205 , ENSE00003461022 , ENSE00003468921 , ENSE00003672483 , ENSE00003637566 , ENSE00003634757 , ENSE00003575907 , ENSE00003556340 , ENSE00003226367 , ENST00000356937 , ENSE00003646300 , ENSE00003535326 , ENSE00003477001 , ENSE00003468898 , ENSE00001876481 , ENSE00003645656 , ENSE00003594351 , ENSE00003591780 , ENSE00003621129 , ENSE00003502274 , ENSE00003459912 , ENSE00003568909 , ENSE00003592140 CDK11A, RP1-283E3.
1 2E+06 SNV Homozygous NADK ENSG00000008130 , ENST00000341426 , ENSE00001425950 , ENSE00003520839 , ENSE00001704992 , ENSE00003693808 , ENSE00003514689 , ENSE00003498213 , ENSE00003692625 , ENSE00003537469 , ENSE00003606510 , ENSE00003487616 , ENSE00003541571 , ENSE00001430349 , ENST00000341991 , ENSE00001399432 , ENST00000378625 , ENSE00000862102 , ENSE00000862099 , ENSE00000862098 , ENSE00000862097 , ENSE00001036406 , ENST00000344463 , ENSE00001627098 , ENST00000342348 , ENSE00001545357 , ENSE00001478092 , ENST00000469045 , ENSE00001889162 , ENSE00003552425 , ENSE00003563592 , ENSE00003660860 , ENSE00003646914 , ENSE00003542699 , ENSE00001907368 , ENSE00001846753 , ENST00000480499 , ENSE00001833463 , ENSE00001935920 , ENST00000497747 , ENSE00001854922 , ENSE00001867642 , ENST00000477235 , ENSE00001875142 , ENSE00001870563 , ENST00000489538 , ENSE00001949887 , ENSE00003552703 , ENST00000497615 , ENSE00001828299 , ENSE00001830936 , ENST00000497186 , ENSE00001875307 , ENSE00001856899 , ENSE00001916343NADK
1 4E+06 SNV Homozygous C1orf174 ENSG00000198912 , ENST00000486765 , ENSE00003665229 , ENSE00003481256 , ENSE00003620441 , ENSE00001872953 , ENSE00001958105 , ENST00000361605 , ENSE00003665457 , ENSE00003466374 , ENSE00003548802 , ENSE00001891341 , ENST00000474140 , ENSE00001810609 , ENSE00001305119C1orf174
1 7E+06 SNV Homozygous THAP3 ENSG00000041988 , ENST00000054650 , ENSE00001474647 , ENSE00001402591 , ENSE00003406981 , ENSE00003477092 , ENSE00003674101 , ENSE00002956509 , ENST00000307896 , ENSE00001953794 , ENSE00001474622 , ENSE00001911752 , ENST00000484669 , ENSE00001838698 , ENSE00003575953 , ENSE00003607356 , ENSE00003420323 , ENST00000487819 , ENSE00001811514 , ENSE00001812175 , ENSE00003679469 , ENSE00001850664 , ENST00000472925 , ENSE00001868761 , ENSE00001933780THAP3
1 1E+07 SNV Unknown MTOR ENSG00000198793 , ENST00000376838 , ENSE00001345243 , ENSE00003653682 , ENSE00003530156 , ENSE00003523148 , ENSE00003615787 , ENSE00003537296 , ENSE00003629136 , ENSE00001167794 , ENSE00001167801 , ENSE00001167809 , ENSE00001167814 , ENSE00001167821 , ENSE00001167829 , ENSE00001167837 , ENSE00001167844 , ENSE00001167852 , ENSE00001167858 , ENSE00001167869 , ENSE00001041990 , ENSE00001471843 , ENST00000361445 , ENSE00001167893 , ENSE00001167905 , ENSE00003513153 , ENSE00003571700 , ENSE00003482987 , ENSE00001167940 , ENSE00001167950 , ENSE00001167960 , ENSE00001167966 , ENSE00001167973 , ENSE00001167981 , ENSE00000743767 , ENSE00000743769 , ENSE00000743771 , ENSE00001435329 , ENSE00000743775 , ENSE00000743777 , ENSE00000743779 , ENSE00000743781 , ENSE00000743783 , ENSE00000743785 , ENSE00000743788 , ENSE00000743790 , ENSE00000743792 , ENSE00000743794 , ENSE00000743796 , ENSE00000743799 , ENSE00000743801 , ENSE00000743803 , ENSE00000743805 , ENSE00000743807 , ENSE00000743810 , ENSE00000743812 , ENSE00000743813 MTOR
1 1E+07 SNV Unknown MIIP ENSG00000116691 , ENST00000478749 , ENSE00001470129 , ENSE00003497712 , ENSE00003463042 , ENSE00003567102 , ENSE00003531108 , ENSE00001940719 , ENST00000235332 , ENSE00000818973 , ENSE00003517689 , ENSE00003645178 , ENSE00003513763 , ENSE00003546551 , ENSE00003636418 , ENSE00003579615 , ENSE00003617293 , ENSE00001841836 , ENST00000436478 , ENSE00001646823 , ENSE00003661860 , ENSE00001629397 , ENST00000466860 , ENSE00001947124 , ENSE00001906510 , ENSE00003614485 , ENSE00001955238 , ENST00000498685 , ENSE00001852453 , ENSE00001817974 , ENSE00003629065 , ENSE00001949205MIIP
1 2E+07 SNV Homozygous RP1-43E13.2 , EMC1ENSG00000230424 , ENSG00000127463 , ENST00000477853 , ENSE00001943800 , ENSE00003672321 , ENSE00003538409 , ENSE00003461478 , ENSE00003498692 , ENSE00003641737 , ENSE00000908608 , ENSE00000908606 , ENSE00000908604 , ENSE00000908602 , ENSE00000872911 , ENSE00000908600 , ENSE00000908598 , ENSE00000908596 , ENSE00001801402 , ENSE00001740696 , ENSE00001638308 , ENSE00001664299 , ENSE00001638237 , ENSE00001676545 , ENSE00003597230 , ENSE00001797601 , ENSE00001265682 , ENST00000375199 , ENSE00003611596 , ENSE00001893412 , ENSE00001952537 , ENST00000375208 , ENSE00001330592 , ENSE00001942094 , ENST00000467423 , ENSE00001953347 , ENSE00001911242EMC1
1 2E+07 SNV Homozygous DDOST ENSG00000244038 , ENST00000602624 , ENSE00001465599 , ENSE00000756208 , ENSE00000756209 , ENSE00000756210 , ENSE00000756211 , ENSE00000756212 , ENSE00003511750 , ENSE00003696592 , ENSE00003189747 , ENSE00003701820 , ENSE00003368657 , ENST00000375048 , ENSE00001465622 , ENST00000415136 , ENSE00001742522 , ENSE00001697710 , ENST00000464364 , ENSE00003510449 , ENSE00001952963DDOST
1 2E+07 SNV Heterozygous HP1BP3 ENSG00000127483 , ENST00000312239 , ENSE00001725405 , ENSE00003664977 , ENSE00003544551 , ENSE00000756341 , ENSE00003546950 , ENSE00001279286 , ENSE00001465477 , ENSE00001211353 , ENSE00001465489 , ENSE00001279326 , ENSE00003627984 , ENSE00002245255 , ENSE00001427252 , ENST00000375003 , ENSE00001465393 , ENSE00001465376 , ENST00000419948 , ENSE00001709526 , ENSE00001787650 , ENST00000438032 , ENSE00003609204 , ENSE00001761624 , ENST00000424732 , ENSE00001767516 , ENSE00003682895 , ENSE00001649722HP1BP3
1 2E+07 SNV Unknown EIF4G3 ENSG00000075151 , ENST00000264211 , ENSE00001542805 , ENSE00001683487 , ENSE00001604595 , ENSE00001672406 , ENSE00002176939 , ENSE00003484684 , ENSE00003564924 , ENSE00003683156 , ENSE00001690531 , ENSE00001784396 , ENSE00001726513 , ENSE00001712596 , ENSE00001804546 , ENSE00001764077 , ENSE00001604127 , ENSE00001703965 , ENSE00001658251 , ENSE00001594127 , ENSE00001690105 , ENSE00003489381 , ENSE00003472324 , ENSE00003490165 , ENSE00003618120 , ENSE00003613920 , ENSE00001686750 , ENSE00003671517 , ENSE00001066154 , ENSE00003477705 , ENSE00003647587 , ENSE00003337316 , ENSE00003227684 , ENST00000400422 , ENSE00001765035 , ENSE00003235835 , ENSE00001465229 , ENSE00001465230 , ENST00000602326 , ENSE00001735790 , ENSE00002247070 , ENSE00003457551 , ENST00000374937 , ENSE00002305967 , ENSE00002279576 , ENST00000536266 , ENSE00002311263 , ENSE00003588050 , ENSE00003471241 , ENSE00002294743 , ENST00000544689 , ENSE00002261758 , ENSE00002301119 , ENSE00002255470 , ENST00000356916 , ENSE00001433382 , ENSE00001419647 EIF4G3
1 2E+07 SNV Homozygous ID3 ENSG00000117318 , ENST00000374561 , ENSE00001463824 , ENSE00000758534 , ENSE00001463830 , ENST00000463312 , ENSE00001939682 , ENSE00001863188 , ENST00000486541 , ENSE00001907104 , ENSE00001819586ID3
1 2E+07 SNV Unknown NIPAL3 ENSG00000001461 , ENST00000374399 , ENSE00001432973 , ENSE00003585417 , ENSE00003670970 , ENSE00003569258 , ENSE00001603157 , ENSE00001776100 , ENSE00001655999 , ENSE00001642364 , ENSE00003659521 , ENSE00003575842 , ENSE00001679113 , ENSE00001208933 , ENST00000003912 , ENSE00001463427 , ENSE00003476526 , ENSE00001463425 , ENSE00003648257 , ENSE00003550216 , ENSE00001463422 , ENST00000339255 , ENSE00001463418 , ENSE00001463416 , ENST00000432012 , ENSE00001711005 , ENSE00001383586 , ENSE00003516460 , ENSE00003603799 , ENSE00001664457NIPAL3
1 3E+07 SNV Homozygous RPS6KA1 ENSG00000117676 , ENST00000526040 , ENSE00002171940 , ENSE00003658122 , ENSE00003588824 , ENSE00003674954 , ENSE00003233494 , ENST00000374168 , ENSE00002251149 , ENSE00003553031 , ENSE00003486086 , ENSE00003630393 , ENSE00003562371 , ENSE00003557941 , ENSE00003624622 , ENSE00003563498 , ENSE00003499674 , ENSE00003507729 , ENSE00003470424 , ENSE00003507535 , ENSE00003564726 , ENSE00003573880 , ENSE00003521520 , ENSE00003471820 , ENSE00003583645 , ENSE00003529141 , ENSE00003533361 , ENSE00003488069 , ENSE00001951242 , ENST00000374166 , ENSE00002183218 , ENSE00002194644 , ENSE00001462663 , ENST00000526792 , ENSE00002192529 , ENSE00003474922 , ENSE00003576123 , ENSE00003560372 , ENSE00002191370 , ENST00000529454 , ENSE00002144676 , ENSE00003677749 , ENST00000374162 , ENST00000530003 , ENSE00001753243 , ENST00000531113 , ENSE00002146075 , ENSE00003612557 , ENSE00003556316 , ENSE00003531142 , ENSE00003467047 , ENSE00003633595 , ENSE00003523839 , ENSE00003671915 , ENSE00003516216 , ENSE00003690758 , ENSE00003489482 RPS KA1
1 3E+07 SNV Heterozygous RPS6KA1 ENSG00000117676 , ENST00000374168 , ENSE00002251149 , ENSE00003658122 , ENSE00003553031 , ENSE00003486086 , ENSE00003630393 , ENSE00003562371 , ENSE00003557941 , ENSE00003624622 , ENSE00003563498 , ENSE00003499674 , ENSE00003507729 , ENSE00003470424 , ENSE00003507535 , ENSE00003564726 , ENSE00003573880 , ENSE00003521520 , ENSE00003471820 , ENSE00003583645 , ENSE00003529141 , ENSE00003533361 , ENSE00003488069 , ENSE00001951242 , ENST00000374166 , ENSE00002183218 , ENSE00002194644 , ENSE00001462663 , ENST00000526792 , ENSE00002192529 , ENSE00003474922 , ENSE00003576123 , ENSE00003560372 , ENSE00002191370 , ENST00000374162 , ENSE00002144676 , ENST00000530003 , ENSE00001753243 , ENST00000531113 , ENSE00002146075 , ENSE00003612557 , ENSE00003556316 , ENSE00003674954 , ENSE00003531142 , ENSE00003467047 , ENSE00003633595 , ENSE00003523839 , ENSE00003671915 , ENSE00003516216 , ENSE00003690758 , ENSE00003489482 , ENSE00003574838 , ENSE00003558617 , ENSE00003543547 , ENSE00003609506 , ENSE00002145613 , ENST00000374163 RPS KA1
1 3E+07 SNV Homozygous GPN2 ENSG00000142751 , ENST00000374135 , ENSE00001899852 , ENSE00003489087 , ENSE00003679218 , ENSE00003481397 , ENSE00001462565 , ENST00000374133 , ENSE00001905314 , ENSE00001538148 , ENST00000477418 , ENSE00001891592 , ENSE00003489486 , ENSE00001841904GPN2
1 3E+07 SNV Homozygous TRNP1 ENSG00000253368 , ENST00000522111 , ENSE00002107275 , ENSE00002093924TRNP1
1 3E+07 SNV Heterozygous PPP1R8 ENSG00000117751 , ENST00000311772 , ENSE00001435421 , ENSE00003613106 , ENSE00003693617 , ENSE00003574066 , ENSE00003676902 , ENSE00003461118 , ENSE00001949814 , ENST00000236412 , ENSE00001362819 , ENSE00003498666 , ENSE00003628142 , ENSE00003502212 , ENSE00003686484 , ENSE00001883755 , ENST00000373931 , ENSE00001461947 , ENSE00003675606 , ENSE00000956265 , ENST00000431586 , ENSE00001591740 , ENSE00001804260PPP R8
1 3E+07 SNV Homozygous SRSF4 ENSG00000116350 , ENST00000373795 , ENSE00001461590 , ENSE00001042695 , ENSE00003643122 , ENSE00003573522 , ENSE00003642524 , ENSE00001911200 , ENST00000546138 , ENSE00002270497 , ENSE00002286081 , ENST00000466448 , ENSE00001950760 , ENSE00003602888 , ENSE00003578857 , ENSE00003626486 , ENSE00001461592SRSF4
1 3E+07 SNV Homozygous SRSF4 ENSG00000116350 , ENST00000373795 , ENSE00001461590 , ENSE00001042695 , ENSE00003643122 , ENSE00003573522 , ENSE00003642524 , ENSE00001911200 , ENST00000546138 , ENSE00002270497 , ENSE00002286081 , ENST00000466448 , ENSE00001950760 , ENSE00003602888 , ENSE00003578857 , ENSE00003626486 , ENSE00001461592SRSF4
1 3E+07 SNV Homozygous SRSF4 ENSG00000116350 , ENST00000373795 , ENSE00001461590 , ENSE00001042695 , ENSE00003643122 , ENSE00003573522 , ENSE00003642524 , ENSE00001911200 , ENST00000546138 , ENSE00002270497 , ENSE00002286081 , ENST00000466448 , ENSE00001950760 , ENSE00003602888 , ENSE00003578857 , ENSE00003626486 , ENSE00001461592SRSF4
1 3E+07 SNV Homozygous MECR ENSG00000116353 , ENST00000373791 , ENSE00001711082 , ENSE00003671182 , ENSE00003606944 , ENSE00003555300 , ENSE00003514783 , ENSE00003576980 , ENSE00003657858 , ENSE00003614856 , ENSE00003616183 , ENSE00001889974 , ENST00000263702 , ENSE00003463736 , ENSE00003541531 , ENSE00001897993 , ENST00000473030 , ENSE00001850479 , ENSE00003640958 , ENSE00003525696 , ENSE00003580021 , ENSE00003471099 , ENSE00003657271 , ENSE00003492562 , ENSE00001833500 , ENST00000478505 , ENSE00003604258 , ENSE00003506002 , ENSE00003596883 , ENSE00001924630 , ENST00000490529 , ENSE00001921668 , ENSE00001809767 , ENST00000463052 , ENSE00001893411 , ENSE00003550544 , ENSE00001958942 , ENSE00001941581 , ENSE00001902512 , ENST00000489248 , ENSE00001836699 , ENSE00001871015 , ENSE00001940329 , ENST00000475861 , ENSE00001852418 , ENSE00003516623 , ENST00000474946 , ENSE00001894075 , ENSE00001953775 , ENST00000464915 , ENSE00001921968 , ENSE00001841017 , ENST00000482610 , ENSE00001886748 , ENSE00001845275 , ENSE00001912797 , ENSE00001857949MECR
1 31905889^31905890Insertion Heterozygous SERINC2 ENSG00000168528 , ENST00000373710 , ENSE00001461351 , ENSE00001461350 , ENSE00003618497 , ENSE00003644553 , ENSE00003622655 , ENSE00003606452 , ENSE00003581428 , ENSE00003475719 , ENSE00003650780 , ENSE00003535882 , ENSE00003628526 , ENST00000536859 , ENSE00002305003 , ENSE00002289096 , ENST00000373709 , ENSE00001461347 , ENSE00001946740 , ENST00000536384 , ENSE00002304183 , ENSE00002224058 , ENST00000491976 , ENSE00001840098 , ENSE00001859009 , ENSE00003694261 , ENSE00003653057 , ENSE00003553664 , ENSE00003459306 , ENSE00003590100 , ENSE00003669511 , ENSE00003630039 , ENSE00003624933 , ENSE00003549179SERINC2
1 3E+07 SNV Heterozygous ZBTB8OS ENSG00000176261 , ENST00000468695 , ENSE00001826660 , ENSE00003589102 , ENSE00003681847 , ENSE00003470229 , ENSE00003621651 , ENSE00003650439 , ENSE00001326521 , ENST00000373506 , ENSE00001460713 , ENSE00003467000 , ENSE00003671945 , ENSE00003602152 , ENSE00003502846 , ENSE00001818109 , ENST00000498691 , ENSE00003494650 , ENSE00001842596 , ENSE00001877639 , ENST00000478041 , ENSE00001855061 , ENSE00001940345 , ENST00000473294 , ENSE00001833927 , ENSE00003640849 , ENSE00003559633 , ENST00000436661 , ENSE00003524664 , ENSE00003544839 , ENSE00003501757 , ENST00000373501 , ENSE00001460707 , ENSE00003585636 , ENST00000476493 , ENSE00001850109 , ENSE00003682770 , ENSE00003517136 , ENSE00001871846 , ENST00000465588 , ENSE00001910521 , ENSE00001842328 , ENST00000483138 , ENSE00001894343 , ENSE00003459256 , ENST00000479075 , ENSE00001909410 , ENSE00001917657 , ENST00000473383 , ENSE00001945560ZBTB8OS
1 4E+07 SNV Homozygous ZMYM1 ENSG00000197056 , ENST00000417119 , ENSE00001777626 , ENSE00001704777 , ENSE00003477630 , ENSE00003535611 , ENSE00003498284 , ENSE00003698994 , ENSE00003701996 , ENSE00003697440 , ENSE00003700711 , ENSE00003699331 , ENSE00001603563 , ENST00000359858 , ENSE00001460290 , ENSE00001849248 , ENST00000466390 , ENSE00001918490 , ENSE00001904439 , ENSE00003566845 , ENSE00001889732 , ENST00000488455 , ENSE00001880330 , ENSE00001861667 , ENSE00003560859 , ENSE00003701808 , ENSE00003695940 , ENSE00003695342 , ENSE00003699567 , ENSE00001944666 , ENSE00003697044 , ENSE00001878524 , ENST00000475654 , ENSE00001374249 , ENSE00001824630 , ENST00000373329 , ENSE00003698724 , ENSE00001460277 , ENST00000373330 , ENSE00001460287 , ENSE00001460285 , ENST00000476269 , ENSE00001890424 , ENSE00001919741ZMYM1
1 4E+07 SNV Homozygous CLSPN ENSG00000092853 , ENST00000251195 , ENSE00001079142 , ENSE00003624322 , ENSE00003573755 , ENSE00000765315 , ENSE00000765316 , ENSE00000765317 , ENSE00000765318 , ENSE00000765320 , ENSE00000765376 , ENSE00000594892 , ENSE00000765378 , ENSE00003536964 , ENSE00000765382 , ENSE00000765410 , ENSE00000861197 , ENSE00001036904 , ENSE00000861199 , ENSE00000765426 , ENSE00000765461 , ENSE00000765500 , ENSE00000861200 , ENSE00000861201 , ENSE00000765532 , ENSE00000765534 , ENSE00001958448 , ENST00000373220 , ENSE00001238398 , ENSE00001373488 , ENST00000520551 , ENSE00002096453 , ENST00000318121CLSPN
1 4E+07 SNV Unknown CLSPN ENSG00000092853 , ENST00000251195 , ENSE00001079142 , ENSE00003624322 , ENSE00003573755 , ENSE00000765315 , ENSE00000765316 , ENSE00000765317 , ENSE00000765318 , ENSE00000765320 , ENSE00000765376 , ENSE00000594892 , ENSE00000765378 , ENSE00003536964 , ENSE00000765382 , ENSE00000765410 , ENSE00000861197 , ENSE00001036904 , ENSE00000861199 , ENSE00000765426 , ENSE00000765461 , ENSE00000765500 , ENSE00000861200 , ENSE00000861201 , ENSE00000765532 , ENSE00000765534 , ENSE00001958448 , ENST00000373220 , ENSE00001238398 , ENSE00001373488 , ENST00000520551 , ENSE00002096453 , ENST00000318121CLSPN
1 4E+07 SNV Heterozygous ADPRHL2 ENSG00000116863 , ENST00000373178 , ENSE00001399758 , ENSE00000766217 , ENSE00003398800 , ENSE00003398258 , ENSE00000766220 , ENSE00000861244ADPRHL2
1 4E+07 SNV Heterozygous THRAP3 ENSG00000054118 , ENST00000354618 , ENSE00001459618 , ENSE00001354450 , ENSE00001298923 , ENSE00001291272 , ENSE00000955947 , ENSE00003566879 , ENSE00003479354 , ENSE00003660836 , ENSE00000766231 , ENSE00001079145 , ENSE00001079144 , ENSE00001402345 , ENST00000469141 , ENSE00001829811 , ENSE00001910590 , ENSE00002179918THRAP3
1 4E+07 SNV Unknown MACF1 ENSG00000127603 , ENST00000545844 , ENSE00002210687 , ENSE00002164985 , ENSE00003584786 , ENSE00003466663 , ENSE00003679312 , ENSE00003602769 , ENSE00002273289 , ENSE00001633058 , ENSE00003639143 , ENSE00001691519 , ENSE00002708865 , ENSE00003461801 , ENSE00001713164 , ENSE00001641956 , ENSE00001760927 , ENSE00001654662 , ENSE00001621722 , ENSE00001771617 , ENSE00001765360 , ENSE00001679208 , ENSE00001217237 , ENSE00001218134 , ENSE00003690465 , ENSE00003484227 , ENSE00003474074 , ENSE00003591734 , ENSE00003499885 , ENSE00003520092 , ENSE00003649450 , ENSE00003674352 , ENSE00003499725 , ENSE00003679603 , ENSE00003466382 , ENSE00003684463 , ENSE00003649898 , ENSE00003605315 , ENSE00003688828 , ENSE00003683045 , ENSE00003527187 , ENSE00003674754 , ENSE00003678072 , ENSE00003621022 , ENSE00003526687 , ENSE00003535713 , ENSE00003462003 , ENSE00003615518 , ENSE00001693302 , ENSE00001612539 , ENSE00001805045 , ENSE00001643168 , ENSE00001727162 , ENSE00001734332 , ENSE00001599839 , ENSE00001784267 , ENSE00001769328 MACF1
1 4E+07 SNV Homozygous CAP1 ENSG00000131236 , ENST00000372797 , ENSE00001458655 , ENSE00001458701 , ENSE00000899727 , ENSE00001192144 , ENSE00001192143 , ENSE00001192141 , ENSE00001192138 , ENSE00003580138 , ENSE00003554678 , ENSE00003459410 , ENSE00003477815 , ENSE00003512323 , ENSE00001458693 , ENST00000372802 , ENSE00001458691 , ENSE00001192162 , ENSE00001458689 , ENSE00001458688 , ENST00000414893 , ENSE00001623537 , ENSE00001458665 , ENSE00001458664 , ENSE00001769605 , ENST00000372792 , ENSE00001192151 , ENSE00001458654 , ENST00000372798 , ENSE00001458681 , ENSE00001458680 , ENST00000340450 , ENSE00001850738 , ENSE00001836506 , ENST00000372805 , ENSE00001822157 , ENSE00001937537 , ENST00000435719 , ENSE00001644002 , ENSE00001746536 , ENST00000479759 , ENSE00001939084 , ENSE00003630218 , ENSE00003466857 , ENSE00003536326 , ENSE00003591535 , ENSE00003634946 , ENSE00001871348CAP1
1 4E+07 SNV Homozygous CAP1 ENSG00000131236 , ENST00000372797 , ENSE00001458655 , ENSE00001458701 , ENSE00000899727 , ENSE00001192144 , ENSE00001192143 , ENSE00001192141 , ENSE00001192138 , ENSE00003580138 , ENSE00003554678 , ENSE00003459410 , ENSE00003477815 , ENSE00003512323 , ENSE00001458693 , ENST00000372802 , ENSE00001458691 , ENSE00001192162 , ENSE00001458689 , ENSE00001458688 , ENST00000414893 , ENSE00001623537 , ENSE00001458665 , ENSE00001458664 , ENSE00001769605 , ENST00000372792 , ENSE00001192151 , ENSE00001458654 , ENST00000372798 , ENSE00001458681 , ENSE00001458680 , ENST00000340450 , ENSE00001850738 , ENSE00001836506 , ENST00000372805 , ENSE00001822157 , ENSE00001937537 , ENST00000435719 , ENSE00001644002 , ENSE00001746536 , ENST00000479759 , ENSE00001939084 , ENSE00003630218 , ENSE00003466857 , ENSE00003536326 , ENSE00003591535 , ENSE00003634946 , ENSE00001871348CAP1
1 4E+07 SNV Homozygous CAP1 ENSG00000131236 , ENST00000372797 , ENSE00001458655 , ENSE00001458701 , ENSE00000899727 , ENSE00001192144 , ENSE00001192143 , ENSE00001192141 , ENSE00001192138 , ENSE00003580138 , ENSE00003554678 , ENSE00003459410 , ENSE00003477815 , ENSE00003512323 , ENSE00001458693 , ENST00000372802 , ENSE00001458691 , ENSE00001192162 , ENSE00001458689 , ENSE00001458688 , ENST00000414893 , ENSE00001623537 , ENSE00001458665 , ENSE00001458664 , ENSE00001769605 , ENST00000372792 , ENSE00001192151 , ENSE00001458654 , ENST00000372798 , ENSE00001458681 , ENSE00001458680 , ENST00000340450 , ENSE00001850738 , ENSE00001836506 , ENST00000372805 , ENSE00001822157 , ENSE00001937537 , ENST00000435719 , ENSE00001644002 , ENSE00001746536 , ENST00000479759 , ENSE00001939084 , ENSE00003630218 , ENSE00003466857 , ENSE00003536326 , ENSE00003591535 , ENSE00003634946 , ENSE00001871348CAP1
1 4E+07 SNV Homozygous CAP1 ENSG00000131236 , ENST00000372797 , ENSE00001458655 , ENSE00001458701 , ENSE00000899727 , ENSE00001192144 , ENSE00001192143 , ENSE00001192141 , ENSE00001192138 , ENSE00003580138 , ENSE00003554678 , ENSE00003459410 , ENSE00003477815 , ENSE00003512323 , ENSE00001458693 , ENST00000372802 , ENSE00001458691 , ENSE00001192162 , ENSE00001458689 , ENSE00001458688 , ENST00000414893 , ENSE00001623537 , ENSE00001458665 , ENSE00001458664 , ENSE00001769605 , ENST00000372792 , ENSE00001192151 , ENSE00001458654 , ENST00000372798 , ENSE00001458681 , ENSE00001458680 , ENST00000340450 , ENSE00001850738 , ENSE00001836506 , ENST00000372805 , ENSE00001822157 , ENSE00001937537 , ENST00000435719 , ENSE00001644002 , ENSE00001746536 , ENST00000479759 , ENSE00001939084 , ENSE00003630218 , ENSE00003466857 , ENSE00003536326 , ENSE00003591535 , ENSE00003634946 , ENSE00001871348CAP1
1 4E+07 SNV Homozygous CAP1 ENSG00000131236 , ENST00000372797 , ENSE00001458655 , ENSE00001458701 , ENSE00000899727 , ENSE00001192144 , ENSE00001192143 , ENSE00001192141 , ENSE00001192138 , ENSE00003580138 , ENSE00003554678 , ENSE00003459410 , ENSE00003477815 , ENSE00003512323 , ENSE00001458693 , ENST00000372802 , ENSE00001458691 , ENSE00001192162 , ENSE00001458689 , ENSE00001458688 , ENST00000414893 , ENSE00001623537 , ENSE00001458665 , ENSE00001458664 , ENSE00001769605 , ENST00000372792 , ENSE00001192151 , ENSE00001458654 , ENST00000372798 , ENSE00001458681 , ENSE00001458680 , ENST00000340450 , ENSE00001850738 , ENSE00001836506 , ENST00000372805 , ENSE00001822157 , ENSE00001937537 , ENST00000435719 , ENSE00001644002 , ENSE00001746536 , ENST00000479759 , ENSE00001939084 , ENSE00003630218 , ENSE00003466857 , ENSE00003536326 , ENSE00003591535 , ENSE00003634946 , ENSE00001871348CAP1
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Chromosome Region Type Zygosity Gene Cards ENSEMBL gene_name (Homo_sapiens_ensembl_v74_mRNA)
1 1647893^1647894Insertion Unknown CDK11A , RP1-283E3.8ENSG00000008128 , ENSG00000268575 , ENST00000356200 , ENSE00001425777 , ENSE00003646560 , ENSE00003652156 , ENSE00003507378 , ENSE00003476013 , ENSE00003538477 , ENSE00003629837 , ENSE00003673770 , ENSE00003484918 , ENSE00003573320 , ENSE00003490604 , ENSE00003540484 , ENSE00003493098 , ENSE00003532668 , ENSE00003466910 , ENSE00003647264 , ENSE00001714517 , ENSE00003525046 , ENSE00003500548 , ENST00000598846 , ENSE00003169804 , ENSE00003525671 , ENSE00003579997 , ENSE00003467598 , ENSE00003549784 , ENSE00003604931 , ENSE00003496413 , ENSE00003582288 , ENSE00003663196 , ENSE00003558967 , ENSE00003590009 , ENSE00003636205 , ENSE00003461022 , ENSE00003468921 , ENSE00003672483 , ENSE00003637566 , ENSE00003634757 , ENSE00003575907 , ENSE00003556340 , ENSE00003226367 , ENST00000356937 , ENSE00003646300 , ENSE00003535326 , ENSE00003477001 , ENSE00003468898 , ENSE00001876481 , ENSE00003645656 , ENSE00003594351 , ENSE00003591780 , ENSE00003621129 , ENSE00003502274 , ENSE00003459912 , ENSE00003568909 , ENSE00003592140 CDK11A, RP1-283E3.8
1 1650787 SNV Unknown CDK11A , RP1-283E3.8ENSG00000008128 , ENSG00000268575 , ENST00000356200 , ENSE00001425777 , ENSE00003646560 , ENSE00003652156 , ENSE00003507378 , ENSE00003476013 , ENSE00003538477 , ENSE00003629837 , ENSE00003673770 , ENSE00003484918 , ENSE00003573320 , ENSE00003490604 , ENSE00003540484 , ENSE00003493098 , ENSE00003532668 , ENSE00003466910 , ENSE00003647264 , ENSE00001714517 , ENSE00003525046 , ENSE00003500548 , ENST00000378638 , ENSE00003675617 , ENSE00001478182 , ENSE00003490829 , ENST00000509982 , ENSE00003646300 , ENSE00003535326 , ENSE00003477001 , ENSE00003468898 , ENSE00003555976 , ENSE00003612771 , ENSE00003645656 , ENSE00003649099 , ENSE00003648668 , ENSE00003557609 , ENSE00001643586 , ENSE00002060556 , ENST00000404249 , ENSE00003563203 , ENSE00001357141 , ENST00000460465 , ENST00000498810 , ENSE00001832645 , ENSE00001912903CDK11A
1 1650797 SNV Unknown CDK11A , RP1-283E3.8ENSG00000008128 , ENSG00000268575 , ENST00000356200 , ENSE00001425777 , ENSE00003646560 , ENSE00003652156 , ENSE00003507378 , ENSE00003476013 , ENSE00003538477 , ENSE00003629837 , ENSE00003673770 , ENSE00003484918 , ENSE00003573320 , ENSE00003490604 , ENSE00003540484 , ENSE00003493098 , ENSE00003532668 , ENSE00003466910 , ENSE00003647264 , ENSE00001714517 , ENSE00003525046 , ENSE00003500548 , ENST00000598846 , ENSE00003169804 , ENSE00003525671 , ENSE00003579997 , ENSE00003467598 , ENSE00003549784 , ENSE00003604931 , ENSE00003496413 , ENSE00003582288 , ENSE00003663196 , ENSE00003558967 , ENSE00003590009 , ENSE00003636205 , ENSE00003461022 , ENSE00003468921 , ENSE00003672483 , ENSE00003637566 , ENSE00003634757 , ENSE00003575907 , ENSE00003556340 , ENSE00003226367 , ENST00000356937 , ENSE00003646300 , ENSE00003535326 , ENSE00003477001 , ENSE00003468898 , ENSE00001876481 , ENSE00003645656 , ENSE00003594351 , ENSE00003591780 , ENSE00003621129 , ENSE00003502274 , ENSE00003459912 , ENSE00003568909 , ENSE00003592140 CDK11A, RP1-283E3.8
1 1650832 SNV Unknown CDK11A , RP1-283E3.8ENSG00000008128 , ENSG00000268575 , ENST00000356200 , ENSE00001425777 , ENSE00003646560 , ENSE00003652156 , ENSE00003507378 , ENSE00003476013 , ENSE00003538477 , ENSE00003629837 , ENSE00003673770 , ENSE00003484918 , ENSE00003573320 , ENSE00003490604 , ENSE00003540484 , ENSE00003493098 , ENSE00003532668 , ENSE00003466910 , ENSE00003647264 , ENSE00001714517 , ENSE00003525046 , ENSE00003500548 , ENST00000598846 , ENSE00003169804 , ENSE00003525671 , ENSE00003579997 , ENSE00003467598 , ENSE00003549784 , ENSE00003604931 , ENSE00003496413 , ENSE00003582288 , ENSE00003663196 , ENSE00003558967 , ENSE00003590009 , ENSE00003636205 , ENSE00003461022 , ENSE00003468921 , ENSE00003672483 , ENSE00003637566 , ENSE00003634757 , ENSE00003575907 , ENSE00003556340 , ENSE00003226367 , ENST00000356937 , ENSE00003646300 , ENSE00003535326 , ENSE00003477001 , ENSE00003468898 , ENSE00001876481 , ENSE00003645656 , ENSE00003594351 , ENSE00003591780 , ENSE00003621129 , ENSE00003502274 , ENSE00003459912 , ENSE00003568909 , ENSE00003592140 CDK11A, RP1-283E3.8
1 11186751 SNV Unknown MTOR ENSG00000198793 , ENST00000376838 , ENSE00001345243 , ENSE00003653682 , ENSE00003530156 , ENSE00003523148 , ENSE00003615787 , ENSE00003537296 , ENSE00003629136 , ENSE00001167794 , ENSE00001167801 , ENSE00001167809 , ENSE00001167814 , ENSE00001167821 , ENSE00001167829 , ENSE00001167837 , ENSE00001167844 , ENSE00001167852 , ENSE00001167858 , ENSE00001167869 , ENSE00001041990 , ENSE00001471843 , ENST00000361445 , ENSE00001167893 , ENSE00001167905 , ENSE00003513153 , ENSE00003571700 , ENSE00003482987 , ENSE00001167940 , ENSE00001167950 , ENSE00001167960 , ENSE00001167966 , ENSE00001167973 , ENSE00001167981 , ENSE00000743767 , ENSE00000743769 , ENSE00000743771 , ENSE00001435329 , ENSE00000743775 , ENSE00000743777 , ENSE00000743779 , ENSE00000743781 , ENSE00000743783 , ENSE00000743785 , ENSE00000743788 , ENSE00000743790 , ENSE00000743792 , ENSE00000743794 , ENSE00000743796 , ENSE00000743799 , ENSE00000743801 , ENSE00000743803 , ENSE00000743805 , ENSE00000743807 , ENSE00000743810 , ENSE00000743812 , ENSE00000743813 MTOR
1 12082926 SNV Unknown MIIP ENSG00000116691 , ENST00000478749 , ENSE00001470129 , ENSE00003497712 , ENSE00003463042 , ENSE00003567102 , ENSE00003531108 , ENSE00001940719 , ENST00000235332 , ENSE00000818973 , ENSE00003517689 , ENSE00003645178 , ENSE00003513763 , ENSE00003546551 , ENSE00003636418 , ENSE00003579615 , ENSE00003617293 , ENSE00001841836 , ENST00000436478 , ENSE00001646823 , ENSE00003661860 , ENSE00001629397 , ENST00000466860 , ENSE00001947124 , ENSE00001906510 , ENSE00003614485 , ENSE00001955238 , ENST00000498685 , ENSE00001852453 , ENSE00001817974 , ENSE00003629065 , ENSE00001949205MIIP
1 21267993 SNV Unknown EIF4G3 ENSG00000075151 , ENST00000264211 , ENSE00001542805 , ENSE00001683487 , ENSE00001604595 , ENSE00001672406 , ENSE00002176939 , ENSE00003484684 , ENSE00003564924 , ENSE00003683156 , ENSE00001690531 , ENSE00001784396 , ENSE00001726513 , ENSE00001712596 , ENSE00001804546 , ENSE00001764077 , ENSE00001604127 , ENSE00001703965 , ENSE00001658251 , ENSE00001594127 , ENSE00001690105 , ENSE00003489381 , ENSE00003472324 , ENSE00003490165 , ENSE00003618120 , ENSE00003613920 , ENSE00001686750 , ENSE00003671517 , ENSE00001066154 , ENSE00003477705 , ENSE00003647587 , ENSE00003337316 , ENSE00003227684 , ENST00000400422 , ENSE00001765035 , ENSE00003235835 , ENSE00001465229 , ENSE00001465230 , ENST00000602326 , ENSE00001735790 , ENSE00002247070 , ENSE00003457551 , ENST00000374937 , ENSE00002305967 , ENSE00002279576 , ENST00000536266 , ENSE00002311263 , ENSE00003588050 , ENSE00003471241 , ENSE00002294743 , ENST00000544689 , ENSE00002261758 , ENSE00002301119 , ENSE00002255470 , ENST00000356916 , ENSE00001433382 , ENSE00001419647 EIF4G3
1 24785393 SNV Unknown NIPAL3 ENSG00000001461 , ENST00000374399 , ENSE00001432973 , ENSE00003585417 , ENSE00003670970 , ENSE00003569258 , ENSE00001603157 , ENSE00001776100 , ENSE00001655999 , ENSE00001642364 , ENSE00003659521 , ENSE00003575842 , ENSE00001679113 , ENSE00001208933 , ENST00000003912 , ENSE00001463427 , ENSE00003476526 , ENSE00001463425 , ENSE00003648257 , ENSE00003550216 , ENSE00001463422 , ENST00000339255 , ENSE00001463418 , ENSE00001463416 , ENST00000432012 , ENSE00001711005 , ENSE00001383586 , ENSE00003516460 , ENSE00003603799 , ENSE00001664457NIPAL3
1 36226120 SNV Unknown CLSPN ENSG00000092853 , ENST00000251195 , ENSE00001079142 , ENSE00003624322 , ENSE00003573755 , ENSE00000765315 , ENSE00000765316 , ENSE00000765317 , ENSE00000765318 , ENSE00000765320 , ENSE00000765376 , ENSE00000594892 , ENSE00000765378 , ENSE00003536964 , ENSE00000765382 , ENSE00000765410 , ENSE00000861197 , ENSE00001036904 , ENSE00000861199 , ENSE00000765426 , ENSE00000765461 , ENSE00000765500 , ENSE00000861200 , ENSE00000861201 , ENSE00000765532 , ENSE00000765534 , ENSE00001958448 , ENST00000373220 , ENSE00001238398 , ENSE00001373488 , ENST00000520551 , ENSE00002096453 , ENST00000318121CLSPN
1 39914363 SNV Unknown MACF1 ENSG00000127603 , ENST00000545844 , ENSE00002210687 , ENSE00002164985 , ENSE00003584786 , ENSE00003466663 , ENSE00003679312 , ENSE00003602769 , ENSE00002273289 , ENSE00001633058 , ENSE00003639143 , ENSE00001691519 , ENSE00002708865 , ENSE00003461801 , ENSE00001713164 , ENSE00001641956 , ENSE00001760927 , ENSE00001654662 , ENSE00001621722 , ENSE00001771617 , ENSE00001765360 , ENSE00001679208 , ENSE00001217237 , ENSE00001218134 , ENSE00003690465 , ENSE00003484227 , ENSE00003474074 , ENSE00003591734 , ENSE00003499885 , ENSE00003520092 , ENSE00003649450 , ENSE00003674352 , ENSE00003499725 , ENSE00003679603 , ENSE00003466382 , ENSE00003684463 , ENSE00003649898 , ENSE00003605315 , ENSE00003688828 , ENSE00003683045 , ENSE00003527187 , ENSE00003674754 , ENSE00003678072 , ENSE00003621022 , ENSE00003526687 , ENSE00003535713 , ENSE00003462003 , ENSE00003615518 , ENSE00001693302 , ENSE00001612539 , ENSE00001805045 , ENSE00001643168 , ENSE00001727162 , ENSE00001734332 , ENSE00001599839 , ENSE00001784267 , ENSE00001769328 MACF1
1 42657270 SNV Unknown FOXJ3 ENSG00000198815 , ENST00000372572 , ENSE00001458130 , ENSE00000870156 , ENSE00000956595 , ENSE00000956594 , ENSE00000956593 , ENSE00000956592 , ENSE00000956591 , ENSE00001045400 , ENSE00001270464 , ENSE00001711680 , ENSE00001704775 , ENSE00002267420 , ENSE00001458126 , ENSE00001458127 , ENSE00001458128 , ENST00000372573 , ENSE00001458135 , ENST00000361776 , ENSE00001146583 , ENSE00001418309 , ENST00000361346 , ENST00000545068 , ENSE00002321804 , ENSE00002206037 , ENST00000445886 , ENSE00001671225 , ENSE00001632529FOXJ3
1 47799639 SNV Unknown CMPK1 ENSG00000162368 , ENST00000371873 , ENSE00001561138 , ENSE00003537405 , ENSE00001064475 , ENSE00001064474 , ENSE00003510178 , ENSE00001831502 , ENST00000371871 , ENSE00001456348 , ENSE00003492018 , ENSE00001800434 , ENST00000471289 , ENSE00001834380 , ENSE00001955888 , ENST00000450808 , ENSE00001911899 , ENSE00002161970 , ENST00000371870 , ENSE00001907839 , ENSE00003512512 , ENSE00001626456CMPK1
1 52861871 SNV Unknown ORC1 ENSG00000085840 , ENST00000371568 , ENSE00001455517 , ENSE00000957637 , ENSE00000957636 , ENSE00001064538 , ENSE00003533164 , ENSE00003648305 , ENSE00003594240 , ENSE00003466978 , ENSE00003658000 , ENSE00000915827 , ENSE00000915828 , ENSE00000915829 , ENSE00000915830 , ENSE00000915831 , ENSE00000915832 , ENSE00001455522 , ENSE00001191483 , ENST00000371566 , ENSE00001455512 , ENSE00001455513 , ENSE00001455515ORC1
1 98144726 SNV Unknown DPYD ENSG00000188641 , ENST00000370192 , ENSE00001837520 , ENSE00001067062 , ENSE00001003444 , ENSE00001179015 , ENSE00001248261 , ENSE00001402719 , ENSE00001401691 , ENSE00001293694 , ENSE00001175939 , ENSE00001067066 , ENSE00001175948 , ENSE00001416589 , ENSE00001433514 , ENSE00001431920 , ENSE00001430871 , ENSE00001429819 , ENSE00001428755 , ENSE00003676911 , ENSE00001175981 , ENSE00001337292 , ENSE00001761942 , ENSE00003527026 , ENSE00001844147DPYD
1 107599918 SNV Unknown PRMT6 ENSG00000198890 , ENST00000361318 , ENSE00001436623 , ENST00000370078 , ENSE00001451674PRMT6
1 112308953 SNV Unknown DDX20 ENSG00000064703 , ENST00000369702 , ENSE00001450683 , ENSE00000783731 , ENSE00000783732 , ENSE00003686144 , ENSE00003670557 , ENSE00003530441 , ENSE00003682768 , ENSE00003608070 , ENSE00003654711 , ENSE00003529832 , ENSE00001142728 , ENST00000475700 , ENSE00001845128 , ENSE00001909181 , ENSE00001828315DDX20
1 112309123 SNV Unknown DDX20 ENSG00000064703 , ENST00000369702 , ENSE00001450683 , ENSE00000783731 , ENSE00000783732 , ENSE00003686144 , ENSE00003670557 , ENSE00003530441 , ENSE00003682768 , ENSE00003608070 , ENSE00003654711 , ENSE00003529832 , ENSE00001142728 , ENST00000475700 , ENSE00001845128 , ENSE00001909181 , ENSE00001828315DDX20
1 112309331 SNV Unknown DDX20 ENSG00000064703 , ENST00000369702 , ENSE00001450683 , ENSE00000783731 , ENSE00000783732 , ENSE00003686144 , ENSE00003670557 , ENSE00003530441 , ENSE00003682768 , ENSE00003608070 , ENSE00003654711 , ENSE00003529832 , ENSE00001142728 , ENST00000475700 , ENSE00001845128 , ENSE00001909181 , ENSE00001828315DDX20
1 117529458 SNV Unknown PTGFRN ENSG00000134247 , ENST00000393203 , ENSE00001514453 , ENSE00001069102 , ENSE00000800583 , ENSE00000800584 , ENSE00000800585 , ENSE00000800586 , ENSE00000800587 , ENSE00000800588 , ENSE00001450113PTGFRN
1 151315287 SNV Unknown RFX5 ENSG00000143390 , ENST00000290524 , ENSE00001045122 , ENSE00000959768 , ENSE00000959767 , ENSE00003689514 , ENSE00000959765 , ENSE00003634711 , ENSE00003647996 , ENSE00003624294 , ENSE00003532823 , ENSE00001045114 , ENSE00001954626 , ENST00000368870 , ENSE00001448153 , ENSE00001512940 , ENSE00001448155 , ENST00000452671 , ENSE00001885806 , ENSE00001448154 , ENSE00001865079 , ENST00000452513 , ENSE00001706186 , ENSE00001448160 , ENST00000392746 , ENSE00001549200 , ENSE00001704212 , ENSE00001682849RFX5
1 153615820 SNV Unknown CHTOP ENSG00000160679 , ENST00000368694 , ENSE00001447780 , ENSE00001072605 , ENSE00001176715 , ENSE00001176723 , ENSE00001176707 , ENSE00001940609 , ENST00000368687 , ENSE00001447754 , ENSE00003488452 , ENST00000368686 , ENSE00001447752 , ENSE00001447751CHTOP
1 156640156 SNV Unknown NES ENSG00000132688 , ENST00000368223 , ENSE00001446624 , ENSE00001074047 , ENSE00000959085 , ENSE00001054729NES
1 159002377 SNV Unknown IFI16 ENSG00000163565 , ENST00000340979 , ENSE00001446388 , ENSE00003501235 , ENSE00003688589 , ENSE00003645835 , ENSE00003475029 , ENSE00003631371 , ENSE00003524485 , ENSE00003571328 , ENSE00003472774 , ENSE00002221418 , ENST00000368131 , ENSE00003481880 , ENSE00001877836 , ENST00000493884 , ENSE00001919476 , ENSE00003629945 , ENSE00003590004 , ENSE00003619957 , ENSE00003607892 , ENSE00003478574 , ENSE00003502956 , ENSE00003630748 , ENSE00001850420 , ENSE00003544186 , ENST00000483916 , ENSE00003507446 , ENST00000368132 , ENSE00003664980 , ENSE00003573471 , ENST00000295809 , ENSE00001511230 , ENST00000359709 , ENSE00002324212 , ENSE00001285450 , ENST00000430894 , ENST00000448393 , ENSE00002618709 , ENSE00002616329 , ENST00000562225 , ENSE00002626735 , ENSE00003651582 , ENSE00003603419 , ENSE00001446385IFI16
1 159002389 SNV Unknown IFI16 ENSG00000163565 , ENST00000340979 , ENSE00001446388 , ENSE00003501235 , ENSE00003688589 , ENSE00003645835 , ENSE00003475029 , ENSE00003631371 , ENSE00003524485 , ENSE00003571328 , ENSE00003472774 , ENSE00002221418 , ENST00000368131 , ENSE00003481880 , ENSE00001877836 , ENST00000493884 , ENSE00001919476 , ENSE00003629945 , ENSE00003590004 , ENSE00003619957 , ENSE00003607892 , ENSE00003478574 , ENSE00003502956 , ENSE00003630748 , ENSE00001850420 , ENSE00003544186 , ENST00000483916 , ENSE00003507446 , ENST00000368132 , ENSE00003664980 , ENSE00003573471 , ENST00000295809 , ENSE00001511230 , ENST00000359709 , ENSE00002324212 , ENSE00001285450 , ENST00000430894 , ENST00000448393 , ENSE00002618709 , ENSE00002616329 , ENST00000562225 , ENSE00002626735 , ENSE00003651582 , ENSE00003603419 , ENSE00001446385IFI16
1 165619079 SNV Unknown MGST3 ENSG00000143198 , ENST00000367889 , ENSE00001931710 , ENSE00003598372 , ENSE00003680235 , ENSE00003545335 , ENSE00003608858 , ENSE00003586250 , ENST00000367888 , ENSE00001068385 , ENSE00001445860 , ENST00000461308 , ENSE00001941434 , ENSE00001853753 , ENST00000495447 , ENSE00001946593 , ENSE00001942927 , ENSE00003588039 , ENSE00003553046 , ENSE00003605370 , ENSE00001957098 , ENST00000367885 , ENSE00001445854 , ENSE00001445853 , ENSE00003585562 , ENST00000367884 , ENSE00001445852 , ENSE00001445851 , ENST00000488688 , ENSE00001556443 , ENSE00003557023 , ENSE00001949316 , ENST00000367883 , ENSE00001445850 , ENST00000367886 , ENSE00001445857 , ENSE00001510852 , ENST00000477450 , ENSE00001884166 , ENSE00001899637MGST3
1 171486912 SNV Unknown PRRC2C ENSG00000117523 , ENST00000426496 , ENSE00001381039 , ENSE00003664356 , ENSE00003633848 , ENSE00003653650 , ENSE00003578430 , ENSE00003660063 , ENSE00003645844 , ENSE00003683382 , ENSE00003460632 , ENSE00003600536 , ENSE00003484235 , ENSE00001682082 , ENSE00001747804 , ENSE00001608944 , ENSE00001794288 , ENSE00001602651 , ENSE00001151016 , ENSE00001151012 , ENSE00001226837 , ENSE00000789770 , ENSE00000789771 , ENSE00000789772 , ENSE00000789775 , ENSE00000789776 , ENSE00000789777 , ENSE00000789778 , ENSE00002397175 , ENSE00000958958 , ENSE00002342555 , ENSE00003588737 , ENSE00003628667 , ENSE00002217873 , ENST00000392078 , ENSE00003606342 , ENSE00000789773 , ENSE00000789774 , ENSE00001626731 , ENST00000476522 , ENSE00001765091 , ENSE00003540284 , ENSE00003677165 , ENSE00001948032 , ENSE00003517945 , ENSE00003531071 , ENSE00003578790 , ENSE00003543911 , ENSE00003556100 , ENSE00003585201 , ENSE00003562068 , ENSE00001815038 , ENST00000367742 , ENSE00001372716 , ENST00000338920 , ENSE00002232520PRRC2C
1 179852074 SNV Unknown TOR1AIP1 ENSG00000143337 , ENST00000528443 , ENSE00001900701 , ENSE00003536688 , ENSE00003591554 , ENSE00003633018 , ENSE00003483184 , ENSE00003703708 , ENSE00003707546 , ENSE00003711472 , ENSE00003633147 , ENSE00002177471 , ENST00000271583 , ENSE00002179326 , ENSE00002193587 , ENSE00002189988 , ENST00000606911 , ENSE00002178422 , ENSE00003653233 , ENSE00003698492 , ENST00000435319 , ENSE00003708339 , ENSE00001626479 , ENST00000531630 , ENSE00001646296 , ENSE00003706301 , ENST00000527391 , ENSE00002172961 , ENSE00003581939TOR1AIP1
1 179989742 SNV Unknown CEP350 ENSG00000135837 , ENST00000367607 , ENSE00001858805 , ENSE00001510509 , ENSE00001120524 , ENSE00001068581 , ENSE00003624312 , ENSE00001120486 , ENSE00002203514 , ENSE00002295549 , ENSE00002237521 , ENSE00002280932 , ENSE00002254018 , ENSE00001068573 , ENSE00002265286 , ENSE00002284597 , ENSE00002208125 , ENSE00002274615 , ENSE00002215439 , ENSE00001008346 , ENSE00001008341 , ENSE00001008349 , ENSE00003568893 , ENSE00003523821 , ENSE00001068566 , ENSE00002259252 , ENSE00002206720 , ENSE00002322539 , ENSE00002241783 , ENSE00002306411 , ENSE00002211042 , ENSE00002220456 , ENSE00000822653 , ENSE00003558346 , ENSE00003557070 , ENSE00003538330 , ENSE00003608883 , ENSE00003570991 , ENSE00003653064 , ENSE00001829752CEP350
1 186363119 SNV Unknown C1orf27 ENSG00000157181 , ENST00000419367 , ENSE00001872260 , ENSE00001068236 , ENSE00001068238 , ENSE00001068241 , ENSE00001068234 , ENSE00001068244 , ENSE00001068242 , ENSE00001068243 , ENSE00001068237 , ENSE00003544641 , ENSE00003627566 , ENSE00001126065 , ENSE00002681063 , ENST00000287859 , ENSE00002681260 , ENSE00001068239 , ENSE00001927245C orf27
1 210004199 SNV Unknown DIEXF ENSG00000117597 , ENST00000491415 , ENSE00001443261 , ENSE00000792137 , ENSE00000792138 , ENSE00000792139 , ENSE00000792140 , ENSE00000792141 , ENSE00000792142 , ENSE00000792143 , ENSE00000792144 , ENSE00000792145 , ENSE00000792146 , ENSE00001933838DIEXF
1 210415570 SNV Unknown SERTAD4 ENSG00000082497 , ENST00000367012 , ENSE00001443240 , ENSE00003545749 , ENSE00003626378 , ENSE00001443238SERTAD4
1 226054333 SNV Unknown TMEM63A ENSG00000196187 , ENST00000366835 , ENSE00001442720 , ENSE00001071044 , ENSE00003594321 , ENSE00001015499 , ENSE00000961978 , ENSE00000961977 , ENSE00000961976 , ENSE00000961975 , ENSE00000961974 , ENSE00003489139 , ENSE00000961972 , ENSE00001286300 , ENSE00003545178 , ENSE00003572269 , ENSE00003471182 , ENSE00001286263 , ENSE00000961966 , ENSE00000961965 , ENSE00000961964 , ENSE00000961963 , ENSE00000961962 , ENSE00003682827 , ENSE00001442724 , ENSE00001435173 , ENSE00001442725 , ENST00000537914 , ENSE00002277611 , ENSE00003557585 , ENSE00003500918 , ENSE00003651048 , ENSE00002298956 , ENSE00002311456 , ENSE00002268690TMEM63A
1 227216775 SNV Unknown CDC42BPA ENSG00000143776 , ENST00000366767 , ENSE00001879316 , ENSE00002426973 , ENSE00002400117 , ENSE00002429768 , ENSE00002419086 , ENSE00003629030 , ENSE00000961918 , ENSE00001289505 , ENSE00001373065 , ENSE00001381144 , ENSE00001015669 , ENSE00001211868 , ENSE00001071170 , ENSE00001378802 , ENSE00001367385 , ENSE00001211986 , ENSE00003693306 , ENSE00003676176 , ENSE00003537828 , ENSE00003596523 , ENSE00001145213 , ENSE00002387746 , ENSE00002354098 , ENSE00002367862 , ENSE00002403310 , ENSE00002365189 , ENSE00002400705 , ENSE00002340561 , ENSE00002327112 , ENSE00002385152 , ENSE00002416553 , ENSE00003563828 , ENSE00003510454 , ENSE00003643494 , ENSE00001937758 , ENST00000366769 , ENSE00002407991 , ENSE00001937562 , ENST00000448940 , ENSE00002418747 , ENSE00001422698 , ENSE00001620271 , ENST00000366764 , ENSE00002734855 , ENST00000334218 , ENST00000366766 , ENSE00001442573 , ENST00000442054 , ENSE00001720573 , ENSE00001764028 , ENST00000535525 , ENSE00002307519 , ENSE00002414025 , ENSE00002206005 , ENST00000366765 CDC42BPA
1 227935444 SNV Unknown SNAP47 ENSG00000143740 , ENST00000475930 , ENSE00001884192 , ENSE00001946581 , ENSE00001855567 , ENST00000315781 , ENSE00001442551 , ENSE00002266428 , ENSE00003664029 , ENSE00003568577 , ENSE00001254564 , ENST00000366759 , ENSE00001442552 , ENST00000426344 , ENSE00001804183 , ENSE00001775065 , ENST00000470038 , ENSE00001896563 , ENSE00001824722SNAP47
1 230415148 SNV Unknown GALNT2 ENSG00000143641 , ENST00000543760 , ENSE00002235063 , ENSE00003662413 , ENSE00003522264 , ENSE00003574562 , ENSE00003492256 , ENSE00003621838 , ENSE00003631244 , ENSE00001007561 , ENSE00001007560 , ENSE00001007564 , ENSE00003503459 , ENSE00003533449 , ENSE00003551620 , ENSE00003477846 , ENSE00003542410 , ENSE00002283626 , ENST00000366672 , ENSE00001442291 , ENSE00001935591 , ENST00000485438 , ENSE00001883091 , ENSE00001941089 , ENSE00003642457 , ENSE00003651246 , ENSE00003680181 , ENSE00001864694GALNT2
1 236175327 SNV Unknown NID1 ENSG00000116962 , ENST00000264187 , ENSE00001442138 , ENSE00000793456 , ENSE00000793457 , ENSE00000793458 , ENSE00000793459 , ENSE00000793460 , ENSE00000793461 , ENSE00000793462 , ENSE00000793463 , ENSE00000793464 , ENSE00000793465 , ENSE00000793466 , ENSE00000793467 , ENSE00001022659 , ENSE00001022658 , ENSE00001022661 , ENSE00001022668 , ENSE00001022662 , ENSE00001022663 , ENSE00001935339NID1
1 236700807 SNV Unknown LGALS8 ENSG00000116977 , ENST00000481485 , ENSE00001914874 , ENSE00001296183 , ENSE00003563486 , ENSE00003687068 , ENSE00001881449 , ENST00000454943 , ENSE00002142726 , ENSE00001226690 , ENSE00003627786 , ENSE00003626684 , ENSE00001805925 , ENST00000527974 , ENSE00002153194 , ENSE00003657852 , ENSE00003646448 , ENSE00000805382 , ENSE00003491296 , ENSE00003551645 , ENSE00002151250 , ENST00000430527 , ENSE00002142899 , ENSE00002403746 , ENST00000352231 , ENSE00001366064 , ENSE00002173650 , ENST00000406509 , ENSE00002341903 , ENSE00002339766 , ENSE00001660069 , ENST00000526589 , ENSE00002327211 , ENSE00002155166 , ENSE00001865851 , ENST00000529489 , ENSE00001649570 , ENSE00002161269 , ENST00000341872 , ENSE00001354441 , ENSE00001831257 , ENST00000450372 , ENSE00001371155 , ENST00000366584 , ENSE00001381502 , ENSE00001911385 , ENST00000238181 , ENSE00001702754 , ENSE00002186407 , ENST00000532826 , ENSE00002174100 , ENSE00003542086 , ENSE00003519090 , ENSE00002140798 , ENST00000528782 , ENSE00003542456 , ENSE00002141770 LGALS8
1 236700857 SNV Unknown LGALS8 ENSG00000116977 , ENST00000481485 , ENSE00001914874 , ENSE00001296183 , ENSE00003563486 , ENSE00003687068 , ENSE00001881449 , ENST00000454943 , ENSE00002142726 , ENSE00001226690 , ENSE00003627786 , ENSE00003626684 , ENSE00001805925 , ENST00000527974 , ENSE00002153194 , ENSE00003657852 , ENSE00003646448 , ENSE00000805382 , ENSE00003491296 , ENSE00003551645 , ENSE00002151250 , ENST00000430527 , ENSE00002142899 , ENSE00002403746 , ENST00000352231 , ENSE00001366064 , ENSE00002173650 , ENST00000406509 , ENSE00002341903 , ENSE00002339766 , ENSE00001660069 , ENST00000526589 , ENSE00002327211 , ENSE00002155166 , ENSE00001865851 , ENST00000529489 , ENSE00001649570 , ENSE00002161269 , ENST00000341872 , ENSE00001354441 , ENSE00001831257 , ENST00000450372 , ENSE00001371155 , ENST00000366584 , ENSE00001381502 , ENSE00001911385 , ENST00000238181 , ENSE00001702754 , ENSE00002186407 , ENST00000532826 , ENSE00002174100 , ENSE00003542086 , ENSE00003519090 , ENSE00002140798 , ENST00000528782 , ENSE00003542456 , ENSE00002141770 LGALS8
1 236706862 SNV Unknown LGALS8 , RP11-385F5.4ENSG00000116977 , ENSG00000230325 , ENST00000527974 , ENSE00002153194 , ENSE00003563486 , ENSE00003687068 , ENSE00003627786 , ENSE00003626684 , ENSE00003657852 , ENSE00003646448 , ENSE00000805382 , ENSE00003491296 , ENSE00003551645 , ENSE00002151250 , ENST00000352231 , ENSE00001366064 , ENSE00001226690 , ENSE00002173650 , ENST00000526589 , ENSE00002327211 , ENSE00002155166 , ENSE00001296183 , ENSE00001865851 , ENST00000341872 , ENSE00001354441 , ENSE00001831257 , ENST00000450372 , ENSE00001371155 , ENST00000366584 , ENSE00001381502 , ENSE00001911385 , ENST00000238181 , ENSE00001702754 , ENSE00002186407 , ENST00000366583 , ENSE00001442101 , ENSE00003542086 , ENSE00003519090 , ENSE00003542456 , ENSE00003681484 , ENSE00003675731 , ENSE00001896584 , ENST00000416919 , ENSE00001547611 , ENSE00002292435 , ENST00000323938 , ENSE00002149712 , ENSE00002197664 , ENSE00001917270 , ENST00000526634 , ENSE00001696280 , ENSE00002164570 , ENST00000525042 , ENSE00002154186 , ENSE00002221943 , ENST00000528259 , ENSE00001800144 LGALS8
1 237048500 SNV Unknown MTR ENSG00000116984 , ENST00000366577 , ENSE00001884168 , ENSE00003601386 , ENSE00003508071 , ENSE00001166501 , ENSE00003670237 , ENSE00003544646 , ENSE00003627998 , ENSE00003643307 , ENSE00003584442 , ENSE00003543860 , ENSE00003570655 , ENSE00003660391 , ENSE00003499808 , ENSE00003465483 , ENSE00003596150 , ENSE00003548759 , ENSE00003621485 , ENSE00003661804 , ENSE00001069631 , ENSE00000908104 , ENSE00001166419 , ENSE00000908106 , ENSE00001166408 , ENSE00001166403 , ENSE00000793568 , ENSE00000961552 , ENSE00000961554 , ENSE00000961556 , ENSE00000961558 , ENSE00001069115 , ENSE00001166366 , ENSE00003688474 , ENSE00001442090 , ENST00000535889 , ENSE00002302873 , ENSE00002321043 , ENST00000366576 , ENSE00001675434 , ENSE00001595816 , ENSE00001180362MTR
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Row Index Peak Namem/z Ret. Time
598 598 sp|O14773|TPP1_HUMANN/A N/A
360 360 tr|B4DGU4|B4DGU4_HUMANN/A N/A
875 875 sp|O43776|SYNC_HUMANN/A N/A
785 785 tr|C9JDE9|C9JDE9_HUMAN N/A N/A
729 729 sp|P04259|K2C6B_HUMANN/A N/A
634 634 sp|P41252|SYIC_HUMANN/A /A
937 937 sp|O43278|SPIT1_HUMANN/A N/A
513 513 sp|P35908|K22E_HUMANN/A N/A
852 852 tr|D6REX3|D6REX3_HUMANN/A N/A
291 291 sp|Q9HAV7|GRPE1_HUMANN/A N/
762 762 tr|X6R700|X6R700_HUMANN/A N/A
558 558 sp|Q92820|GGH_HUMANN/A N/A
680 680 sp|P00387|NB5R3_HUMANN/A N/A
887 887 sp|Q99959-2|PKP2_HUMANN/A N/A
601 601 tr|A0A087X1Z3|A0A087X1Z3_HUMANN/A N/A
739 739 sp|P23229-9|ITA6_HUMANN/A N/A
735 735 sp|P62873|GBB1_HUMANN/A N/A
813 813 sp|P62304|RUXE_HUMANN/A N/A
888 888 sp|Q92896-3|GSLG1_HUMANN/A N/A
728 728 sp|Q9NZB2|F120A_HUMANN/A N/A
796 796 tr|I3L1P8|I3L1P8_HUMANN/A N/A
395 395 sp|P11216|PYGB_HUMANN/A N/A
826 826 tr|F5H895|F5H895_HUMANN/A N/A
611 611 tr|J3KN36|J3KN36_HUMANN/A N/A
769 769 sp|Q9BRR6|ADPGK_HUMANN/A N/
948 948 sp|P00533|EGFR_HUMANN/A N/A
77 77 sp|P13804|ETFA_HUMANN/A N/A
910 910 tr|A0A087WV22|A0A087WV22_HUMANN/A N/A
772 772 sp|Q15738|NSDHL_HUMANN/A N/A
569 569 sp|Q9NYU2|UGGG1_HUMANN/A N/
430 430 sp|P11166|GTR1_HUMANN/A N/A
312 312 sp|P53007|TXTP_HUMANN/A N/A
671 671 tr|F5GZ78|F5GZ78_HUMANN/A N/A
509 509 tr|Q5VV89|Q5VV89_HUMANN/A N/
916 916 tr|C9JQD4|C9JQD4_HUMANN/A N/A
859 859 sp|Q9P0S9|TM14C_HUMANN/A N/A
899 899 sp|Q9NX58|LYAR_HUMANN/A N/A
507 507 sp|P07711|CATL1_HUMANN/ N/A
263 263 sp|P04792|HSPB1_HUMANN/A N/A
448 448 sp|Q9NQG5|RPR1B_HUMANN/A N/
466 466 tr|A0A087WV15|A0A087WV15_HUMANN/A N/A
894 894 sp|Q96BR5|COA7_HUMANN/A N/A
871 871 sp|P11047|LAMC1_HUMANN/A N/A
200 200 sp|Q96FQ6|S10AG_HUMANN/A N/A
624 624 sp|Q6DRA6|H2B2D_HUMANN/A N/
615 615 tr|Q5QPL9|Q5QPL9_HUMANN/A N/
811 811 sp|Q01804|OTUD4_HUMANN/A N/
831 831 sp|P49006|MRP_HUMANN/A N/A
106 106 sp|P26038|MOES_HUMANN/A N/A
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N Unused Total %Cov %Cov(50) %Cov(95) Accession Name Species Peptides(95%)
1 406.2 406.2 67.55 56.02 52.54 sp|Q15149|PLEC_HUMANPlectin OS=Homo sapiens GN=PLEC PE=1 SV=3UMAN 221
2 257.09 257.09 70.87 62.38 56.54 sp|Q09666|AHNK_HUMANNeuroblast differentiation-associated protein AHNAK OS=Homo sapiens GN=AHNAK PE=1 SV=2HUMAN 181
3 256.77 256.77 78.17 74.37 73.1 sp|O75369|FLNB_HUMANFilamin-B OS=Homo sapiens GN=FLNB PE=1 SV=2HUMAN 171
4 230.75 247.34 73.33 68.87 67.09 sp|P21333|FLNA_HUMANFilamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4HUMAN 182
4 0 245.86 72.54 68.85 67.05 tr|Q5HY54|Q5HY54_HUMANFilamin-A OS=Homo sapiens GN=FLNA PE=1 SV=1HUMAN 181
4 0 245.66 73.09 68.93 67.14 tr|Q60FE5|Q60FE5_HUMANFilamin A OS=Homo sapiens GN=FLNA PE=1 SV=1HUMAN 181
5 215.25 215.25 59.5 51.62 46.71 sp|P78527|PRKDC_HUMANDNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3HUMAN 148
6 204.27 204.27 66.79 58.37 55.87 sp|P35579|MYH9_HUMANMyosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4HUMAN 150
7 198.26 198.26 68.37 62.38 59.3 sp|Q13813|SPTN1_HUMANSpectrin alpha chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTAN1 PE=1 SV=3HUMAN 117
8 192.38 192.38 76.36 73.55 69.37 sp|Q00610|CLH1_HUMANClathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5HUMAN 136
8 0 192.31 76.18 73.38 69.21 tr|A0A087WVQ6|A0A087WVQ6_HUMANClathrin heavy chain OS=Homo sapiens GN=CLTC PE=1 SV=1HUMAN 136
9 182.7 182.7 65.87 62.29 58.26 sp|P49327|FAS_HUMANFatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3HUMAN 115
10 181.15 181.15 65.57 60.53 56.68 sp|Q01082|SPTB2_HUMANSpectrin beta chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTBN1 PE=1 SV=2HUMAN 109
11 169.99 169.99 44.19 38.53 34.55 sp|Q14204|DYHC1_HUMANCytoplasmic dynein 1 heavy chain 1 OS=Homo sapiens GN=DYNC1H1 PE=1 SV=5HUMAN 112
12 168.34 168.34 69.22 63.2 61.24 sp|Q9Y490|TLN1_HUMANTalin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3UMAN 108
13 160.8 160.8 86.94 85.59 85.59 sp|P07437|TBB5_HUMANTubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2HUMAN 163
14 160.5 160.5 88.36 87.46 87.16 sp|P04406|G3P_HUMANGlyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3HUMAN 212
15 158.33 158.33 73.62 68.78 68.65 sp|P08238|HS90B_HUMANHeat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4HUMAN 172
16 155.48 155.48 84.75 80.79 78.53 sp|P14618|KPYM_HUMANPyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4HUMAN 182
17 147.96 147.96 88.8 85.33 79.73 sp|P63261|ACTG_HUMANActin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1HUMAN 230
18 141.38 141.38 62.92 56.55 52.25 sp|O75643|U520_HUMANU5 small nuclear ribonucleoprotein 200 kDa helicase OS=Homo sapiens GN=SNRNP200 PE=1 SV=2HUMAN 83
19 138.96 139.38 83.42 80.46 79.14 sp|O43707|ACTN4_HUMANAlpha-actinin-4 OS=Homo sapiens GN=ACTN4 PE=1 SV=2HUMAN 117
20 137.02 137.02 76.81 72.49 72.49 sp|P13639|EF2_HUMANElongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4HUMAN 125
21 136.04 136.04 80.34 78.64 73.53 sp|P11142|HSP7C_HUMANHeat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1HUMAN 147
22 135.87 135.87 85.84 82.19 79.83 sp|P08670|VIME_HUMANVimentin OS=Homo sapiens GN=VIM PE=1 SV=4HUMAN 164
23 135.22 135.22 57.28 47.51 43.02 sp|Q92616|GCN1L_HUMANTranslational activator GCN1 OS=Homo sapiens GN=GCN1L1 PE=1 SV=6HUMAN 81
24 131.74 131.74 67.13 62.76 59.06 sp|P07814|SYEP_HUMANBifunctional glutamate/proline--tRNA ligase OS=Homo sapiens GN=EPRS PE=1 SV=5HUMAN 78
25 128.74 128.74 90.02 86.92 86.7 sp|P68363|TBA1B_HUMANTubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1HUMAN 134
26 126.96 127.17 83.41 80.88 80.88 sp|P06733|ENOA_HUMANAlpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2HUMAN 156
27 125.38 125.38 64.78 60.9 57.25 sp|P42704|LPPRC_HUMANLeucine-rich PPR motif-containing protein, mitochondrial OS=Homo sapiens GN=LRPPRC PE=1 SV=3HUMAN 75
28 121.1 121.1 78.91 76.8 74.69 sp|P55072|TERA_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=4HUMAN 104
29 120.09 120.09 57.35 54.02 49.35 tr|F8VPD4|F8VPD4_HUMANCAD protein OS=Homo sapiens GN=CAD PE=1 SV=1HUMAN 72
29 0 119.4 56 52.49 47.96 sp|P27708|PYR1_HUMANCAD protein OS=Homo sapiens GN=CAD PE=1 SV=3HUMAN 72
30 116.17 116.17 52.85 45.87 42.18 sp|Q6P2Q9|PRP8_HUMANPre-mRNA-processing-splicing factor 8 OS=Homo sapiens GN=PRPF8 PE=1 SV=2HUMAN 71
31 115.23 115.23 42.02 34.73 30.64 sp|Q7Z6Z7|HUWE1_HUMANE3 ubiquitin-protein ligase HUWE1 OS=Homo sapiens GN=HUWE1 PE=1 SV=3HUMAN 83
32 112.71 112.71 74.89 73.38 70.35 sp|P68104|EF1A1_HUMANElongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1HUMAN 132
33 112.6 112.6 74.86 73.25 71.27 sp|P22314|UBA1_HUMANUbiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3HUMAN 80
34 106.52 106.52 66.22 61.57 59.21 sp|Q08211|DHX9_HUMANATP-dependent RNA helicase A OS=Homo sapiens GN=DHX9 PE=1 SV=4HUMA 77
35 105.35 132.55 53.8 46.71 44.03 sp|P35580|MYH10_HUMANMyosin-10 OS=Homo sapiens GN=MYH10 PE=1 SV=3HUMAN 88
36 105.29 105.29 75.39 69.72 65.91 sp|P55060|XPO2_HUMANExportin-2 OS=Homo sapiens GN=CSE1L PE=1 SV=3HUMAN 86
37 104.15 104.64 80.02 76.48 72.72 sp|Q14974|IMB1_HUMANImportin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 SV=2HUMAN 79
38 102.98 102.98 54.68 48.7 46.59 sp|P46940|IQGA1_HUMANRas GTPase-activating-like protein IQGAP1 OS=Homo sapiens GN=IQGAP1 PE=1 SV=1HUMAN 55
39 99.72 99.72 35.4 25.95 22.05 sp|Q5T4S7|UBR4_HUMANE3 ubiquitin-protein ligase UBR4 OS=Homo sapiens GN=UBR4 PE=1 SV=1HUMAN 72
40 99.68 99.68 75 66.53 61.44 sp|Q14697|GANAB_HUMANNeutral alpha-glucosidase AB OS=Homo sapiens GN=GANAB PE=1 SV=3HUMAN 57
41 99.58 99.58 64.73 47.88 47.88 sp|Q00839|HNRPU_HUMANHeterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE=1 SV=6HUMAN 79
42 99.47 99.47 71.65 66.64 63.26 sp|O00410|IPO5_HUMANImportin-5 OS=Homo sapiens GN=IPO5 PE=1 SV=4HUMAN 62
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N Unused Total %Cov %Cov(50) %Cov(95) Accession Name Species Peptides(95%)
1 391.83 391.83 65.48 55.36 49.25 sp|Q15149|PLEC_HUMANPlectin OS=Homo sapiens GN=PLEC PE=1 SV=3UMAN 214
2 258.4 258.4 74.76 68.08 65.43 sp|P21333|FLNA_HUMANFilamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4HUMAN 194
2 0 256.81 73.99 68.05 65.36 tr|Q5HY54|Q5HY54_HUMANFilamin-A OS=Homo sapiens GN=FLNA PE=1 SV=1HUMAN 193
2 0 256.67 74.66 68.13 65.46 tr|Q60FE5|Q60FE5_HUMANFilamin A OS=Homo sapiens GN=FLNA PE=1 SV=1HUMAN 193
3 252.92 252.92 71.17 60.78 56.1 sp|Q09666|AHNK_HUMANNeuroblast differentiation-associated protein AHNAK OS=Homo sapiens GN=AHNAK PE=1 SV=2HUMAN 185
4 231.83 245.31 76.63 72.94 70.48 sp|O75369|FLNB_HUMANFilamin-B OS=Homo sapiens GN=FLNB PE=1 SV=2HUMAN 181
5 202.26 202.26 68.16 58.72 55.36 sp|P35579|MYH9_HUMANMyosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4HUMAN 174
6 201.67 201.67 78.63 75.1 73.67 sp|Q00610|CLH1_HUMANClathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5HUMAN 152
6 0 201.53 78.44 74.93 73.5 tr|A0A087WVQ6|A0A087WVQ6_HUMANClathrin heavy chain OS=Homo sapiens GN=CLTC PE=1 SV=1HUMAN 152
7 190.94 190.94 67.68 59.87 57.2 sp|Q13813|SPTN1_HUMANSpectrin alpha chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTAN1 PE=1 SV=3HUMAN 119
8 189.67 189.67 56.06 48.11 42.66 sp|P78527|PRKDC_HUMANDNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3HUMAN 148
9 184.3 184.3 70.8 65.8 63.32 sp|Q9Y490|TLN1_HUMANTalin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3UMAN 120
10 176.97 176.97 66.55 57.59 54.8 sp|P49327|FAS_HUMANFatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3HUMAN 112
11 171.48 171.48 79.83 70.3 70.3 sp|P08238|HS90B_HUMANHeat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4HUMAN 191
12 167.69 167.69 81.54 75.89 75.89 sp|P14618|KPYM_HUMANPyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4HUMAN 176
13 166.69 166.69 90.15 88.66 87.46 sp|P04406|G3P_HUMANGlyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3HUMAN 208
14 166.04 166.04 69.08 59.18 52.28 sp|Q01082|SPTB2_HUMANSpectrin beta chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTBN1 PE=1 SV=2HUMAN 99
15 152.83 152.83 85.14 84.68 84.68 sp|P07437|TBB5_HUMANTubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2HUMAN 153
16 146.55 146.55 88.47 87.8 84.7 sp|P68363|TBA1B_HUMANTubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1HUMAN 137
17 146.26 146.26 94.4 89.07 81.6 sp|P60709|ACTB_HUMANActin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1HUMAN 214
18 141.69 141.69 44.23 34.89 30.35 sp|Q14204|DYHC1_HUMANCytoplasmic dynein 1 heavy chain 1 OS=Homo sapiens GN=DYNC1H1 PE=1 SV=5HUMAN 105
19 139.78 139.78 80.42 75.06 74.13 sp|P13639|EF2_HUMANElongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4HUMAN 126
20 137.15 137.65 83.64 79.36 77.39 sp|O43707|ACTN4_HUMANAlpha-actinin-4 OS=Homo sapiens GN=ACTN4 PE=1 SV=2HUMAN 107
21 136.72 136.72 89.27 82.19 78.11 sp|P08670|VIME_HUMANVimentin OS=Homo sapiens GN=VIM PE=1 SV=4HUMAN 147
22 134.35 134.35 71.76 67.46 63.69 sp|P07814|SYEP_HUMANBifunctional glutamate/proline--tRNA ligase OS=Homo sapiens GN=EPRS PE=1 SV=5HUMAN 82
23 131.38 131.38 80.09 73.38 71.65 sp|P68104|EF1A1_HUMANElongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1HUMAN 151
24 130.95 130.95 57.07 50.37 44.9 sp|O75643|U520_HUMANU5 small nuclear ribonucleoprotein 200 kDa helicase OS=Homo sapiens GN=SNRNP200 PE=1 SV=2HUMAN 86
25 130.83 130.83 56.16 47.14 41.71 sp|Q92616|GCN1L_HUMANTranslational activator GCN1 OS=Homo sapiens GN=GCN1L1 PE=1 SV=6HUMAN 83
26 129.26 129.26 83.87 78.11 78.11 sp|P06733|ENOA_HUMANAlpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2HUMAN 155
27 127.31 127.31 70.8 63.41 57.68 sp|P42704|LPPRC_HUMANLeucine-rich PPR motif-containing protein, mitochondrial OS=Homo sapiens GN=LRPPRC PE=1 SV=3HUMAN 79
28 127.12 127.12 81.85 78.42 78.42 sp|Q14974|IMB1_HUMANImportin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 SV=2HUMAN 102
29 124.92 124.92 80.95 75.8 73.33 sp|P55060|XPO2_HUMANExportin-2 OS=Homo sapiens GN=CSE1L PE=1 SV=3HUMAN 97
30 120.56 120.56 81.39 76.8 75.81 sp|P55072|TERA_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=4HUMAN 107
31 120.52 120.52 72.12 70.04 66.82 sp|P22314|UBA1_HUMANUbiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3HUMAN 85
32 117.57 117.57 79.26 75.7 74.46 sp|P11142|HSP7C_HUMANHeat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1HUMAN 142
33 115.19 115.19 41.29 32.14 28.97 sp|Q7Z6Z7|HUWE1_HUMANE3 ubiquitin-protein ligase HUWE1 OS=Homo sapiens GN=HUWE1 PE=1 SV=3HUMAN 86
34 111.97 111.97 56.75 50.28 46.44 tr|F8VPD4|F8VPD4_HUMANCAD protein OS=Homo sapiens GN=CAD PE=1 SV=1HUMAN 73
34 0 111.25 55.42 48.85 45.12 sp|P27708|PYR1_HUMANCAD protein OS=Homo sapiens GN=CAD PE=1 SV=3HUMAN 73
35 111.4 111.4 66.32 56.91 52.2 sp|P46940|IQGA1_HUMANRas GTPase-activating-like protein IQGAP1 OS=Homo sapiens GN=IQGAP1 PE=1 SV=1HUMAN 63
36 108.13 137.57 59.67 48.13 43.22 sp|P35580|MYH10_HUMANMyosin-10 OS=Homo sapiens GN=MYH10 PE=1 SV=3HUMAN 90
37 104.2 104.2 67.24 62.91 57.56 sp|Q08211|DHX9_HUMANATP-dependent RNA helicase A OS=Homo sapiens GN=DHX9 PE=1 SV=4HUMA 76
38 104.01 104.01 71.9 69.56 60.32 sp|O14980|XPO1_HUMANExportin-1 OS=Homo sapiens GN=XPO1 PE=1 SV=1HUMAN 64
39 103.43 103.43 68.62 60.41 53.33 sp|Q86VP6|CAND1_HUMANCullin-associated NEDD8-dissociated protein 1 OS=Homo sapiens GN=CAND1 PE=1 SV=2HUMA 64
40 101.96 101.96 61.58 49.45 48.73 sp|Q00839|HNRPU_HUMANHeterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE=1 SV=6HUMAN 87
41 101.03 101.03 52.46 45.78 39.31 sp|Q6P2Q9|PRP8_HUMANPre-mRNA-processing-splicing factor 8 OS=Homo sapiens GN=PRPF8 PE=1 SV=2HUMAN 68
42 100.44 100.44 69.71 66.63 62.89 sp|Q13200|PSMD2_HUMAN26  proteasome non-ATPase regulatory subunit 2 OS=Homo sapiens GN=PSMD2 PE=1 SV=3HUMAN 65
Supplementary table 8B
















































A375 null and WT - all detected peptides covering potential mutant 
position
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Peptide 
Name Sequence no of AAs




1 ASLEAAIADAEQHGELAIK 19 79, 83 2+, 3+
2 WEAAHVAEQLR 11 79, 83 3+









6 SIITYVSSLYDTMPR 15 65 2+, 3+
7 LIINLVTSIGDVVNHDPVVGDR 22 50, 65 2+, 3+
8 GTAAAAAAAAAAAAK 15 75, 79 2+, 3+
9 VSGSPEQAVEENLSSYFLDR 20 79 3+
10 ILGEVINALK 10 20, 50, 65 2+
Green = isotope labelled AA Highlighted = fraction with the highest abundance of peptide highlighted = most abundant charge state
Bold = mutation place
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DNAseq_hg38_VarScan2_p005_cov1
Chrom Index Chrom_id Position Ref Var
NC_000001.11 1-69511-AG 1 69511 A G
NC_000001.11 1-942451-TC 1 942451 T C
NC_000001.11 1-953279-TC 1 953279 T C
NC_000001.11 1-964350-TG 1 964350 T G
NC_000001.11 1-973858-GC 1 973858 G C
NC_000001.11 1-976215-AG 1 976215 A G
NC_000001.11 1-978953-CG 1 978953 C G
NC_000001.11 1-979472-GC 1 979472 G C
NC_000001.11 1-979496-TC 1 979496 T C
NC_000001.11 1-981169-AG 1 981169 A G
NC_000001.11 1-999842-CA 1 999842 C A
NC_000001.11 1-1044368-AT 1 1044368 A T
NC_000001.11 1-1072052-GA 1 1072052 G A
NC_000001.11 1-1334174-TC 1 1334174 T C
NC_000001.11 1-1490373-TC 1 1490373 T C
NC_000001.11 1-1534019-TC 1 1534019 T C
NC_000001.11 1-1616547-TC 1 1616547 T C
NC_000001.11 1-1640326-GA 1 1640326 G A
NC_000001.11 1-1668373-CT 1 1668373 C T
NC_000001.11 1-1719406-GA 1 1719406 G A
NC_000001.11 1-1734736-CT 1 1734736 C T
NC_000001.11 1-1734812-GA 1 1734812 G A
NC_000001.11 1-1754601-GT 1 1754601 G T
NC_000001.11 1-1923929-CT 1 1923929 C T
NC_000001.11 1-1927692-CT 1 1927692 C T
NC_000001.11 1-1956754-CA 1 1956754 C A
NC_000001.11 1-1968747-TC 1 1968747 T C
NC_000001.11 1-1968793-TC 1 1968793 T C
NC_000001.11 1-2502461-CT 1 2502461 C T
NC_000001.11 1-2509919-TC 1 2509919 T C
NC_000001.11 1-2512975-GA 1 2512975 G A
NC_000001.11 1-2556714-AG 1 2556714 A G
NC_000001.11 1-2595307-AG 1 2595307 A G
NC_000001.11 1-3411794-TC 1 3411794 T C
NC_000001.11 1-3412703-GA 1 3412703 G A
NC_000001.11 1-3473163-CT 1 3473163 C T
NC_000001.11 1-3499885-CA 1 3499885 C A
NC_000001.11 1-3505333-AG 1 3505333 A G
NC_000001.11 1-3579915-TC 1 3579915 T C
NC_000001.11 1-3761369-TC 1 3761369 T C
NC_000001.11 1-3836572-AT 1 3836572 A T
NC_000001.11 1-3891029-GC 1 3891029 G C
NC_000001.11 1-6124032-AG 1 6124032 A G
NC_000001.11 1-6245232-CA 1 6245232 C A
NC_000001.11 1-6253878-CT 1 6253878 C T
NC_000001.11 1-6418980-GA 1 6418980 G A
NC_000001.11 1-6554331-AC 1 6554331 A C
NC_000001.11 1-6554355-AG 1 6554355 A G
NC_000001.11 1-6554475-GA 1 6554475 G A
NC_000001.11 1-6575171-AG 1 6575171 A G
NC_000001.11 1-6645884-CT 1 6645884 C T
NC_000001.11 1-6887657-CT 1 6887657 C T
NC_000001.11 1-7737443-CG 1 7737443 C G
NC_000001.11 1-7820623-TG 1 7820623 T G
NC_000001.11 1-7827433-TC 1 7827433 T C
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Index11_hg38_cov10_p005
Chrom Position Ref Var Index
1 953279 T C 1-953279-TC
1 1044368 A T 1-1044368-AT
1 1490373 T C 1-1490373-TC
1 1534019 T C 1-1534019-TC
1 1623412 T C 1-1623412-TC
1 1668373 C T 1-1668373-CT
1 1719406 G A 1-1719406-GA
1 1734736 C T 1-1734736-CT
1 1754601 G T 1-1754601-GT
1 3891029 G C 1-3891029-GC
1 6253878 C T 1-6253878-CT
1 6554331 A C 1-6554331-AC
1 6633037 A G 1-6633037-AG
1 6645884 C T 1-6645884-CT
1 6887657 C T 1-6887657-CT
1 9744635 C T 1-9744635-CT
1 11126694 G A 1-11126694-GA
1 12022869 A G 1-12022869-AG
1 15427166 G A 1-15427166-GA
1 15506048 T C 1-15506048-TC
1 15807483 T C 1-15807483-TC
1 15807492 T C 1-15807492-TC
1 15929512 T C 1-15929512-TC
1 16251299 C T 1-16251299-CT
1 16938425 C T 1-16938425-CT
1 16939065 C T 1-16939065-CT
1 16986248 C T 1-16986248-CT
1 19238850 C G 1-19238850-CG
1 20650507 A C 1-20650507-AC
1 20661380 G C 1-20661380-GC
1 20765422 C T 1-20765422-CT
1 20941500 G C 1-20941500-GC
1 21880156 T C 1-21880156-TC
1 22509184 A G 1-22509184-AG
1 22520216 G A 1-22520216-GA
1 23092790 G A 1-23092790-GA
1 23559007 T C 1-23559007-TC
1 23854472 T C 1-23854472-TC
1 26284400 A C 1-26284400-AC
1 26557020 A C 1-26557020-AC
1 26884230 T C 1-26884230-TC
1 26993865 T C 1-26993865-TC
1 27838846 A C 1-27838846-AC
1 27882855 A G 1-27882855-AG
1 29148829 C T 1-29148829-CT
1 29148882 C G 1-29148882-CG
1 29149136 T G 1-29149136-TG
1 29216125 A G 1-29216125-AG
1 32695611 T C 1-32695611-TC
1 34981997 C G 1-34981997-CG
1 35097364 G A 1-35097364-GA
1 35760347 T C 1-35760347-TC
1 35760519 C A 1-35760519-CA
1 36092018 G A 1-36092018-GA
1 36286832 C T 1-36286832-CT
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